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1 Summary 
1.1 Summary 
The urea cycle comprises a series of biochemical reactions and converts the waste 
nitrogen into urea. This cycle is located exclusively in the liver. A genetic defect in 
any of the enzymes and transporters involved in this pathway can cause a urea cycle 
disorder (UCD) resulting in hyperammonemia with a high mortality and morbidity. The 
affected UCD patients can manifest at any age with a broad phenotypic variability of 
which the molecular basis and pathology is not yet fully understood. The present 
work focuses on two UCDs, caused by mutations in the argininosuccinate lyase 
(ASL) or carbamoyl phosphate synthetase 1 (CPS1) genes leading to deficiency in 
ASL or CPS1, respectively.  
ASL, a cytosolic homotetrameric urea cycle enzyme, catalyzes the cleavage of 
argininosuccinate into arginine and fumarate. Argininosuccinic aciduria (ASA, OMIM 
#207900), caused by ASL deficiency (ASLD), is a rare autosomal-recessive UCD 
with a wide clinical spectrum ranging from asymptomatic to severe neonatal-onset 
life-threatening forms. We investigated the role of naturally occurring ASL transcript 
variants and of the residual activities of mutant ASL to understand better the clinical 
and biochemical variability of ASA. We found that exon 2 and 7-deleted (ex2del and 
ex7del) ASL are the most common transcript variants expressed in different tissues 
at low levels compared to wild type (WT). The transcript variant ASL-ex2del forms a 
stable truncated protein with no relevant activity but a dose-dependent dominant 
negative effect on the enzymatic activity after co-expression with WT or mutant ASL 
p.E189G, whereas the variant ASL-ex7del is unstable but, nevertheless, appears to 
have a dominant negative effect on mutant ASL. The predominant occurrence of 
ASL-ex7del transcript found in two ASA patients in combination with the 
heterozygous mutant p.E189G suggested the pathophysiological relevance of this 
transcript variant. Further, we found residual activities > 3% of ASL WT in nine of all 
known (n=11) variant ASL mutants identified in patients associated with late-onset 
and/or mild clinical and biochemical courses. Surprisingly, six variant ASL mutants 
(p.R95C, p.I100T, p.V178M, p.E189G, p.V335L and p.R379C) with high residual 
activities (≥18% of ASL WT) showed no or only slightly increased (<2 folds of WT) Km 
values, but nevertheless displayed thermal instability. These findings were supported 
by structural modelling predictions for ASL heterotetramer/homotetramer formation. 
                                                                                                                        Summary 
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Taken together, our results suggest that the investigated ASL transcript variants, if 
expressed at high levels, as well as relevant levels of ASL residual activities of 
mutant proteins mainly caused by a folding defect can contribute to the phenotypic 
variability in ASA patients. Especially, in a stable mutant such as the ex2del ASL 
variant, the effect is even more striking leading to marked impairment of ASL activity.  
CPS1, the first rate-limiting mitochondrial urea cycle enzyme, catalyzes 
carbamoyl phosphate (CP) formation from ammonia, bicarbonate and two ATPs, and 
requires the essential allosteric activator N-acetyl-L-glutamate (NAG) in a global 
reaction with three steps: phosphorylation of bicarbonate, formation of carbamate 
and phosphorylation of carbamate. Most clinical mutations found in CPS1 deficiency 
(CPS1D, OMIM #237300) are “private”, i.e. only found in single families with no or 
little recurrence. Here, we investigated the molecular characteristics of the only 
known frequently recurrent CPS1 mutation, p.Val1013del, found in nine unrelated 
patients of Turkish descent using recombinant CPS1s (WT or V1013del) expressed 
in baculovirus/insect cells. We found that CPS1 WT and V1013del mutant were 
expressed at comparable levels and could be purified to homogeneity. The mutant 
exhibited no significant residual activities in the assays for the CP synthesis reaction 
and neither for the partial reactions. In the CPS1 structural model, the location of 
valine 1013 is close to the predicted carbamate tunnel that links both phosphorylation 
sites. The deletion of this residue, by shortening the β-strand of the A subdomain of 
the carbamate phosphorylation domain (an ATP grasp domain), could distort this 
carbamate tunnel and possibly hamper the connection between both phosphorylation 
steps. Our findings indicate that the mutation p.Val1013del inactivates the enzyme 
but does not render the enzyme grossly unstable or insoluble. 
With these investigations, we contribute to the understanding of non-classical 
UCDs, namely the variant ASA forms and a recurrent CPS1 mutant on the molecular 
basis. At the same time, the results obtained open the way towards novel therapeutic 
targets. Specifically, further studies should determine the stabilising potential of 
pharmacological chaperons on instable mutant ASL.  
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1.2 Zusammenfassung 
Der Harnstoffzyklus ist der Hauptweg zur Entgiftung von neurotoxischem Ammoniak 
und besteht aus einer Serie biochemischer Reaktionen, an deren Ende Harnstoff 
entsteht. Der Zyklus ist ausschliesslich in der Leber lokalisiert. Ein genetischer Defekt 
eines der am Harnstoffzyklus beteiligten Enzyme oder Transporter kann eine 
entsprechende Harnstoffzyklusstörung auslösen, die zu Hyperammonämie mit einer 
hohen Mortalität und Morbidität führen kann. Die betroffenen Patienten können in 
jedem Alter erstmals erkranken und eine breite phänotypische Variabilität zeigen, 
wobei die molekularen Mechanismen und deren Pathologie noch nicht völlig 
verstanden sind. Die vorliegende Arbeit ist auf zwei Harnstoffzyklusstörungen 
fokussiert, den Defekt der Argininosukzinat Lyase (ASL) und der Carbamoylphosphat 
Synthetase 1 (CPS1), welche zu ASL oder CPS1 Mangel führen.  
ASL ist ein zytosolisches homotetrameres Harnstoffzyklusenzym, das die 
Reaktion von Argininosukzinat zu Arginin und Fumarat katalysiert. Die 
Argininbernsteinsäurekrankheit (ASA, OMIM #207900), die durch einen ASL-Mangel 
verursacht wird, ist eine seltene autosomal-rezessiv vererbte Harnstoffzyklusstörung 
mit breitem klinischem Spektrum, das von asymptomatischen bis hin zu 
lebensgefährlichen Verlaufsformen reicht. Um die klinische und biochemische 
Variabilität der ASA besser zu verstehen, haben wir untersucht, welche Rolle 
natürlich vorkommende ASL Transkript-Varianten und die Restaktivitäten der ASL 
Mutanten spielen. Wir konnten zeigen, daß exon 2- und 7-Deletionen (ex2del und 
ex7del) von ASL die am meisten vorkommenden Transkript-Varianten sind und in 
unterschiedlichen Geweben auf niedrigem Level im Vergleich zum Wildtyp (WT) 
exprimiert werden. Die Transkript-Variante ASL-ex2del bildet ein stabiles, verkürztes 
Protein ohne relevante Enzymaktivität. Hingegen hat das mutierte Protein einen 
dosierungsabhängigen dominant-negativen Effekt auf die Enzymaktivität, wenn es 
mit WT oder der Mutante p.E189G ko-exprimiert wird. Die Variante ASL-ex7del ist 
dagegen instabil, weist aber dennoch einen dominant-negativen Effekt auf das 
mutierte ASL Protein p.E189G auf. Das überwiegende Auftreten der ASL-ex7del 
Transkript-Varianten, das in zwei ASA Patienten in Kombination mit einer 
heterozygoten Mutation p.E189G gefunden wurde, deutet auf die 
pathophysiologische Relevanz dieser Transkript-Variante hin.  
Ausserdem haben wir eine Restaktivität >3% von ASL WT) bei 9 der 11 
bekannten varianten ASL Mutanten detektiert, welche in Patienten mit spät 
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einsetzendem und/oder mildem  klinischen und biochemischen Verlauf identifiziert 
wurden. Erstaunlicherweise zeigten die sechs varianten ASL Mutanten (p.R95C, 
p.I100T, p.V178M, p.E189G, p.V335L und p.R379C) mit hoher enzymatischer 
Restaktivität (≥18% von ASL WT) keine oder nur leicht gesteigerte (< 2-fach von WT) 
Km Werte, aber dennoch thermische Instabilität. Diese Untersuchungsergebnisse 
wurden von Strukturmodellen, welche die ASL Heterotetramer/Homotetramer-Bildung 
darstellen, unterstützt. Insgesamt deuten unsere Ergebnisse drauf hin, dass sowohl 
die untersuchten ASL Transkript-Varianten, die stark exprimiert sind, als auch die 
relevanten ASL Restaktivitäten der mutierten Proteine, welche hauptsälich von einem 
Faltungsdefekt verursacht sind, zur phänotypischen Variabilität von ASA Patienten 
beitragen. Besonders auffallend ist der Effekt in einer stabilen Mutante wie der ASL-
ex2del Variante, die eine ausgeprägte Beeinträchtigung der ASL Aktivität zur Folge 
hat.      
CPS1 ist das erste und geschwindigkeitsbestimmende mitochondriale 
Harnstoffzyklusenzym, das die Synthese von Carbamoylphosphat (CP) aus 
Ammoniak, Bikarbonat und zwei ATP-Molekülen katalysiert. Die globale Reaktion 
erfordert obligat den allosterischen Aktivator N-Acetyl-L-Glutamat (NAG) und erfolgt 
in drei Teilschritten: Phosphorylierung von Bikarbonat, Entstehung von Carbamat 
durch die Anlagerung von Ammoniak unter Abspaltung des Phosphatrestes sowie 
Phosphorylierung von Carbamat. Die meisten klinischen Mutationen bei einem CPS1 
Mangel (CPS1D, OMIM #237300) sind „privat“, d.h. sie treten fast nur in einzelnen 
Familien auf.  
In der vorliegender Arbeit haben wir die molekularen Eigenschaften der 
einzigen bekannten häufig auftretenden Mutation, p.Val1013del, die in neun nicht 
verwandten Patienten türkischer Abstammung identifiziert wurde, mittels in 
Bakulovirus/Insektenzellen exprimierter rekombinanter CPS1 Proteine (WT oder 
V1013del) untersucht. CPS1 WT und V1013del Mutante wurden auf vergleichbarem 
Niveau exprimiert und zur Homogenität gereinigt. Die Mutante zeigte keine 
signifikanten Restaktivitäten in den Assays für die Reaktion der CP Synthese und 
auch nicht für die beiden Teilreaktionen. In dem CPS1 Strukturmodell liegt der 
Valinrest V1013 nah beim prognostizierten Carbamat Tunnel, der beide 
Phosphorylierungsstellen verknüpft. Die Entfernung des Valinrestes im β-Strang der 
A Subdomäne der Carbamat Phosphorylierungsdomäne (eine ATP Zugriffsdomäne) 
könnte den Carbamat Tunnel deformieren und damit das Zusammenspiel der beiden 
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Phosphorylierungsschritte verhindern. Unsere Ergebnisse deuten darauf hin, dass 
die Mutation p.V1013del das Enzym inaktiviert, jedoch nicht zu Instabilität oder 
Unlöslichkeit des Enzyms führt.  
Mit diesen Untersuchungen können wir zum besseren Verständnis der nicht- 
klassischen Harnstoffzyklusstörungen, insbesondere der varianten ASA Formen und 
einer relativ häufig auftretenden CPS1 Mutante auf molekularer Ebene beitragen. 
Gleichzeitig weisen die erhaltenen Ergebnisse den Weg zu neuen therapeutischen 
Ansätzen. Naheliegend wären Studien, die das Stabilisierungspotential von 
pharmakologischen Chaperonen für instabile ASL Mutanten untersuchen. 
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2 Introduction 
2.1 Nitrogen metabolism and urea cycle 
2.1.1 Overview 
All living organisms depend on nitrogen as essential component of proteins, nucleic 
acids and several other important compounds. During catabolism of any of the 
numerous nitrogenous compounds, waste nitrogen in the form of ammonia is formed. 
Surplus ammonia cannot be stored and has to be removed fast to avoid its 
(neuro)toxicity.  
 
Fig.1: Pathways for ammonia detoxification within the liver. 
(A): Primary pathway for ammonia removal: ureagenesis within the periportal hepatocytes. 
Sections within dotted line occur within the cell mitochondria. (B) Glutamine synthesis within 
the perivenous hepatocytes. ASL, argininosuccinate lyase; Arg, arginine; ASS, 
argininosuccinate synthetase; CPS1, carbamoyl phosphate synthetase 1; GS, glutamine 
synthetase; HCO3-, bicarbonate; OTC, ornithine transcarbamoylase (adapted from [1]). 
In mammals, the major metabolic pathway for the metabolism of waste nitrogen is the 
urea cycle. In other words, the urea cycle functions as the primary pathway of 
ammonia detoxification in the liver. Ammonia in the hepatic portal vein is delivered to 
the liver, where it is incorporated into either urea via ureagenesis within the periportal 
hepatocytes (hepatocytes present around the portal vein) (Fig. 1(A)), or glutamine via 
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the glutamine synthetase (GS) reaction within the perivenous hepatocytes 
(hepatocytes present around the hepatic vein) (Fig. 1(B)) [1-4]. Ammonia at low 
concentrations is effectively removed by GS, not by ureagenesis. The two pathways 
of ammonia detoxification in the liver represent a low-affinity but high-capacity system 
for ureagenesis and a high-affinity system for glutamine synthesis [5].  
 
2.1.2 Nitrogen metabolism 
2.1.2.1 Nitrogen cycle 
Nitrogen exists abundantly (80%) as a gaseous form (N2) in the atmosphere, in 
organic form in the soil, and as an ion such as ammonium (NH4+) or nitrate (NO3-) in 
plants and microbes [6]. Continuous cycling of nitrogen occurs between the soil, 
plants, animal and the atmosphere including the following steps: (1) formation of 
ammonia by bacterial fixation of N2; (2) nitrification of ammonia to nitrate by soil 
organisms; (3) conversion of nitrate to ammonia by higher plants; (4) synthesis of 
amino acids from ammonia by all organisms, and conversion of nitrate to N2 by 
denitrifying soil bacteria (Fig. 2) [7]. Thus, the nitrogen cycle is also a process in 
which nitrogen is converted between its various chemical forms. All metabolic 
pathways including nitrogen are based on a recycling of ammonia in its neutral or 
charged form ammonium. In living organisms, nonprotein nitrogen occurs primarily as 
ammonia and ammonium, which is a major constitute of the protein and nucleic acid 
pools [6]. Further, approximately 99% of the ammonia-ammonium pool is in the 
ionized (NH4+) form during physiological conditions [8].  
 
Fig. 2: The nitrogen cycle.  
Details of the cycle are described in the text ( taken from [7]). 
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2.1.2.2 Protein turnover and nitrogen balance 
Cells continually turn over body proteins to supply amino acids for various purposes 
such as the synthesis of essential protein and other nitrogenous compounds 
(purines, pyrimidines, creatine, porphyrins) [9]. When proteins break down, they 
release amino acids, which form an “amino acid pool” within the cells and circulating 
blood, together with other amino acids from dietary protein. The rate of protein 
degradation and the amount of protein intake may vary, but the pattern of amino 
acids within the pool maintains fairly constant [10]. In healthy adults, protein 
synthesis balances with degradation, and dietary protein intake balances with 
nitrogen excretion in the urine, feces and sweat.  
Quantitatively, liver and muscle are the most important organs in the protein 
turnover.  Nutritional control of muscle and liver protein turnover is mediated by 
certain amino acids and hormones such as insulin, corticosteroids and thyroid 
hormone for muscle, and insulin and glucagon mainly for liver [9, 11, 12].  
Usually, protein requirement is estimated by nitrogen balance, which refers to 
the nitrogen equilibrium between anabolism and catabolism. It can be measured by 
assessing dietary nitrogen intake versus urinary nitrogen output as urea and 
controlled by the amounts and composition of the diet as well as by changes in 
protein turnover. There is positive and negative nitrogen balance. The former status 
is the net storage of nitrogenous compounds, which occurs when the nitrogen intake 
is greater than its excretion, implies tissue formation and growth. The latter status is 
the net breakdown of stored nitrogenous compounds, which occurs when nitrogen 
output exceeds its intake, indicates wasting or destruction of tissue [10].  
 
2.1.2.3 Removal of nitrogen from amino acids 
Amino acids derived from the dietary protein are the source of most amino groups. 
The first step in amino acids degradation is the removal of nitrogen from the carbon 
skeleton. In the cytosol of hepatocytes, the amino group from most amino acids is 
transferred to α-ketoglutarate to form glutamate, which enters mitochondria and is 
then oxidatively deaminated to produce ammonium ion (NH4+) (Fig. 3) [7] [13]. The 
reactions involved in removing nitrogen from amino acids are known as 
transamination, which is catalyzed by aminotransferases or transaminases at the 
presence of pyridoxal phosphate as a cofactor. Some of the ammonia generated in 
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this process is recycled for a variety of biosynthetic pathways. In skeletal muscle, 
excess amino groups are generally transferred to pyruvate to form alanine, which 
transports amino groups to the liver. Depending on the organism, the amino nitrogen 
excess is either excreted directly as ammonia in most aquatic species such as bony 
fishes, or converted into urea in ureotelic animals or uric acid in birds and reptiles for 
excretion.  
 
Fig. 3: Schematic reaction for removal of nitrogen from amino acid. 
Details of the reaction are described in the text (modified from [13]).  
 
2.1.2.4 Role of glutamate and glutamine  
In living systems, reduced nitrogen in the form of NH4+ is incorporated first into amino 
acids and then into other nitrogen-containing bimolecules. The amino acids 
glutamate and glutamine play a key role in the nitrogen metabolism, acting as main 
storage pool for amino groups. In other words, glutamate und glutamine are 
important nitrogen donors in a wide variety of biosynthetic reactions. Glutamate is the 
most important excitatory neurotransmitter in the brain [14] and the precursor of 
glutamine. The ubiquitously expressed GS, which catalyzes the synthesis of 
glutamine from glutamate, is a main regulatory enzyme in nitrogen metabolism. On 
the other hand, at least six end products of glutamine metabolism are allosteric 
inhibitors of GS, resulting in a constant adjustment of glutamine metabolism to match 
immediate physiological requirements  [7].   
In brain, there is also an intercellular glutamine cycle, releasing glutamine to 
the extracellular space to be taken up into neurons, where it is converted back to 
glutamate by the action of glutaminase [5, 15, 16]. Moreover, glutamine appears to 
represent a temporary storage form of waste nitrogen for most extra-hepatic organs 
lacking a complete urea cycle [16]. In liver, periportal glutaminase and perivenous GS 
are simultaneously active leading to an intercellular glutamine cycle with periportal 
degradation and perivenous resynthesis of glutamine at the expense of energy [5, 
17, 18].  
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2.1.2.5 Pathophysiology of hyperammonemia 
Despite ammonia has an important role in nitrogen homeostasis, endogenous amino 
acid synthesis and acid-base balance, it is (neuro)toxic when present at high 
concentrations (> 50 µmol/L in plasma) [9]. Hyperammonemia refers to a clinical 
condition characterized by elevated ammonia levels in blood and tissues by its 
increased production and/or decreased detoxification indicating abnormal nitrogen 
homeostasis [19]. It increases the risk of irreversible brain damage, of 
neurodevelopmental retardation or even death, when ammonia has already reached 
above 400-500 µmol/L [19]. In urea cycle disorders (UCDs), organic acidemias, fatty 
acid oxidation defects, bypass of the major site of detoxification such as hepatic 
cirrhosis, Reye syndrome, postchemotherapy, or exposure to various toxins and 
drugs, patients can present with severe hyperammonemia [20]. The urea cycle is the 
major part of ammonia detoxification in the mammalian organisms (Fig. 1). Primary 
hyperammonemia is therefore caused by inherited defects of the urea cycle enzymes 
or transporters, while inborn or acquired defects outside the urea cycle can lead to 
secondary hyperammonemia [19].  
Under conditions of hyperammonemia, there are several pathophysiological 
alterations but the entire neurotoxicity is still not yet fully understood [21]: (1) 
pathologic brain changes like brain edema, brainstem herniation, astrocytic swelling, 
white-matter damage and neural loss [22]; (2) amino acid disturbances including 
increased glutamine concentrations in the brain leading to astrocytic damage, 
swelling and cell death of the glutamatergic neurons as well as decreased arginine 
levels [20]; (3) alterations in neurotransmission systems such as accumulated 
extracellular glutamate in the glutamatergic system [23, 24], loss of cholinergic 
neurons leading to decreased choline acetyltransferase activity levels in cholinergic 
system [23, 25], elevated tryptophan (precursor for serotonin) and 5-
hydroxyindoleacetic acid (metabolite of serotonin) in cerebrospinal fluid [26-28], 
cerebral energy deficit [29-31], cerebral exposure [23], altered potassium ion and 
water channels contributing to brain edema formation [32, 33].  
Clinical signs and symptoms in hyperammonemia are unspecific but most affect 
cerebral function. The duration of the hyperammonemic coma and the maximum 
ammonia level are negatively correlated with the patient’s neurological outcome. 
Delayed diagnosis or treatment of hyperammonemia can lead to neurologic damage 
and death. 
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2.1.3 Urea cycle 
2.1.3.1 Urea cycle pathway 
The urea cycle is a complex series of biochemical reactions that converts the waste 
nitrogen in the form of ammonia into urea ((NH2)2CO) and is fully expressed only in 
the liver. This cycle was first described by Krebs and Henseleit in 1932 [34]. It is 
highly conserved in all mammalian species and spans two cellular compartments: the 
first two steps take place in the mitochondria and the subsequent three steps in the 
cytosol (Fig. 4). The urea cycle has three functions: (1) detoxification of nitrogen in 
the form of ammonia; (2) de novo biosynthesis of endogenous arginine; (3) 
maintenance of the acid-base homeostasis.  
Mitochondrion Cytosol
Citrulline
Ornithine
Aspartate
Urea
ARG1
OTC
NH3 + HCO3
Carbamoyl-
phosphate
Glutamate
NAGS
N-Acetyl-
L-glutamate
(NAG)
Fumarate
Argininosuccinate Malate+ 2 ATP
+ H2O
+ 1 ATP
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+
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Fig. 4: The urea cycle and associated metabolic pathways.  
The urea cycle takes place in five steps in the liver. The involved six enzymes and two 
transporters are marked in orange rectangle and circle, respectively.  ARG1, arginase 1; 
ASL, argininosuccinate lyase; ASS, argininosuccinate synthetase; Cit-NO cycle, citrulline-
nitric oxide cycle; CPS1, carbamoyl phosphate synthetase; GDH, glutamate dehydrogenase; 
GLS, glutaminase; iNOS, inducible nitric oxide synthase; NAD(P), nicotinamide adenine 
dinucleotide (phosphate); NAGS, N-acetylglutamate synthase; OAT, ornithine 
aminotransferase; OMP, orotidine monophosphate; OTC, ornithine transcarbamylase; P5CR, 
pyrroline-5-carboxylate reductase; P5CS, ∆1-pyrroline-5-carboxylate synthetase; UMP, 
uridine monophosphate  (modified from [35]).  
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The net effect of the urea cycle is to convert two nitrogen atoms derived from 
ammonia and aspartate to produce urea. The individual reactions are shown in Fig. 
4: (1)  Production of carbamoyl phosphate (CP) from ammonia and bicarbonate: 
2ATP + NH3 + HCO3- → 2ADP + Pi + CP, this reaction takes place in mitochondria 
and is catalyzed by carbamoyl phosphate synthetase 1 (CPS1) in the presence of the 
essential allosteric activator N-acetyl-L-glutamate (NAG) [36-52]; (2) Formation of 
citrulline from CP and ornithine catalyzed by ornithine transcarbamylase (OTC) in the 
mitochondria with the release of Pi: ornithine + CP → citrulline + Pi + H+, the 
produced citrulline is transported from mitochondria into the cytosol by the 
mitochondrial ornithine/citrulline transporter ORNT1;  (3) Entering of the second 
amino group from aspartate by a condensation reaction between the amino group of 
aspartate and the carbonyl group of citrulline to form argininosuccinate: citrulline + 
aspartate + ATP → argininosuccinate + AMP + pyrophosphate (PPi) + H+, this 
cytosolic reaction is catalyzed by argininosuccinate synthetase (ASS); (4) The 
argininosuccinate is then cleaved by argininosuccinate lyase to form arginine and 
fumarate: argininosuccinate → arginine + fumarate, fumarate returns to the urea 
cycle through the aspartate cycle; (5) The produced endogenous arginine is further 
cleaved by arginase to yield urea and ornithine: arginine → urea + ornithine,  
ornithine is transported by the transporter ORNT1 into the mitochondria to initiate 
another round of the urea cycle [7, 9]. The biochemical reactions of the urea cycle 
also produce three physiological important metabolites: ornithine, citrulline and 
arginine.  
 
2.1.3.2 Properties of individual urea cycle enzymes 
The complete urea cycle requires the activity of six enzymes including NAGS, CPS1, 
OTC, ASS, ASL, ARG1 and two transporters, citrin and ORTN1. An overview on the 
molecular genetic characteristics in this pathway is summarized in Table 1. The first 
three urea cycle enzymes are mitochondrial and the other three are cyctosolic. 
Although some urea cycle enzymes are present in several tissues, the full set of urea 
cycle enzymes is only expressed in periportal hepatocytes. This section will only 
describe the six enzymes and mainly focus on the mitochondrial CPS1 and the 
cytosolic ASL enzymes.  
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Table 1: Overview on molecular genetics in urea cycle  
Enzymes / 
transporters 
EC # Gene 
Gene/ 
locus 
OMIM * 
Protein 
location 
Gene 
location 
Exons 
(coding) 
Amino 
acids 
MW $ 
(kDa) 
 N-acetylglutamate 
synthase 
2.3.1.1 NAGS 608300 Mitochondria 17q21.31 7 534 58 
Carbamoylphosphate 
synthetase 1 
6.3.4.16 CPS1 608307 Mitochondria 2p35 38 1500 160 
Ornithine 
transcarbamylase 
2.1.3.3 OTC 300461 Mitochondria 
 
Xp21.1 
10 354 40 
Argininosuccinate 
synthetase 
6.3.4.5 ASS1 603470 Cytosol 9q34.1 14 412 45 
Argininosuccinate 
lyase 
4.3.2.1 ASL 608310 Cytosol 7q11.21 16 464 52 
Arginase 1 3.5.3.1 ARG1 608313 Cytosol 6q23 8 330 35 
Ornithine/citrulline 
transporter ORNT1 
- SLC25A15 603861 
Inner 
mitochondrial 
membrane 
13q14 6 301 33 
aspartate/glutamate 
carrier Citrin 
- SLC25A13 603859 
Inner 
mitochondrial 
membrane 
7q21.3 18 675 74 
EC #: enzyme commission number; OMIM *: Online Mendelian Inheritance in Man number; 
$ indicates the molecular weight for monomer 
  
2.1.3.2.1 N-acetylglutamate synthase (NAGS) 
NAGS (EC 2.3.1.1), a member of the N-acetyltransferase family of enzymes, 
catalyzes the formation of N-acetylglutamate (NAG) from glutamate and acetyl 
coenzyme A in the mitochondrial matrix. The produced NAG is the essential allosteric 
activator for CPS1 in mammals indicating that NAGS may have a key role as a 
regulator of ureagenesis by modulating the activity of CPS1 through NAG [53]. NAGS 
is expressed primarily in the liver and small intestine; the intestinal transcript is 
smaller in size than the liver transcript [54]. The human NAGS gene is located on 
chromosome 17q21.31 [55]. It consists of 7 exons spanning about 4 kb and encodes 
a preprotein of 534 amino acids with a molecular weight of 58 kDa [54]. Based on 
sequence similarity to mouse NAGS, the human NAGS cDNA was isolated from a 
liver library. Three regions with different degrees of sequence conservation were 
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identified: N-terminal mitochondrial targeting signal of 49 amino acids (63% identity 
with mouse NAGS), the variable domain of 45 amino acids (35% identity) and the 
conserved domain of 440 amino acids (92% identity) [54]. When the NAGS protein is 
transported into mitochondria, its N-terminal mitochondrial targeting peptide is 
subsequently cleaved at positions 31 and 49 amino acids resulting in the “long 
mature” and “short mature” protein, respectively [56]. The “short mature” NAGS 
exhibits the highest enzymatic activity. Mammalian NAGS activity increases in the 
presence of arginine and is also stimulated by protamines and other cationic 
polypeptides [57].  
 
2.1.3.2.2 Carbamoyl phosphate synthetase 1 (CPS1) 
2.1.3.2.2.1  Reactions catalyzed by CPS1 
CPS1 (EC 6.3.4.16) is the first rate-limiting enzyme of the urea cycle, which catalyzes 
the synthesis of CP from ammonia, bicarbonate and two molecules of ATP in a global 
reaction (2ATP + HCO3- + NH3 → NH2CO2PO32- + ADP + Pi) with three steps (Fig. 5) 
[36, 38, 40, 58]. In the first step, bicarbonate (HCO3-) is phosphorylated by ATP to 
form carboxyphosphate (HCO3PO32-). In the second step, carboxyphosphate reacts 
with ammonia to produce carbamate (H2NCO2-). In the third step, the resulting 
carbamate is phosphorylated by another ATP yielding final product CP 
(H2NCO2PO32-). In principal, these reactions can independently take place at the two 
catalytic centres of bicarbonate (step 1) and carbamate (step 3) phosphorylations 
reflecting partial reactions of bicarbonate-dependent ATP hydrolysis (ATPase) in the 
absence of ammonia and ATP synthesis from ADP and CP, respectively [59-63]. 
However, the stoichiometry of the CPS1 global reaction requires a coupling of the 
partial reactions at the two phosphorylation sites via conformational changes as 
shown in E. coli [64-67]. Moreover, the reaction requires the allosteric activator NAG 
without which CPS1 is inactive. In other words, the CPS1 activity is regulated by the 
allosteric effector which triggers the signals that are transmitted to the active sites 
thereby changing the affinity for ATP binding [68, 69].  
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Fig. 5: Linear scheme of multidomain organization and reaction steps of mature 
human CPS1.  
CPS1 consists of 40-kDa N-terminal and 120-kDa C-terminal moieties marked with grey-
shaded background bars corresponding to the small and large subunits of E. coli CPS, 
respectively. The colored bars represent the different CPS1 domains with indicated specific 
functions as defined in [50]. Their approximate molecular weights (kDa) and the domain 
start/end residue numbers are given above and below each domain, respectively. 
Biochemical partial reactions are indicated below the domain that catalyzes them. ISD, 
intersubunit interaction domain; GSD, glutaminase domain; BPSD, bicarbonate 
phosphorylation domain; UFSD, unknown function domain; CPSD, carbamate 
phosphorylation domain; CPSD, carbamate phosphorylation domain; ASD, allosteric domain 
which binds NAG (modified from [63]).  
 
2.1.3.2.2.2  Organization and function of CPS1 multidomain 
The CPS1 enzyme has been purified from mammalian species such as human, rat 
and bovine [51, 70, 71]. The precursor form of CPS1 synthesized on free polysomes 
in the cytosol is transported to the mitochondria and then further converted to the 
mature form by proteolytic cleavage of its N-terminal mitochondria targeting 
sequence of 38 residues [40, 72-74]. The mature CPS1 is a large enzyme with 
complex multidomain. The N-terminal and C-terminal moieties of 40 and 120 kDa 
CPS1 corresponding to the small and large subunits of E. coli CPS, respectively (Fig. 
5) [75], are fused by a short protease-sensitive peptidic bridge [63]. Unlike the small 
subunit of bacterial CPSs, the 40-kDa N-terminal moiety of CPS1 is unable to 
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hydrolyze glutamine [63]. Studies suggest that this domain might have a role in 
structural organization as well as in mediating the conformation of the active catalytic 
centres revealed by the existence of missense mutations affecting this region and the 
abolition of CPS activity upon deletion of the N-terminal domain of CPS1 [76, 77]. It 
has also been shown internal homology between the N- and C-terminal halves (each 
60 kDa) of the 120 kDa moiety [38, 40, 43, 78]. The 120 kDa synthetase domain with 
two homologous halves has likely arisen by duplication and tandem fusion of an 
ancestral gene [79]. Moreover, each homologous half of this 120-kDa moiety is 
composed of N- and C-terminal domains of ~40 and ~20 kDa [78, 80-82]. The 40-
kDa domains of the N- (BPSD in Fig. 5) and of the C-half (CPSD in Fig. 5) of the 120-
kDa moiety catalyze the phosphorylation of bicarbonate and of carbamate, 
respectively. The C-terminal 20-kDa domain of the N-half (UFSD in Fig. 5) has been 
suggested to play a key integrating role for creating the CPS1 multidomain 
architecture and proposed as “integrating domain” [83]. The C-terminal 20-kDa 
domain of the C-half (ASD in Fig. 5) is the NAG binding site involved in regulation of 
CPS1 [52, 75, 82, 84-88].  
 
2.1.3.2.2.3  E. coli CPS 
There is only one form of CPS in prokaryotes which uses glutamine as the source of 
nitrogen. The E. coli CPS is an (α,β)4-heterotetramer [84] and exists as the α,β-
heterodimer in the presence of uridine monophosphate (UMP) [89]. The α- and β-
subunits also referred to as the small and large subunits are encoded by the carA 
and carB genes, respectively [90, 91]. The small subunit of CPS shows a distinctly 
bilobal in appearance with the N- (corresponding to ISD in Fig. 5) and C-terminal 
domains (corresponding to GSD in Fig. 5); the former delineated by Leu 1 to Leu 153 
has not been crystallographically depicted in other proteins so far and the latter 
delinated by Asn 154 to Lys 382 matches with glutamine amidotransferase which 
hydrolyzes the glutamine used as the source as ammonia [75, 89]. The large subunit 
consists of four major components including the carboxyphosphate domain 
(corresponding to BPSD in Fig. 5), oligomerization domain (corresponding to UFSD 
in Fig. 5), carbamoyl phosphate domain (corresponding to CPSD in Fig. 5) and the 
allosteric domain (corresponding to ASD in Fig. 5). Structural investigation by X-ray 
crystallographic analysis of E. coli CPS revealed that the three active sites (one in 
small subunit and two in large subunit) on the protein widely separated from each 
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other are connected by a molecular tunnel with a total length of approximately 100 Å, 
suggesting that CPS utilizes this channel to facilitate the translocation of reaction 
intermediates from one side to another [89, 92]. The E. coli CPS is activated by the 
arginine precursor ornithine and by IMP, and inhibited by UMP [75].  
 
2.1.3.2.2.4  Eukaryotic CPSs and human CPS1 
In eukaryotic systems three different types of CPS have been identified so far: (1) 
mitochondrial CPS I (referred to as CPS1) functions in the production of arginine and 
urea and employs free ammonia as the source of nitrogen; (2) cytosolic CPS II is 
involved in pyrimidine biosynthesis and hydrolyzes glutamine for the production of the 
required ammonia; (3) CPS III (a urea-specific CPS in certain invertebrates and 
fishes) utilizes glutaminase as the nitrogen source but functions in the arginine and 
urea cycles [89]. Like CPS I, CPS III is a fused monofunctional enzyme, whereas 
CPS II exists as a fused multifunctional protein. Moreover, a residue substitution at 
the active site of the small subunit from cysteine in E. coli CPS to serine in rat CPS I 
cause the inability of CPS I to hydrolyze glutamine, while this active site cysteine 
residue is conserved in CPS III [89].  
The human CPS1 gene (Mendelian Inheritance of Man (MIM) *608307) has 
been cloned and characterized [74] and mapped to chromosome 2q35 [93, 94]. It 
consists of 37 introns and 38 exons spanning >120 kb of genomic DNA [44, 95, 96]. 
The full-length CPS1 cDNA encodes a polypeptide of 1500 amino acids with a 
calculated molecular mass of approximately 160 kDa. Human CPS1 is activated by 
NAG and cannot use glutamine as the source of nitrogen [36]. Evidence in the frog 
enzyme showed that the GSD domain of CPS1 still remains the entry site for the 
ammonia substrate probably contributing to the lower Km for ammonia observed in 
CPS I relative to other CPSs [97]. 
Human CPS1 is encoded by a single gene which resulted from an ancient 
gene fusion event [79]. CPS1 is located in the mitochondrial matrix and mainly 
expressed in hepatocytes and in epithelia cells of the intestinal mucosa as well as at 
low levels in kidney tissue and pancreas [42, 98-100]. Up to date, no crystal structure 
of the entire human CPS1 is available except for the allosteric regulatory domain. 
The best studied human CPS1 exhibited very similar properties with the rat CPS I 
because of the high sequence similarity (95% identity) [37]. Although the rat CPS I 
has been used as a model for human CPS1 [101], the structure of the rat or any 
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other CPS I has not yet been determined. Nevertheless, E. coli CPS can be used to 
model human CPS1 in studying the impact of mutations affecting the catalytic 
domains which are homologous in the both enzymes [102]. Recently, recombinant 
production of CPS1 in insect and yeast cell systems provided useful tools to 
rationalize the effects of disease-causing CPS1 mutations on enzyme stability and 
functionality [52, 76, 103].    
 
2.1.3.2.3 Ornithine transcarbamylase (OTC) 
OTC (EC 2.1.3.3), localized in the mitochondria of mammalian liver, is the second 
urea cycle enzyme that catalyzes the synthesis of citrulline from ornithine and CP. It 
has been highly purified from the bovine, human and rat livers and well characterized 
[104-109]. The OTC gene (MIM *311250) is mapped to the short arm of X 
chromosome within band Xp21.1 [110]. It consists of 10 exons spanning a region of 
73 kb and has an open reading frame of 1062 nucleotides encoding a precursor 
protein of 354 amino acids with a molecular weight of 40 kDa [111-113]. The 
precursor OTC containing a 32-residue leader peptide is synthesized in the cytosol of 
hepatocytes and then translocated through both mitochondria membranes in an 
energy-dependent manner [114, 115], after which the leader peptide is proteolytically 
cleaved in two distinct steps to produce mature 36-kDa OTC monomer [113, 116]. 
The functional enzyme exists as a homotrimer and its crystal structure has been 
solved [117, 118]. The active sites are located at the interface between the protein 
monomers and each active site has two residues from an adjacent monomer 
contributing to substrate binding [119].   
OTC is expressed mainly in the liver, but it can also be detected in the 
intestinal epithelial cells. Its gene can be regulated by glucocorticoids and other 
transcriptional factors such as C/EBP and HNF-4 [119]. Recently, evidence suggests 
that OTC could possibly also function as a signaling molecule during active cell 
proliferation (e.g., during liver regeneration) [119].  
 
2.1.3.2.4 Argininosuccinate synthetase (ASS1) 
ASS1 (EC 6.3.4.5; common gene symbol alias: ASS) [120] is a cytosolic urea cycle 
enzyme which is involved in the synthesis of arginine [121] and catalyzes the 
synthesis of argininosuccinate from citrulline and aspartate consuming one ATP 
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[122]. Besides its key role in liver urea synthesis, it may play a limiting role in arginine 
synthesis for NO production [123, 124]. There are multiple processed ASS 
pseudogenes localized on 11 chromosomes [125, 126], however none of them is 
expressed [127, 128]. The ASS1 gene (MIM *603470) is located on the long arm of 
chromosome 9 at band 9q.34 [120, 125]. It spans 63 kb and consists of 16 exons (of 
which 14 are coding and the start codon is in exon 3) with an open reading frame of 
1236 bp encoding a peptide of 412 amino acid residues which are highly conserved 
in human, bovine, rat and mouse [123, 129, 130]. Within the ASS1 gene, the 
translational initiation codon is located in exon 3, because the first two exons encode 
5’ untranslated sequence [131]. It has been observed that there is tissue-specific 
alternative splicing in ASS exon 2 [132].  
ASS is a homotetrameric protein composed of approximately 45-kDa 
monomers [120]. It is a ubiquitously expressed enzyme, but mainly found in periportal 
hepatocytes of the liver and in kidney [133]. The localization and regulation of ASS 
are quite different depending on arginine utilization. Hormones including 
glucocorticoids, glucagon and insulin, and nutrients constitute the major regulating 
factors [123]. An increase in specific ASS mRNA level was shown in rats induced by 
feeding with high protein diet [134, 135]. Moreover, glutamine was also found to 
induce the increase of ASS mRNA level in rat hepatocytes leading to increase in ASS 
activity [136]. On the other hand, ASS is repressed by the concentration of arginine in 
the medium in some cultured cell lines [137-139]. Recently, the crystal structure 
revealed three domains, namely, nucleotide-binding domain containing an “N-type” 
ATP pyrophosphatase consensus sequence, synthetase domain and C-terminal 
oligomerization domain in human ASS enzyme [140].  
 
2.1.3.2.5 Argininosuccinate lyase (ASL) 
2.1.3.2.5.1  ASL function and gene structure  
ASL (EC 4.3.2.1) is the second cytosolic urea cycle enzyme which catalyzes the 
cleavage of argininosuccinate into arginine and fumarate. In human, ASL is essential 
for ammonia detoxification via the urea cycle, whereas in lower organisms it is 
required for the biosynthesis of arginine [141]. Recently, it has been shown that ASL 
is also required for systemic NO production [124]. ASL belongs to a superfamily of 
metabolic enzymes including aspartase [142], adenylosuccinate lyase [143], class II 
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fumarase [144] and 3-carboxyl-cis,cis-muconate lactonizing enzyme [145] that 
possess three highly conserved regions and catalyze similar cleavages [146]. The 
active enzyme is a homotetramer composed of four identical subunits each with a 
molecular weight of about 52 kDa [147]. ASL protein is predominantly expressed in 
the liver, but can also be found in other tissues such as fibroblasts, kidney, heart, 
small intestine, brain, muscle, pancreas and red blood cells [99, 147-153].  
The ASL gene has now been identified in a variety of species including E. coli, 
yeast, algae, rat and human [154]. ASL cDNA clone containing an open reading 
frame of 464 amino acids has been isolated from human liver cDNA library [147]. The 
human ASL gene (MIM *603810) is located at chromosome 7q11.21 [155, 156] 
spanning approximately 25 kb composed of 16 exons [147]. One region on human 
chromosome 22 cross-hybridising to 5’-ASL-cDNA was assumed to be a pseudogene 
but late found to code for Ig-λ like mRNA [147, 155, 157]. Recently, a partial 
sequence on chromosome 7, about 3 million bases (Mb) upstream of the ASL gene 
was identified as a novel ASL pseudogene [158]. Additionally, it has been observed 
in different tissues that alternative splicing events occur frequently at the ASL locus 
leading to exon deletions. Amongst them, deletions of exons 2 or 7 are the most 
common [159].   
 
2.1.3.2.5.2  Relationship to crystallins 
Crystallins are diverse group of water soluble and highly stable structural proteins 
which accumulate in the eye lens and contribute to its refractive properties [160-162]. 
There are two categories in crystallins: (1) the ubiquitous crystallins including α, β 
and γ-crystallin are distributed in all vertebrate lenses; (2) the taxon-specific 
crystallins such as δ-crystallins are only present in certain species [163, 164]. α-
crystallin, a small heat shock protein, exists as a large hetero-oligomeric complex 
with an average molecular weight of about 800 kDa [165, 166]. It is composed of two 
highly homologous subunits αA- and αB-crystallins which share about 55-60% 
sequence similarity and serve as molecular chaperone by preventing the aggregation 
of partly unfolded proteins [167-169]. αA-crystallin, only found in the lens, can 
increase thermal stability of both δ-crystallin and ASL by interaction with partly 
unfolded ASL and δ-crystallin to form high molecular weight hetero-oligomers [164]. 
Moreover, it has been shown that α-crystallin can protect ASL activity during freezing 
and thawing by hydrophobic interactions [170].  
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The human ASL enzyme and δ-crystallin were evolutionally related proteins. 
They share about 68.5% and 86.9% amino acid sequence identity and similarity, 
respectively [171]. Gene sharing of ASL and δ-crystallin has also been demonstrated 
for birds and reptiles [171]. δ-crystallin is the dominant structural protein in lenses of 
birds and reptiles but apparently is absent in mammals [161]. Gene duplication has 
resulted in two tandemly arranged, extremely similar δ-crystallin genes, δ1 and δ2-
crystallin. The δ1 and δ2 genes express approximately equal amounts of δ-crystallin 
mRNA in the lens of duck [172], while δ1 produces most mRNA (90-99%) in lens of 
chicken that is specialized for its refractive role [173, 174]. ASL activity is only shown 
in δ2-crystallin but lacking in δ1-crystallin in chicken [175] and duck [176]. The δ2 
gene encoding the ASL activity is preferentially expressed in non-eye tissues of 
chicken and duck. Despite δ1 gene encodes the crystallin protein lacking ASL 
activity, it is also found in non-transparent tissues outside of the eye in both species 
[177]. ASL/δ-crystallin, a major soluble protein of transparent eye lens of birds and 
reptiles, is a mixture of tetramers comprising all possible combinations of two δ1 and 
δ2 crystallins [177].  It is an enzyme-crystallin with little ASL activity in chicken [171] 
and pigeon [178] lenses but high enzymatic activity in duck [171, 178, 179], ostrich 
[180] and goose [181]. Native δ-crystallin is a tetrameric protein with a molecular 
mass about 200 kDa [160] as is mammalian ASL. The relative amount of ASL activity 
of the tetramers was related to the relative amount of their δ2 polypeptides. Taken 
together, ASL plays a dual role both as a catalyst and a structural component [131].  
 
2.1.3.2.5.3  Intragenic complementation at the ASL locus 
Intragenic complementation has been observed at the ASL gene locus in ASL-
deficient cell strains [182-184]. The tetrameric structure of ASL accounts for this 
phenomenon. On complementation, a hybrid protein produced from the two distinct 
types of mutant subunits obtains an increase in functional activity that is greater than 
observed in either mutant alone. As suggested by the crystal structure of ASL, the 
recovered partial ASL activity may be due to the formation of one or more “native-
like” active sites rather than the conformational correction of one mutant monomer by 
the other [182].  
 
2.1.3.2.5.4  ASL crystal structure 
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The structures of human ASL [185] and the homologous δ2-crystallin of duck eye 
lens protein [186] have been determined using X-ray crystallographic techniques. 
Each monomer, composed of three structural domains, is predominately α helical. 
Domains 1 and 3 have similar topologies consisting of two helix-turn-helix motifs 
stacked perpendicularly to each other, whereas the central domain 2 is composed of 
one small β sheet and nine α helices [154]. Five helices form a helical bundle 
arranged coaxially in an up-down-up-down-up topology, and three of these five 
helices from two monomers forming a closely associated dimer are held together by 
mainly hydrophobic interactions. A tetramer is consisted of two such dimers with one 
helix of each monomer interacting at the core to form a four-helix bundle.  
The three regions of highly conserved residues across the superfamily are 
spatially removed from one another in the monomer, but they meet together at each 
of the four “corners” of the tetramer to form four ASL active sites. Each active site of 
ASL contains residues from three different monomers.  
 
2.1.3.2.6 Arginase1 (ARG1)  
Arginase, the terminal enzyme of urea cycle, catalyzes the hydrolysis of arginine to 
ornithine and urea. The produced ornithine is then transported from cytosol into 
mitochondria by the ornithine/citrulline transporter (ORNT1). In mammals, it exists as 
two distinct isoenzymes, arginase1 (ARG1) and arginase2 (ARG2), which are 
encoded by different genes [187]. Although ARG1 and ARG2 catalyse the same 
biochemical reaction, they differ in cellular expression, regulation and subcellular 
localization. The isoform ARG1 (EC 3.5.3.1), known as liver-type arginase, is highly 
expressed in the liver as one of the cytosolic urea cycle enzymes, whereas ARG2 
(kidney-type arginase) is a mitochondrial protein found in a variety of tissues, most 
prominently in kidney. Human ARG1 gene, localized on chromosome 6q23 [188], 
consists of 8 exons encoding a polypeptide of 322 amino acids which demonstrates 
58% sequence identity to human ARG2. Recently, it has been found that ARG1 can 
be highly induced in many tissues and cell types following exposure to a variety of 
cytokines and other agents [189]. ARG1 is a homotrimer with a molecular weight of 
105 kDa. Each 35 kDa subunit contains a binuclear Mn(II) center that is critical for 
catalytic activity. The overall fold of each subunit belongs to the α/β family, consisting 
of a parallel, 8 stranded β-sheet flanked on both sides by numerous α-helices [190].  
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2.1.3.3 Involvement of urea cycle in other pathways 
The complete urea cycle occurs only in liver. However some urea cycle enzymes 
such as ASS and ASL are also expressed in other tissues, where they function to 
generate important metabolites such as ornithine, citrulline and arginine, which are 
precursors important for other pathways. As shown in the Fig. 4, the urea cycle is 
linked with the citrulline-NO cycle by sharing the use of two enzymes ASS and ASL. 
Arginine, an intermediate of urea cycle, serves also as precursor for synthesis of NO, 
polyamines, proline, glutamate, creatine and agmatin in arginine metabolism [191]. 
NO is a short-lived signal molecule which plays diverse roles in cardiovascular, 
immune and neurological systems involving regulation of smooth muscle contraction, 
gene transcription, metabolism, and neurotransmission. Polyamines (putrescine, 
spermidine, and spermine) are ubiquitous small basic molecules with diverse roles in 
cell growth and proliferation. Polyamines are synthesized from arginine, first 
converted into agamatine, or from ornithine catalyzed by arginine decarboxylase 
(ADC) or ornithine decarboxylase (ODC), respectively. Ornithine can also be 
metabolized by ornithine aminotransferase (OAT) to generate proline, which is an 
important component of collagen. Creatine, mostly found in muscle, is synthesized 
from arginine catalyzed by arginine:glycine amidinotransferase (AGAT) and 
guanidinoacetate methyltransferase (GAMT). Arginine can be recycled from citrulline 
via ASS and ASL in the citrulline-NO cycle [189]. 
 
2.1.3.4 Regulation of the urea cycle 
Since the urea cycle enzymes are localized within two distinct subcellular 
compartments (mitochondria and cytosol) and their genes are divided into different 
linkage groups, it appears that different mechanisms regulate gene expression (e.g., 
translational, pre/post-translational, transcriptional) of individual urea cycle genes. It 
has been demonstrated that the activities of all urea cycle enzymes in rat liver 
exhibited adaptive responses to changes in dietary protein and hormones [192]. 
Moreover, it has been shown that changes in mRNA levels for the urea cycle 
enzymes induced by diet are largely coordinated but these mRNAs differ in their 
responses to specific hormones [135]. This suggests that regulatory mechanisms for 
modulating each of the urea cycle enzymes are not identical. In addition, three 
different mechanisms have been demonstrated for the action of glucagon and 
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dexamethasone on urea cycle enzymes: stabilization of mRNA with increased 
transcription for CPS1 and ARG1, increased transcription primarily for ASS and ASL, 
and enzyme stabilization for OTC [193].  
Long-term changes in enzymatic activity are largely due to changes in enzyme 
mass reflecting alterations in enzyme synthesis rates [135]. In the short term 
regulation of ureagenesis, it mainly refers to the activation of CPS1, since CPS1 is 
the first rate-limiting enzyme in urea cycle and is allosterically regulated by NAG. 
NAG is synthesized from acetyl-CoA and glutamate by NAGS. An autoregulatory 
control of ureagenesis was observed only at moderate loads of amino acids, and 
mediated by glutamate effects on NAG synthesis [194]. The remaining urea cycle 
enzymes are controlled by the concentrations of their substrates.   
Hormones such as glucagon, glucocorticoids, and insulin are major regulators 
of the expression of urea cycle enzymes in liver [189]. Glucagon and glucocorticoids 
elevate the activities and the mRNA levels in urea cycle enzymes except for OTC, 
whereas insulin represses CPS1 and ASL [195]. In contrast, the “urea cycle” 
enzymes expressed in non-hepatic cells are regulated by a wide range of pro- and 
anti-inflammatory cytokines and other agents [189]. Actually, regulation of these 
enzymes is mainly transcriptional in all cell types.  
To date, the molecular bases for transcriptional regulation such as DNA 
regulatory elements involved in hormonal regulation of gene expression in hepatic 
urea cycle enzymes is mainly based on data already described in 1995 [195]. For 
instance, studies on transcriptional regulation of CPS1 expression revealed that a far 
upstream -6.3 kb enhance region [196] is necessary and largely sufficient for liver-
specific, developmental and hormonal regulation of CPS1 expression [197, 198].  
 
2.2 Urea cycle disorders (UCDs) 
2.2.1 UCDs overview 
UCDs are a group of inherited inborn errors of nitrogen metabolism resulting in 
accumulation of ammonia with a high mortality and morbidity. The estimated overall 
incidence in UCDs is about 1 in 35’000 live births in the United States [199], which 
may be in fact higher due to underdiagnosis of deceased cases. Hence, UCDs 
belong to the most common liver-based inborn errors of metabolism (IEMs).  
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Table 2: Overview on clinical characteristics in urea cycle disorders   
Urea cycle 
Disorder 
Phenotype 
OMIM # 
Incidence 
[199, 200] 
Inheritance  
Abnormalitities of 
metabolites 
Specific 
clinical 
features 
NAGS deficiency 237310 < 1:2,000,000 
Autosomal 
recessive 
+ Ammonia,  
- citrulline, - orotic acid in 
urine 
None 
CPS1 deficiency 237300 1:62,000 
Autosomal 
recessive 
+ Ammonia, + glutamine, 
- citrulline, - orotic acid in 
urine 
None 
OTC deficiency 311250 1:14,000 X-linked  
+ Ammonia, + glutamine, 
+ ornithine, - citrulline,   
+ uracil, 
+ orotic acid in urine 
None 
ASS deficiency = 
citrullinemia type 1 or 
classical citrullinemia 
215700 1:57,000 
Autosomal 
recessive 
+ Ammonium, + citrulline, 
- arginine, 
+ orotic acid in urine 
None 
ASL deficiency = 
argininosuccinic aciduria 
207900 1:70,000 
Autosomal 
recessive 
+ Ammonia, + citrulline, 
+ argininosuccinate 
- arginine 
Liver disease, 
fragile hair, 
hypertension 
ARG1 deficiency = 
hyperargininemia 
207800 1:350,000 
Autosomal 
recessive 
+ Arginine 
Spastic 
paraplegia 
HHH syndrome = 
hyperornithinemia-
hyperammonemia-
homocitrullinuria syndrome 
238970 < 1:2,000,000 
Autosomal 
recessive 
+ Ammonia, 
+ ornithine, 
+ homocitrulline in urine 
None 
Citrullinemia type 2 
603471a  
605814b 
1:21,000  
(in Japan) 
Autosomal 
recessive 
+ Ammonia, + citrulline, 
- arginine 
Cholestasis in 
neonates 
# OMIM: Online Mendelian Inheritance in Man; +/- indicates elevated/decreased level in 
plasma; a indicates adult-onset; b indicated neonatal-onset 
UCDs affect the detoxification of surplus nitrogen leading to 
hyperammonemia. Six enzymes (NAGS, CPS1, OTC, ASS1, ASL and ARG1) and 
two mitochondrial transporters (citrin and ORNT1) are involved in the urea cycle. 
Deficiency caused by gene mutation in any of the enzymes or transporters in this 
pathway can lead to a UCD corresponding to NAGS deficiency (NAGSD, OMIM 
#237310), CPS1 deficiency (CPS1, OMIM #237300), OTC deficiency (OTCD, OMIM 
#311250), ASS1 deficiency (ASS1D or classical citrullinemia or citrullinemia type 1, 
OMIM #215700), ASL deficiency (ASLD or argininosuccinic aciduria (ASA), OMIM 
#207900), ARG1 deficiency (ARG1D or hyperargininemia, OMIM #207800), 
citrullinemia type 2 (OMIM #605814 for late-onset and OMIM #603471 for neonatal-
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onset) and the hyperornithinemia-hyperammonemia-homocitrullinuria syndrome 
(HHH syndrome, OMIM #238970), respectively. All of them are inherited as 
autosomal recessive disorders except for the X-linked OTC deficiency. An overview 
on clinical characteristics in UCDs is summarized in Table 2. Although a pedigree 
with evidence of X-linked transmission suggests a diagnosis of OTCD, these 
diseases can be distinguished from one another only by appropriate laboratory 
measurements [131].   
Most affected patients present as neonates. But UCDs can manifest at any 
age with a broad phenotypic variability ranging from asymptomatic to severe life-
threatening courses. However the molecular basis and pathology of this variability is 
not yet fully understood. In addition, the urea cycle is the de novo pathway for 
synthesis of endogenous arginine. Defects in the urea cycle can cause various 
disorders in other related downstream metabolic pathways. This section will describe 
the general clinical picture, diagnosis, treatment, and animal models in UCDs as well 
as the specific disorders with a particular focus on CPS1D and ASLD. 
 
2.2.2 Classification of UCDs 
The clinical presentations of patients with UCDs are virtually similar and mainly 
related to hyperammonemia. The severity of the disease is dependent on the age at 
onset. Therefore, UCDs are classified as either presenting in the neonatal period 
(=early onset) or as late onset. However, it should be noted that this classification is 
an arbitrary division of a continuous spectrum of phenotypic expression.  
2.2.2.1 Neonatal UCDs 
Neonatal onset UCDs are caused by genetic defects resulting in severe impairment 
of urea cycle function. Hyperammonemia is the primary cause of neonatal UCDs 
leading to rapid accumulation of ammonia and other precursor metabolites. Since no 
effective alternative detoxification pathway for ammonia exists in the newborn period 
(<30 days of age), disruption of the urea cycle can result in the rapid development of 
symptoms such as acute cerebral edema with severe neurologic compromise [201, 
202]. If undiagnosed and untreated, the neonatal UCDs will cause mental retardation 
or even early death.  
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2.2.2.2 Late-onset UCDs 
Late-onset UCDs are caused by genetic defects allowing for some partial enzyme or 
transporter function. Individual UCDs may vary regarding their onset from childhood 
to adult, and regarding severity from asymptomatic to mild or severe. Often, 
symptoms in late-onset UCDs occur episodic and related to high protein intake.  
 
2.2.3 Pathogenesis of UCDs 
A defect caused by a mutation in any one of the six enzymes and two transporters 
involved in the urea cycle can result in UCD. The common feature of a UCD is a 
defect in ammonia elimination in liver, leading to a toxic accumulation of ammonia 
(hyperammonemia). The toxic effects of ammonia mainly occur in the central nervous 
system (CNS). Depending on the age of onset as well as the duration and the level of 
ammonia exposure, these effects can be reversible or irreversible [23]. The 
pathophysiology of hyperammonemia has been already described above (in section 
2.2.1.3). Better understanding the pathophysiology of ammonia toxicity to the brain 
will allow the development of new strategies for neuroprotection in UCD patients. 
Enzymatic defects can occur at all steps of the urea cycle. Patients with 
residual activity of urea cycle enzyme < 2-5% of normal show an early onset acute 
clinical course leading to death if not treated [9]. In patients with higher residual 
activities (5-15% of normal), episodic hyperammonemia may occur at any time during 
childhood or later. It has been shown that less severe hyperammonemia occurs in 
ARG1D than in other UCDs [203].  
 
2.2.4 Diagnostic aspects 
The UCDs patients are still affected by a poor outcome. To improve both the survival 
rates as well as the quality of life in surviving patients, the early diagnosis is required. 
The diagnosis of a UCD is mainly based on evaluation of clinical, biochemical, and 
molecular genetic data. In other words, diagnosis is made by quantitative plasma and 
urine amino acids, measurement of orotic acid in urine, enzyme assays and genetic 
analysis.  
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2.2.4.1 Clinical features 
UCDs can manifest at any age. Infants with UCDs always had a normal pregnancy 
and postnatal adaption. Typically, they develop the symptoms rapidly after the first 24 
hours (h) of life. About the half of affected patients present in the neonatal period. 
The median age at presentation was two years in a large cohort of UCD patients 
[204]. Clinical symptoms of UCD patients are mostly associated with 
hyperammonemia leading to neurological impairments due to the toxicity of ammonia 
primarily to the CNS. The most common symptoms are unspecific such as decreased 
level of consciousness, mental retardation, abnormal motor function, and seizures or 
gastrointestinal such as vomiting, poor feeding, diarrhea, nausea, and failure to 
thrive. While signs and symptoms of hyperammonemia are highly unspecific, the 
manifestation can be acute or chronic.   
In acute hyperammonemia, the induced cerebral edema can lead to vomiting, 
seizures, and hyperventilation causing respiratory alkalosis. The neurological 
impairment can range from mild lethargy to deep coma. Patients with acute liver and 
multiorgan failure are also reported [205]. Notably, the clinical features in neonatal 
UCDs resemble a sepsis-like picture, thus bacterial sepsis is a common initial 
misdiagnosis. Concerning differential diagnosis, neonatal hyperammonemia can also 
be caused by other inborn errors such as organic acidemias and fatty acid oxidation 
defects that result in secondary hyperammonemia, or by liver failure or congenital 
infection [35].    
In chronic presentation, hyperammonemia is often less severe. The 
associated symptoms include confusion, lethargy, dizziness, migraine-like headaches, 
tremor, ataxia, dysarthria, learning disabilities, neurodevelopmental delay, mental 
retardation, behavioural changes, vomiting, failure to thrive, protein aversion, 
hepatomegaly [35]. Symptoms are often triggered by infection, fever, vomiting, high-
protein load, trauma, surgery, and several drugs. Some of the patients tend to self-
select a vegetarian diet due to protein aversion.  
 
2.2.4.2 Biochemical diagnosis 
The laboratory hallmark of a UCD is an elevated concentration of plasma ammonia 
(> 100-150 μM). Hyperammonemia is always present in neonatal UCD patients. 
Additionally, respiratory alkalosis is present in about 50% of acute UCDs [206]. 
However, hyperammonemia may not be as severe in late-onset UCD patients. In the 
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case of an unexplained change in consciousness, unusual or unexplained 
neurological impairment, liver failure, or suspected intoxication, ammonia should be 
measured [35].  
Besides ammonia determination, routine laboratory investigations including 
plasma amino acids, blood acylcarnitines, urinary organic acids and orotic acid are 
essential [35]. Quantitative plasma amino acid analysis is useful to differentiate 
among UCDs [202]. For instance, finding of a specific amino acid profile such as 
argininosuccinate allows the diagnosis of ASLD. In ASS1D and ASLD, citrulline 
concentration is increased, but absent or decreased in CPS1D, OTCD, or NAGSD. 
Orotic acid in urine is increased in OTCD but low in CPS1D or NAGSD. Arginine is 
elevated in ARG1D. Ornithine and urinary homocitrulline are elevated in HHH 
syndrome. In some UCDs, hepatic dysfunction may be found including elevated liver 
enzymes, coagulopathy, and histologic changes [207, 208].  
 
2.2.4.3 Enzyme activity assay 
When the metabolite profile is not clear-cut, the diagnosis of a specific UCD can still 
be achieved by enzyme activity analysis for all UCD enzymes by using liver tissue, 
for ASLD and ARG1D with erythrocytes, for CPS1D and OTCD with intestinal 
mucosa, and for ASSD and ASLD with fibroblasts [35]. It should be noted that the 
found enzyme activity does not always correlate with residual activity in vivo or with 
the clinical phenotype due to the excess substrate used in most in vitro assays. 
Moreover, the required invasive sampling such as liver biopsy for mitochondrial 
UCDs limits its application. Enzymatic testing is regarded as an alternative in patients 
with negative genetic analysis.  
 
2.2.4.4 Genetic analysis  
DNA-sequencing-based genetic analysis provides a confirmatory mean for the 
diagnosis in all UCDs. The used DNA is generally extracted from blood cells. This is 
mostly performed by polymerase chain reaction (PCR)-based DNA-sequencing to 
detect mutations. The sensitivity of DNA-based OTC mutation analysis is only about 
80% [209] possibly due to changes in the large intronic sequences of the OTC gene. 
Therefore, array comparative genomic hybridization (aCGH) [210] should be 
considered if initial DNA sequencing was inconclusive. Recently, it was shown in our 
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lab that RNA-based gene testing facilitates identification of  CPS1 mutations when 
cultured lymphocytes are stimulated by phytohaemagglutinin [211].   
In addition, other effective alternative techniques such as next generation DNA 
sequencing [212] become available, which may revolutionize future sequencing 
analysis. Mutation detection in UCDs allows carrier identification, prenatal diagnosis, 
facilitating pedigree analysis, genetic counselling, and defining genotype-phenotype 
correlations at least for some cases, which may provide a benefit for future therapies 
[35] as well as for understanding of their disease-causing role. 
 
2.2.4.5 Prenatal testing  
Prenatal testing can be done by molecular genetic studies or by biochemical testing, 
and it is available for all UCDs. DNA isolated from chorionic villi can be used for 
prenatal mutation analysis. The carrier status of both parents should be confirmed 
prior to the prenatal DNA testing. This provides an early, fast and safe method to 
detect affected fetuses. In the case of no mutation detected in the index patient, 
biochemical testing for the determination of citrulline and argininosuccinate in the 
amniotic fluid can be performed for prenatal diagnosis of ASS1D and ASLD, 
respectively [213]. Additionally, cultured chorionic villus or amniotic fluid cells can 
also be used by the enzyme analysis for ASS and ASL, respectively [214].   
 
2.2.4.6 Newborn screening (NBS) 
Since the early 1960’s, newborn screening (NBS) has been applied for metabolic 
disorders. Initially, it was applied to screen for a single disorder, phenylketonuria 
(PKU), using a simple bacterial inhibition assays (“Guthrie test”). Usually, the whole 
blood spots from neonatal heel (between 24h and 72h after birth) are collected on 
specially designed filter paper (known as Guthrie cards) for NBS tests. In the early 
1990’s, the development of tandem mass spectrometry (TMS=MS/MS) allowed the 
additional detection of a variety of disorders of amino acid, organic acid and fatty acid 
oxidation metabolism by analyzing amino acids and acylcarnitines. TMS provides a 
powerful technology for the rapid and sensitive measurement in NBS. It becomes an 
exciting area of preventive medicine.  
Some of the expanded NBS programs using TMS in most US states, Europe, 
Australia, and Taiwan, included the distal UCDs (ASS1D, ASLD and ARG1D) by 
identifying citrulline, argininosuccinate and arginine, respectively [35]. Proximal UCDs 
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such as NAGSD, CPS1D and OTCD are not included in NBS panels due to the 
unreliable results of low citrulline [215]. Moreover, ASLD screening was cancelled in 
Austria due to the high rate of asymptomatic cases in positive newborns [216], 
although NBS shows its high sensitivity for ASLD. Thus, it still remains open for the 
benefit of UCDs from NBS to obtain a rapid diagnosis allowing proper counselling 
and prospective treatment for the patients’ parents [217].  
 
2.2.5 Treatment of UCDs 
UCDs patients except for asymptomatic patients need a lifelong treatment when the 
diagnosis is made. The overall goal of treatment of UCDs is to correct the 
biochemical abnormalities, and at the same time to maintain the balance between 
protein restriction and nutritional requirements. The outcome is particularly 
dependent on the neurological status caused by hyperammonemia at the time of 
diagnosis and the response to treatment.   
2.2.5.1 Acute treatment 
The acute treatment of UCDs refers to the emergency management of patients in 
hyperammonemic crisis. Since the duration of hyperammonemic coma and peak 
ammonia levels have a strong impact on the neurodevelopmental prognosis, therapy 
should start immediately. In general, it is based on three interdependent principles 
[35, 202, 214]: (1) removal of ammonia by dialysis or continuous hemofiltration; (2) 
reversal of catabolism through caloric supplementation such as infusion of high dose 
glucose with the use of insulin; (3) alternative detoxification by pharmacologic 
scavenging of excess nitrogen. These should be carried out in parallel as quickly as 
possible.  
 
2.2.5.2 Long term therapy 
The current strategy for long term therapy of UCDs is a multidisciplinary combination 
consisting of dietary protein restriction, alternative pathways of nitrogen excretion 
using nitrogen scavenging drugs, and substitution of essential amino acids and 
vitamins [35]. In general, severe UCDs patients need to be treated with all above 
three options, whereas the mild forms of UCDs might not.   
Dietary treatment of UCDs aims primarily to avoid the endogenous protein 
degradation. To keep the balance between the dietary protein intake and 
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overrestriction in patients is a big challenge. Therefore, supplementation of essential 
amino acids as well as vitamins is required. Long-term diet adjustment with nutritional 
monitoring is often necessary in patients with chronic episodes of hyperammonemia. 
In many chronic UCDs patients, diet alone is not sufficient to maintain the nitrogen 
homeostasis. Hence, an alternative detoxification [218] is necessary to increase the 
removal of waste nitrogen by using some compounds such as sodium benzoate, 
phenylacetate and phenylbutyrate. Benzoate or phenylacetate conjugate with glycine 
or glutamine in the liver, respectively, and are excreted as a glycine- or glutamine-
conjugated form resulting in excretion of one or two molecule(s) of nitrogen [219].  
Since the urea cycle is the only pathway for endogenous biosynthesis of 
arginine, UCDs except for ARG1D cause arginine deficiency. Arginine is the 
precursor for several other pathways. Deficiency in arginine leads to a catabolic state 
that stimulates further nitrogen metabolism from protein breakdown. Hence, arginine 
administration is required in most UCD patients. Alternatively, citrulline 
supplementation can be used in ASSD patients [220] and is also provided in NAGSD, 
CPS1D, OTCD, and HHH syndrome [35].   
 
2.2.5.3 Liver transplantation 
Liver transplantation has been used in treatment of most UCDs [221] and considered 
the only available curative therapy for UCDs. Since the long term prognosis of UCD 
patients is generally poor, liver transplantation becomes an important cure for severe 
enzyme deficiency. However, the neurological impairment caused by the initial 
hyperammonemia can not be reserved by this treatment [222]. It is now widely 
considered first line treatment for newborns with CPS1D or OTCD, in patients who 
have no response to medical therapy, and in ASLD associated with cirrhosis. It was 
suggested that liver transplantation should be done in all severe neonatal UCD 
patients except for NAGSD and ideally performed between 3 and 12 months of age 
in stable metabolic condition without severe neurological damage and/or recurrent 
episodes [35]. Additionally, patients with progressive liver disease such as ASLD, 
with recurrent metabolic decompensations threatening the neurological development, 
or with poor quality of life are also recommended for liver transplantation [35]. The 
overall post-transplant UCD patients show similar survival as non-UCD patients. 
Compared to auxiliary liver transplantation, standard orthotopic liver transplantation is 
advantageous with fewer complications in most cases [221].  
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2.2.5.4 Hepatocyte transplantation  
Hepatocyte transplantation has been recently proposed as alternative therapeutic 
option to orthotopic liver transplantation, because the limited availability of donor 
organs [223-225]. Until 2011, a total of 10 patients with UCDs (6 OTCD, 2 ASS1D, 1 
ASLD and 1 CPS1) have been treated with hepatocyte transplantation [225]. 
Metabolic stabilization was achieved with decreased ammonia levels and increased 
urea production in most cases. Although hepatocyte transplantation provided a 
successful bridge to liver transplantation in six patients, metabolic decompensation 
causing death occurred in two patients after hepatocyte transplantation. Thus, this 
new therapeutic technique and its efficacy still remain to be investigated in studies 
before it becomes to a routine treatment.  
 
2.2.5.5 Gene therapy 
Many metabolic diseases including UCDs, caused by mutations resulting in the 
deficiency of a particular enzyme, are compelling candidates for gene therapy. Gene 
delivery, referred to as “the Achilles heel”, is one of the key challenging in gene 
therapy. There are several different gene delivery methods to introduce the genetic 
material into the cells including physical methods (such as electroporation, ultrasound 
and gene gun), viral vectors (such as adenovirus, retrovirus, and adeno-associated 
virus (AVV)) and non-viral methods (such as liposomes or nanoparticles as gene 
carrier). Amongst them, adenoviruses are currently the most promising gene delivery 
vectors in gene therapy [226]. 
OCTD is the most common UCD providing an ideal model disease to treat 
genetic metabolic liver disease including UCDs by liver-targeted gene therapy based 
on phenotype correction. To date, few gene therapy studies have investigated in 
OTC-deficient mouse models the use of adenoviral [227], helper-dependent 
adenoviral [228, 229], AVV [230], recombinant AAV (rAAV) [231, 232], and, more 
recently, shRNA and rAAV-mediated vectors [233]. Although phenotype correction 
was reported in OTC-deficient mice [227], ASS-deficient bovine [234] and mice [235] 
using first generation adenoviral vectors, the rescue is transient due to the cellular 
immunity to viral antigens [236]. Further studies showed prolonged metabolic 
correction in OTC- [227, 228] and ASL-deficient [237] mice, but only short-term 
correction in neonatal ARG1-deficient mice [238] using helper-dependent adenoviral 
vectors. However, the gene therapy using adenoviral gene transfer was not 
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successful in a clinical trial of OTC-deficient patients leading to fatal systemic 
inflammatory response syndrome [239]. Notably, liver targeted gene transfer using 
AAV-based vectors provide promising efficacy for phenotype correction not only in 
mouse models [230] but more importantly in human clinical trials [240, 241]. Recently, 
improved and optimized AAV vectors including self-complementary AAV2/8 vectors 
expressing mouse Otc or a codon-optimized human OTC showed greatly increased 
efficacy in treating OTC-deficient mice indicating potential therapeutic effects in 
OCTD patients [232, 242, 243]. However, the OTC-deficient spfash mouse model has 
a limitation for gene therapy due to its absence of hyperammonemia, which is the 
therapeutic goal. Very recently, a shRNA-based rAAV-mediated gene delivery was 
successfully applied to control severe hyperammonemia in OTC-deficient spfash 
mouse model, even using vector dosages 5-fold lower than those required to control 
orotic aciduria [233]. Additionally, AVV-base gene therapy also provides long-term 
survival of the juvenile lethal ARG1-deficient mouse model [244] and normal 
cognitive development in hyperargininemic mouse [245]. Although gene therapy has 
experienced several “ups and downs”, with the development in technology, it will 
overcome the translational challenges involved in human therapy and might become 
a standard treatment for genetic disease in the near feature.    
  
2.2.6 Mouse models of UCDs 
Mouse models have been established for all six urea cycle enzyme defects [246, 
247]. These include OTC-deficient spf and spfash mouse models, knockout models for 
CPS1, ASS, ASL and ARG1, and a salvageable knockout mouse model for NAGS. 
However, all knockout mouse models of UCDs die in the neonatal period or shortly 
thereafter without treatment.  
2.2.6.1 Salvageable NAGS knockout mouse model 
Recently, a biochemically salvageable NAGS knockout mouse model [247] was 
established. Use of N-carbamyl-L-glutamate (NCG) and citrulline allow rescuing the 
animals and normal development, apparent health, and reproduction. However, the 
knockout mice develop severe hyperammonemia and die within 48 h when this 
rescue intervention interrupts. Moreover, the animals also display elevated plasma 
glutamine, glutamate, and lysine, and reduced citrulline, arginine, ornithine and 
proline levels. 
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2.2.6.2 CPS1 knockout mouse model 
In the CPS1-deficient mouse model [248], exon 17 of CPS1 was disrupted because it 
contains the sequences encoding the most 5’-nucleotide binding domain. CPS1 
activity in liver is completely abolished in all knockout mice which die within 36 h of 
birth due to hyperammonemia.  
 
2.2.6.3 OTC-deficient mouse models 
In two available OTC-deficient mouse models, spf (sparse fur) [249] and spfash 
(abnormal skin and hair) [250] mice, both affected by a missense mutation, with 5-
10% residual OTC activity display several characteristic biochemical hallmarks of 
OTCD including elevated plasma ammonia and glutamine, decreased plasma 
arginine and citrulline, and increased urinary orotic acid.  
 
2.2.6.4 ASS1 knockout mouse model 
For ASSD (citrullinemia type 1), a naturally occurring bovine model [251] and a 
knockout mouse model [252] are available. Exon 4 was interrupted in the ASS 
knockout mouse resulting in death within a few days after birth exhibiting highly 
elevated plasma citrulline and decreased arginine. Additionally, two spontaneous 
hypomorphic alleles of the mouse Ass1 gene was recently described as mouse 
model of ASSD [253]. Some mutant mice died within the first week after birth, others 
survived displaying similar symptoms as found in ASSD patients.  
 
2.2.6.5 ASL knockout mouse model 
ASL-deficient mouse model was generated by replacement of exons 8 and 9, 
creating a frameshift in the mRNA beginning with exon 10 [254]. All homozygote mice 
show deficiency in ASL and ARG1 activity and die within 48 h after birth with elevated 
plasma ammonia, argininosuccinate, glutamine and citrulline, and decreased plasma 
arginine. In addition, a conditional hypomorphic mouse model was generated for 
ASLD [124] by introducing a neomycin selection cassette into intron 9 in the mouse 
Asl gene resulting in 16% residual enzymatic activity. The normal born hypomorphic 
mice died within 3-4 weeks after birth from multiorgan failure showing similar plasma 
amino acid profiles as in ASLD patients with elevated citrulline and argininosuccinate, 
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and reduced arginine. A triple therapy with the combination of sodium benzoate, 
arginine and sodium nitrite increased the survival and weight gain in these 
hypomorphic mice.  
 
2.2.6.6 ARG1 knockout mouse model 
An ARG1 knockout mouse model is also available for ARG1D [255]. The mouse is 
born normally and develops hyperammonemia after 10-12 days with only moderate 
hyperargininemia and markedly reduced ornithine. Symptoms in these mice include 
decerebrate posture, encephalopathy, and tremors in the extremities all of which are 
more severe than in human ARG1D patients. This might be due to the decreased 
level of upregulated kidney ARG2 activity in the knockout mouse which is unable to 
compensate for a loss of liver ARG1 activity. 
 
2.2.7 Individual disease-specific UCD  
UCDs caused by deficiency of individual enzymes or transporters are summarized in 
Table 2. In this section, the specific enzyme deficiencies (NAGS, CPS1, OTC, ASS1, 
ASL and ARG1) are described with a focus on CPS1D and ASLD. 
2.2.7.1 NAGS deficiency (NAGSD) 
NAGSD (OMIM #237310) caused by a defect in NAGS, a very low abundant enzyme 
which catalyzes the synthesis of NAG from glutamate and acetyl-CoA, is the rarest 
and most-recently identified UCD [256]. NAGSD manifests similar clinical symptoms 
and laboratory findings as CPS1D including elevated plasma glutamine, reduced 
citrulline, and normal urinary orotic acid. Liver enzymatic studies [257] and molecular 
genetic diagnostics [258] can distinguish these two proximal UCDs. NAGSD presents 
variable clinical symptoms ranging from early neonatal hyperammonemia to late-
onset. The majority of neonatal NAGSD shows < 5% residual enzymatic activity with 
frequent frameshift or nonsense mutations [258, 259]. It was suggested that the few 
reported NAGSD patients without detectable deleterious mutations having reduced 
NAGS activity may not have primary NAGSD, but have a secondary deficiency of 
NAG due to lacking coenzyme A, acetyl-CoA, L-glutamate, or inhibition of the NAGS 
reaction [256]. Additionally, the neonatal hyperammonemia in NAGSD can also result 
from secondary CPS1D, since NAG is the allosteric activator for CPS1. Furthermore, 
a specific treatment for NAGSD using NCG, a NAG structural analogue, to activate 
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CPSI is available and approved for use in Europe and the US (Carbaglu®, Orphan 
Europe) [55, 258-260]. Hence, NAGSD is the only UCD that can be specifically and 
effectively treated by a drug. Understanding NAGSD may help to better understand 
the regulation of ureagenesis. 
 
2.2.7.2 CPS1 deficiency (CPS1D) 
2.2.7.2.1 Clinical and biochemical findings  
CPS1D (OMIM #237300) results from a genetic defect of CPS1 leading to 
hyperammonemia, which is primary due to mutations in the CPS1 gene or secondary 
due to the lack of its allosteric activator NAG caused by mutations in the NAGS gene. 
The estimated incidence of CPS1D is approximately 1 in 62,000 live births [200]. 
Because CPS1 catalyzes the initial step in the urea cycle, CPS1D manifests with the 
most severe symptoms of all UCDs. The clinical and biochemical features of CPS1D 
are indistinguishable from NAGS with identical biochemical alterations: increased 
plasma ammonia and glutamine, reduced citrulline, and normal urinary orotic acid 
levels. Thus, enzyme activity or genetic mutation analysis are required for a correct 
diagnosis of CPS1D. Its clinical symptoms are variable from severe to asymptomatic 
forms depending on the patients’ age at onset and severity of the enzymatic 
impairment. Like the other neonatal onset forms of UCDs, CPS1D exhibits most 
severe life-threatening hyperammonemia with a residual enzymatic activity < 5% in 
newborn infants [131]. A less severe and late-onset form also exists in CPS1D with 
partial enzymatic activity.  
 
2.2.7.2.2 Treatment  
In general, CPS1D patients are treated in the same way as other UCDs including 
nutritional restriction of protein intake, administration of arginine/citrulline and 
benzoate/sodium phenylacetate. Liver transplantation is used to treat the severe life-
threatening CPS1D patients. Additionally, evidence showed that NCG, an analogue 
of NAG, with therapeutic effect in NAGSD can also improve metabolic correction in 
some anecdotal CPS1D patients. Particularly, NCG treatment might be beneficial for 
CPS1D patients with mutations affecting the affinity for NAG binding [101]. 
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2.2.7.2.3 Mutations and affected functional domains 
A total of 222 clinical mutations including missense, nonsense, insertions/deletions 
(indels), and splice are reported in the CPS1 gene so far [50] and distributed along 
the entire coding region. Most mutations are “private” to individual families with little 
recurrence. Amongst them, single-nucleotide substitutions with missense changes 
are the vast majority of the mutations followed by small deletions and insertions or 
duplications, indels, and large deletions. Nonsense mutations generating truncated 
proteins that lack one or more domains and mutations leading to aberrant proteins 
are necessarily disease-causing. Findings of the majority of the missense mutations 
but corresponding to a smaller fraction compared to that of nonsense changes 
indicate that only a fraction of the missense changes would probably be disease-
causing for CPS1D [50]. In addition, the missense mutations are highly unevenly 
distributed in some CPS1 exons than in others even after removal of the mutations 
affecting the CpG islands. This heterogeneous distribution of missense mutations 
indicates that some enzyme regions are more important than others for enzyme 
stability, folding and functionality [50]. Thus, mutations affecting these regions would 
be expected to have disease-causing potential.  
Generally, missense mutations are found more frequently in the large subunit-
like region of 120 kDa C-terminal moiety including BPSD, CPSD, UFSD and ASD, 
which performs the functions such as substrate binding, catalysis, and NAG 
regulation, than in the small subunit-like region of 40 kDa N-terminal moiety including 
ISD and GSD (see the domain organization in the Fig. 5). Amongst them, BPSD, a 
key catalytic and substrate binding domain is the most frequent localization of clinical 
missense mutations (normalized per 100 amino acids) then followed by UFSD. 
Additionally, three consecutive structural subdomains (A, B, C) in both 
phosphorylation domains exhibit the highest frequency of missense mutations for the 
entire proteins. Studies have also been shown the impact of clinical missense 
mutations affecting BPSD and CPSD on enzyme stability, folding and functionality, 
and disease-causing nature [101-103].  
Interestingly, the peak of highest density of missense mutations is observed at 
exon 24 and the surrounding exons in the UFSD [50] which connects BPSD and 
CPSD. Expression studies of the clinical mutations affecting UFSD suggests that this 
domain has a key integrating role for creating the CPS1 multidomain architecture and 
is proposed as “integrating domain” [83]. Taken together, these findings indicate that 
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subdomains including BPSD, UFSD and CPSD occupy a central position in 
constituting a continuous highly profound region for missense mutations. Moreover, 
peaks of frequent occurrence of missense mutations found in the regulatory C-
terminal ASD reveal the functional importance of CPS1 activity by NAG [50, 101]. 
There are also clinical mutations observed in the small subunit-like region supporting 
its functional importance as well [76].  
 
2.2.7.2.4 Recombinant CPS1 expression systems 
The main aim of employing expression studies is to determine the enzyme 
functionality thus to establish the causality of clinical mutations based on the 
biochemical and structural basis of CPS1D. In other words, establishment of 
expression systems for functional analysis of CPS1 mutant proteins is required for 
establishing structural genotype-phenotype relationships. The large size of CPS1 
gene, the complex multidomain organization of the enzyme and the lack of a human 
CPS1 crystal structure all contribute to the difficulty in establishing such relationship. 
Moreover, it is quite difficult to get an in vitro-in vivo correction in those mutant 
proteins with partial enzymatic activity due to the external and intrinsic factors that 
can influence the in vivo enzyme activity [63]. Further, allelic imbalance may also 
affect the prognosis of CPS1D [261].  
Several expression studies have been shown that the clinical missense mutations 
associated with CPS1D expressed in bacteria [102] and in insect cells [83, 101, 103], 
as well as a common single nucleotide polymorphism expressed in yeast 
(Schizosaccharomyces pombe) [76] could provide an effective approach to define the 
nature of specific amino acid changes. However, the differences between the C-
terminal regulatory and N-terminal domains of the bacterial CPS and human CPS1 
have limited the application of this model in the investigation of clinical mutations 
affecting those domains. Furthermore, the recombinant human CPS1 expressed in 
the baculovirus/insect system show essentially the same kinetic and molecular 
properties for the natural human enzyme and thus provides a valuable tool to identify 
disease-causing mutations [83, 103], which might be helpful for diagnosis and 
prognosis of CPS1D.     
There is another powerful tool to study the contributions of CPS1 genetic 
variants to the wide range of CPS1D phenotypes. This expression system is based 
on modified BACs (bacterial artificial chromosomes) for eukaryotic episomal 
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replication, marker expression, and selection [262]. It allows to analyse the mutations 
located in non-coding regions as well as to test potential splicing and RNA-
processing defects. Thus, this expression system appears to provide advantages of 
using whole-gene constructs to study the effects of sequence variation on gene 
expression and function. 
 
2.2.7.3 OTC deficiency (OTCD) 
OTCD (OMIM #311250) is caused by genetic defect of OTC that catalyzes the 
formation of citrulline from CP and ornithine. OTCD is the most common of UCDs 
with an estimated incidence of 1 in 14,000 live births [263]. In contrast to other UCDs, 
OTCD is the only X-linked UCD with extreme heterogeneity ranging from acute 
neonatal hyperammonemic coma to asymptomatic adult hemizygous males [113]. 
Even the late-onset patients affected by the same mutation can present at different 
ages with diverse clinical courses [264]. This phenotypic heterogeneity might partly 
be due to the variability in the concentration of a substrate or the ability of the liver to 
compensate for enhanced degradation of the OTC protein [113]. In general, 
hemizygous males display the most severe symptoms, while female heterozygotes 
can have quite variable clinical course [131, 209, 265, 266], which is mostly due to 
the X-chromosome inactivation in liver [267]. Up to date, more than 400 “private” 
mutations are identified in OTCD [209]. A “hot spots” of mutation is found in CpG 
dinucleotides in the OTC gene. Approximately 50% of OTCD patients are late-onset 
with partial OTC activity, while the neonatal patients harbouring no significant 
residual activity. Besides hyperammonemia as in other UCDs, reduced citrulline and 
arginine and elevated urinary orotic acid are typical biochemical features in OTCD.  
  
2.2.7.4 ASS deficiency (ASSD, Citrullinemia type 1) 
ASSD (OMIM #215700) is caused by a defect in ASS, which catalyzes citrulline and 
aspartate to form argininosuccinate [121], the immediate precursor of arginine. It is 
biochemically characterized by an increase of plasma citrulline and urine orotic acid 
and a decrease of plasma arginine [268]. The clinical manifestation is very 
heterogeneous from severe to asymptomatic courses. There is no firm correlation 
between genotypes and phenotypes, neither in biochemical metabolites nor in 
enzymatic activities. To date, more than 93 mutations including gross 
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deletions/duplications, have been identified in citrullinemia patients [269]. Amongst 
them, missense mutations are the most common. Mutations are clustered in the 
exons and exon-intron boundaries of the ASS1 gene due to the high rates of 
mutation detection found in various ethnic groups (>90%) [269-271]. Depending on 
the ethnic background, highly frequent mutations have been accordingly detected in 
certain ethnic groups such as Japanese, Korean and Turkish. The treatment strategy 
for citrullinemia is a combination with nutritional restriction of protein intake and 
administration of arginine. Generally, the prognosis for classical citrullinemia patients 
is better than for those with OTCD or CPS1D.    
 
2.2.7.5 ASL deficiency (ASLD, Argininosuccinic aciduria (ASA)) 
2.2.7.5.1 Clinical and biochemical characteristics 
ASA (OMIM #207900) is caused by mutations in the gene encoding ASL, a cytosolic 
urea cycle enzyme that cleaves argininosuccinate into arginine and fumarate, leading 
to deficiency of ASL (ASLD). It is the second most common UCD after OTCD with an 
estimated incidence of 1 in 70,000 live births [200]. The first case of this disease was 
described by Dr. Allan in 1958 [272].  
The clinical presentation of ASA is very variable ranging from severe neonatal-onset 
to asymptomatic late-onset forms. Patients with severe neonatal-onset ASA typically 
present hyperammonemia within the first few days of life as in other UCDs, whereas 
those with late-onset forms can have milder or asymptomatic manifestations with few 
or no episodic hyperammonemia. Biochemically, it is characterized by elevated 
plasma ammonia, citrulline and argininosuccinate (the hallmark of ASLD), and 
reduced arginine levels. Clinical symptoms of ASLD are milder compared to those 
presented in CPS1D or OTCD, which is mostly due to the excretion of significant 
amounts of argininosuccinate, a nitrogen rich compound [201, 273]. Surprisingly, the 
neurocognitive deficits such as mental retardation, behavioural abnormalities, 
learning disability, intellectual disability, developmental delay etc. are more common 
in ASLD than in other UCDs [274]. It is also reported that ASLD patients detected by 
NBS have only biochemical phenotype such as elevated argininosuccinate level in 
urine or blood, but without any clinical symptoms [216, 275]. There are several 
unique clinical phenotypes including hepatic disease, trichorrhexis nodosa (coarse 
and fragile hair) and systemic hypertension in ASA patients.  
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2.2.7.5.2 Molecular pathogenesis of phenotypic variability 
Mutations in the ASL gene results in ASLD with wide phenotypic variability, which 
might be explained by tissue-specific ASL expression [276, 277], genetic 
heterogeneity at the ASL locus [278], intragenic complementation [182-185], residual 
enzyme activity [141, 279], developmental control of ASL gene by DNA methylation 
[280], and frequent alternative splicing at ASL locus [281-283]. In general, there is a 
poor correlation between enzymatic activity and clinical phenotype in ASA patients. 
This might partly be due to the instability of the mutant ASL protein in the cell 
homogenate [157].   
As stated above, the complex clinical phenotype observed in ASA patients 
indicates that the involved mechanisms are beyond the defect in ureagenesis. Very 
recently, it was shown that ASLD leads to a decrease in NO synthesis in both mice 
and humans [124]. Interestingly, treatment with liver-targeted gene therapy could not 
correct the hypertension in ASA mice with decreased NO production [237]. These 
findings suggest that the tissue specific requirement of ASL for NO production, but 
not the blockade of ureagenesis, is responsible for some clinical presentations not 
caused by hyperammonemia such as hypertension in ASA [273]. 
Moreover, arginine is the precursor not only for urea but also for NO 
production catalyzed by NOS. Free radicals generated by “uncoupling” of NOS are 
increased in low arginine substrate availability [284-286]. Indeed, ASA mice show 
increased free radicals of NOS3 suggesting the contribution to tissue damage in ASA, 
since argininosuccinate could be converted into guanidinosuccinic acid, a known 
cellular and neuronal toxin [287-289].  
 
2.2.7.5.3 Mutations and polymorphisms 
To date, 134 mutations spread over the entire ASL gene including nonsense, 
missense, insertions, deletions, and splice are known as well as 160 different 
genotypes in 223 ASLD patients [290]. Many heterogeneous mutations are 
associated with ASLD. Most mutations are “private” in individual families with little 
recurrence. There are three mutations, c.299T>C [290] and c.1153C>T [291] 
reported only in Finnish patients, while c.1060C>T [290] only identified in Arab 
patients, indicating a founder effect.   
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The majority of known mutations are missense changes. Mutations can be 
found in the entire ASL coding region except for exon 1, which comprises only 9 
nucleotides. However, exons 3, 4, 6, 7 and 9 carrying 41% of the mutations [290] 
appear to be mutational hotspots, since they only occupy 25% of the total ASL cDNA 
sequence, while exons 4, 6 and 12 contain functional important residues close to the 
active site and seem not to be a prefered location for mutation occurrence.   
More than 350 polymorphisms have been identified so far across the entire 
ASL gene [290]. Of these, 18 missense changes located in the coding region are 
considered benign. In addition, more than 280 polymorphisms found in the ASL 
intronic regions allowing for allele tracking which might provide a tool for prenatal 
diagnostics in the cases of only one known parental mutation [290].   
 
2.2.7.5.4 Treatment  
The current therapeutic strategies used in the chronic treatment of ASA are the same 
as those for other UCDs including dietary restriction and arginine supplementation, 
which aim to control hyperammonemia, but which are not effective to prevent the 
neurocognitive deficits, hepatic disease or hypertension in ASA [216, 275]. Recently, 
high-dose arginine, a hitherto commonly used strategy, was shown to impair the 
prognosis [292]. As mentioned above, decreased NO production in NOS deficiency is 
partly responsible for the some clinical manifestations of ASA indicating that NOS-
independent NO donor therapy could be beneficial. Treatment with sodium nitrite in 
ASA mice showed comparable survival to traditional treatment including arginine and 
sodium benzoate [124]. Further, NO supplementation was successfully used to treat 
the hypertension in an ASA patient [237]. Although the limited preliminary data in 
humans, these findings imply NO supplementation therapy in ASA may be beneficial 
beyond the vascular complications [273].  
 
2.2.7.5.5 Recombinant ASL expression systems  
The main goal of employing expression studies is to determine the functional role of 
ASL mutations combined to the structural modelling. Different ASL expression 
systems have been established in E. coli [279, 293, 294], yeast [141, 278], and 
eukaryotic cells including COS-1 cells [182, 283] and HEK 293T cells [159]. They all 
provide a useful tool to better understand the molecular basis of ASLD. The existing 
                                                                                                                     Introduction 
 44 
 
expression systems except for HEK 293T cells are mostly used for ASL intragenic 
complementation analysis between missense mutations. Although ASL mutants were 
successfully expressed in the bacterial expression system, this system revealed an 
imperfect correlation of in-vitro enzyme activity with clinical phenotype in ASA [279]. 
HEK 293T cells were used for (co)-expression of truncated ASL transcript variants 
[159] as well as for expression of clinical variant ASL mutants associated with late-
onset and/or mild clinical and biochemical courses (See chapter 2 in manuscripts) to 
study the role of transcript variants and of the residual activity in the phenotypic 
variability of ASA. However, none of the presented expression systems can be 
convincingly used to predict the genotype-phenotype relationships in ASA due to lack 
of understanding of the mechanisms. Moreover, the catalytic function of ASL 
depending on its tetrameric confirmation and thus intragenic complementation among 
specific mutations allowing for residual activity add to the difficulty and complexity for 
the prediction based on the genotype. 
 
2.2.7.6 ARG1 deficiency (ARG1D, Argininemia) 
Argininemia (OMIM #207800) is caused by mutations in the ARG1 gene leading to 
deficiency of ARG1 (ARG1D), a liver-type arginase, which hydrolyses arginine into 
ornithine and urea. ARG1D is the one of the least frequent UCDs with an estimated 
incidence of 1 in 350,000 live births [200]. Many missense mutations found in ARG1D 
patients occur in highly conserved regions of the gene [295, 296]. ARG1D is 
characterized by progressive neurological and intellectual impairment, spasticity, and 
persistent growth retardation [297]. Additionally, the episodic hyperammonemia 
occurs less frequently with lower ammonia levels than those observed in other UCDs, 
which appears to be due to intestinal ureagenesis by ARG2 (kidney-type), encoded 
by a second arginase locus, to compensate in part for the liver-type ARG1D [298]. 
Because of the neurotoxicity of hyperargininemia of unknown mechanism in ARG1D, 
its clinical symptoms are distinct from other UCDs with low plasma arginine levels. 
Accordingly, long-term investigations on ARG1D patients reveal a correlation 
between the plasma arginine levels and the severity of the neurological damage 
[299]. Therefore, dietary supplementation with all essential amino acids other than 
arginine is a necessary therapy for ARG1D.  
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2.3 Aims of the study 
UCDs manifest at any age with broad clinical spectrum from asymptomatic to severe 
neonatal courses. This phenomenon exists particularly in ASLD, since an increasing 
number of ASLD patients with variable and often milder clinical courses are detected 
by extended NBS. The molecular basis and pathology of this phenotypic variability in 
UCDs remains to be clarified. It was reported that different tissues exhibited different 
levels of ASL activity in ASA patients indicating tissue-dependent ASL expression 
[276, 277]. Moreover, it has been shown that alternative ASL splicing occurs 
frequently within the ASL gene [281-283]. Based on these findings, we hypothesized 
that ASL transcription expression is tissue-specific and ASL transcript variants 
contribute to the phenotypic variability in ASA in the first project described below. 
Further, we hypothesized that relevant residual ASL activity contributes to the 
phenotypic variability in late-onset ASA in the second project.  
In the third project, we wanted to characterize the molecular basis for the only 
known frequently recurrent CPS1 mutation, p.Val1013del, found in nine unrelated 
patients of Turkish descent. The reason to study this was that almost all CPS1 
mutations found in CPS1D patients are “private” to individual families, with only very 
little recurrence [50].  
The aims of the first project describing the role of ASL transcript variants in ASA are:  
(1)  to investigate whether ASL transcription expression is tissue-specific  
(2)  to identify the most common ASL transcript variants  
(3)  to illustrate the physiological relevance of transcript variants in ASA  
(4)  to establish an ASL expression system lacking endogenous ASL activity but  
allowing for high ectopic ASL expression  
(5)  to (co)-express diverse recombinant proteins for ASL WT, transcript variants 
and/or mutant p.E189G  
(6)  to determine the residual enzyme activity  
(7)  to predict the effect of single exon deletions on ASL homotetrameric structure  
The aims of the second project for the residual ASL activity of variant mutants are:  
(1)  to express all known variant ASL mutants identified in patients associated 
with late-onset and/or mild clinical and biochemical courses  
(2)  to determine the residual enzyme activity, kinetic parameters and protein 
thermostability  
(3)  to predict the effect of single amino acid substitutions for ASL mutation 
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The aims of the third project for the only known recurrent CPS1 mutant p.Val1013del:  
(1)  to establish the CPS1 expression system in baculovirus/insect cells in our lab 
(2)  to express and purify the recombinant proteins for CPS1 WT and mutant 
p.V1013del 
(3)  to determine the global and partial enzyme activities  
(4)  to determine the protein thermostability 
(5)  to rationalize the effect of deletion of the Val1013 residue 
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3 Manuscripts 
3.1 Chapter 1  
Understanding the Role of Argininosuccinate Lyase Transcript 
Variants in the Clinical and Biochemical Variability of the Urea 
Cycle Disorder Argininosuccinic Aciduria 
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Background: The role of argininosuccinate lyase (ASL) transcripts in disease variability is unclear.
Results: The most common ASL transcript variants decrease the functional enzymatic activity after co-expression with wild
type or mutant ASL.
Conclusion: ASL transcripts expressed at high levels can contribute to the variable phenotype in ASL-deficient patients.
Significance: A new explanation of the molecular basis adds to our understanding of the clinical variability in patients.
Argininosuccinic aciduria (ASA) is an autosomal recessive
urea cycle disorder caused by deficiency of argininosuccinate
lyase (ASL) with a wide clinical spectrum from asymptomatic
to severe hyperammonemic neonatal onset life-threatening
courses. We investigated the role of ASL transcript variants in
the clinical and biochemical variability of ASA. Recombinant
proteins for ASL wild type, mutant p.E189G, and the frequently
occurring transcript variants with exon 2 or 7 deletions were
(co-)expressed in human embryonic kidney 293T cells. We
found that exon 2-deleted ASL forms a stable truncated protein
with no relevant activity but a dose-dependent dominant nega-
tive effect on enzymatic activity after co-expression with wild
type ormutantASL, whereas exon 7-deletedASL is unstable but
seems to have, nevertheless, a dominant negative effect on
mutant ASL. These findings were supported by structural mod-
eling predictions for ASL heterotetramer/homotetramer for-
mation. Illustrating the physiological relevance, the predomi-
nant occurrence of exon 7-deleted ASL was found in two
patients who were both heterozygous for the ASL mutant
p.E189G. Our results suggest that ASL transcripts can contrib-
ute to thehighly variable phenotype inASApatients if expressed
at high levels. Especially, the exon 2-deleted ASL variant may
form a heterotetramer with wild type or mutant ASL, causing
markedly reduced ASL activity.
Argininosuccinate lyase (ASL2; EC 4.3.2.1; OMIM *608310)
catalyzes the reversible hydrolytic cleavage of argininosucci-
nate into arginine and fumarate and contributes to the removal
of waste nitrogen and biosynthesis of arginine within the urea
cycle in ureotelic species (1). ASL is also involved in the argi-
nine-citrulline cycle as part of a multiprotein complex required
for production of nitric oxide (2) as well as in other pathways
(Fig. 1).
The human ASL gene is located on chromosome 7q11.21 (3,
4) and comprises 16 exons encoding 464 amino acids (5, 6). The
resulting monomers have a predicted molecular mass of 52
kDa and form a homotetrameric functional enzyme with four
active sites (7). ASL has significant homology to -crystallin
with an amino acid sequence identity of 64–71% between
human ASL and various -crystallins (8, 9). The -crystallins
are major structural components of avian and reptilian eye
lenses and show significant ASL enzyme activity in duck and
chicken (9, 10). HumanASL is expressed predominantly in liver
(11) but is also detected inmany other tissues, including kidney
(12), small intestine (13, 14), pancreas and muscle (15), heart
(16), brain (17, 18), skin fibroblasts (19), and erythrocytes (20).
Mutations in the ASL gene result in an autosomal recessive
disorder known as argininosuccinic aciduria (ASA; synony-
mous ASL deficiency, ASLD; OMIM number 207900) (21),
which is the second most common disorder in the urea cycle,
with an estimated incidence of 1 per 70,000 live births (22).
The clinical and biochemical phenotype of ASA is highly vari-
able ranging from asymptomatic cases with only a biochemical
phenotype (23–25), some of them diagnosed through newborn
screening, to severe neonatal-onset hyperammonemic enceph-
alopathy (26, 27). Themolecular basis for the diversity ofASA is
not fully understood, and several explanations have been sug-
gested, including tissue-specific ASL expression (27, 28),
genetic heterogeneity at theASL locus (29), intragenic comple-
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mentation (7, 30–32), different levels of residual ASL activity
(33, 34), the developmental control of the ASL gene by DNA
methylation (35), and alternative splicing events at the ASL
locus leading to frequent exon deletions (5, 36, 37).
In this study, we explored the role of naturally occurring ASL
transcript variants in the formation and function of the ASL
homotetramer to better understand the phenotypic variability
of ASA. By combining computational structural analysis using
molecular dynamic (MD) simulations and eukaryotic (co-)ex-
pression of wild type (WT) with the most common transcript
variants formed by deletions of exon 2 or 7, we could show that
exon 2-deleted (ex2del) or exon 7-deleted (ex7del) ASL has a
dominant negative effect on the ASL activity after co-expres-
sion with wild type or mutant ASL, respectively. Suggesting a
physiological role of transcript variants, RNA analysis revealed
a predominant expression of ex7del ASL in two ASA patients
identified with heterozygosity for the ASL mutant p.E189G.
Taken together, these findings suggest that the frequent occur-
rence of ASL transcript variants, when they are expressed at
high levels, can be a factor contributing to the highly variable
clinical and biochemical phenotype of ASA. In particular, the
effect may be evenmore striking in a stable mutant, such as the
ex2del ASL variant, because it may form a heterotetramer with
ASL wild type or naturally occurring missense mutations (i.e.
sequence alterations with a disease-causing role found in ASL-
deficient patients), contributing to reduced ASL activity.
EXPERIMENTAL PROCEDURES
ASL Transcript Expression in Different Tissues
A panel of cDNAs from 17 different human tissues compris-
ing ASL patient fibroblasts and 16 other tissues (Multiple Tis-
sue cDNA Panel Human I and II, Clontech, Mountain View
CA) was used for the amplification of full-length ASL as well as
shorter RNA fragments. In addition, short ASL cDNA frag-
ments derived from skin fibroblasts of 24 ASA patients with 10
different genotypes were amplified. Specific oligonucleotides
ASL-FL-F (5-acgaggaaccgcccaacat-3) (forward) and ASL-
FL-R (5-tgcctctccagtccctgactgt-3) (reverse) were used for
amplification of full-length ASL; primers ASL-SF-F (5-acac-
tatccgtgcggccagg-3) (forward, derived from ASL 5-UTR
sequence) and ASL-SF-R (5-tgagatgggtcatgcacagcg-3)
(reverse, derived from ASL exon 10 sequence) were used for
amplification of a short fragment containing exons 1–9 with a
fragment size of 864 bp. Hot start PCR was performed at an
annealing temperature of 60 °C (62 °C for primer ASL-SF-F
with ASL-SF-R) for 38 cycles (42 cycles for primer ASL-SF-F
with ASL-SF-R) using HOT FIREPol DNA polymerase (Solis
Biodyne, Tartu, Estonia) orHotStarTaqDNAPolymerase (Qia-
genGmbH,Hilden, Germany) prior to gel electrophoresis. PCR
products representing probable splice variants were confirmed
by sequencing using the BigDye Terminator cycle sequencing
kit version 1.1 (ABI sequence, Applied Biosystems). Patients or
their legal guardians had consented to the use of the cultured
skin fibroblasts for research purposes when the skin biopsy was
taken, and cDNA samples were anonymized prior to their use
in this study.
Patient Characteristics and RNA Studies
The 19-year-old male patient, offspring of non-consanguin-
eous parents, was first identified at the age of 13 years withmild
hyperammonemia (250 mol/liter, normal 50), confusion,
and irritability during an episode of gastroenteritis. The diag-
nosis of ASA was made based on characteristic urine metabo-
lites and underlined by typical signs and symptoms such asmild
hepatomegaly but normal liver function, trichorrhexis nodosa,
cognitive impairment (IQ 67), and a natural avoidance of pro-
tein-rich food since early childhood. In addition, there was per-
sistent mild elevation of plasma citrulline (between 80 and 150
mol/liter, normal60). Under treatmentwith L-arginine (150
mg/kg/day) and mild protein restriction, he had been stable
since age 13 apart from a single mild metabolic decompensa-
tion at age 17 years, again during gastroenteritis withmaximum
ammonia (230 mol/liter).
To confirm the diagnosis, DNA sequencing of the ASL gene
by standard methods (6) as well as array comparative genomic
hybridization (38) for exclusion of a deletion on the second
allele revealed only a single heterozygous mutation in exon 7
(c.566A3G, p.E189G), which was not present on the maternal
allele (also, no othermutation was found in themother in DNA
or RNA), whereas the mutation was found in a heterozygous
state in paternal DNA. To identify the second mutant allele,
RT-PCR was performed using RNA (PrimeScript II 1st Strand
cDNA Synthesis kit, TaKaRa Bio) derived from a 3-day full
blood culture treated with phytohemagglutinin and cyclohexi-
mide (39). For control RT-PCR, cDNAs derived from lympho-
cytes, liver, and fibroblasts were used. The patient’s cDNA was
amplified in full-lengthASLaswell as ina short fragmentcompris-
ing exons 1–9, as described above. In addition, primers ASL-SF-F
andASL-SF-R7 (5-ctccccaggggcaggacattg-3) (reverse, derived
from ASL exon 7 sequence) were used for amplification of a
short fragment containing exons 1–7 (fragment size of 670 bp)
FIGURE 1. Involvement of argininosuccinate lyase in various metabolic
andbiochemical pathways. Shown is a schematic illustration of the involve-
ment of ASL in various metabolic and biochemical reactions. Colors are used
to show the affiliation of metabolites and enzymes to different pathways:
urea cycle (blue), nitric oxide synthesis (gold), polyamine synthesis (maroon),
and creatine synthesis (purple). Enzymes aredepicted inovals: argininedecar-
boxylase (ADC), arginine:glycine amidinotransferase (AGAT), arginase (ARG);
argininosuccinate lyase (ASL), argininosuccinate synthetase (ASS), carba-
moylphosphate synthetase 1 (CPS1), guanidinoacetate methyltransferase
(GAMT), nitric-oxide synthase (NOS), ornithine decarboxylase (ODC), and orni-
thine transcarbamylase (OTC).
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to confirm mutation c.566A3G in this transcript. PCR prod-
ucts were sequenced as described above.
In another patient (aged 12 years) with late onset ASA and a
similar clinical and biochemical situation, the mutation
p.E189G was found in a heterozygous state, and the same DNA
and RNA investigations were performed as above. To estimate
expression levels of transcripts, densitometry analysis of RT-
PCR products on gel electrophoresis and of bands detected by
Western blotting was performed by using CarestreamMolecu-
lar Imaging software (Carestream Health). The genetic studies
were done after written informed consent of the patient and his
legal guardians was obtained.
Generation ofWild Type, Mutant ASL p.E189G, and Exon 2- or
7-deleted Splice Variant Constructs
Full-length ASL cDNA (1395 bp) and ex7del ASL transcript
variant (1317 bp) were cut from pCR2.1 carrying the WT ASL
(33) and pCMV6-XL4 carrying the ex7del ASL cDNA (Ori-
Gene, Rockville, MD) using restriction enzymes BamHI and
NotI (both from New England Biolabs (Beverly, MA)), respec-
tively. Restriction products were cloned into the expression
vector pcDNA3 (Invitrogen), yielding pcDNA3-ASL-WT
(P-WT) and pcDNA3-ASL-ex7del (P-ex7del), respectively.
Oligonucleotides ASL-ex2del-F (5-atccggatccatggcctcggag-
gtggctgaggagtgggcc-3) (forward, consisting of a BamHI site,
the 12 nucleotides of ASL exon 1, and 18 nucleotides from 5
exon 3) and ASL-ex2del-R (5-cctctagatgcatgctcgagcggccgc-
tatatctaggc-3) (reverse, with a NotI site added to an ASL
3-UTR sequence) were used to amplify the exon 2-deletedASL
cDNA fromP-WT.The obtained PCRproduct was gel-purified
and cloned into the above expression vector, yielding pcDNA3-
ASL-ex2del (P-ex2del). The mutant p.E189G (c.566A3G) was
constructed as pcDNA3-ASL-E189G (P-E189G) based on P-WT
by site-directed mutagenesis (Phusion Site-directed Mutagenesis
Kit, Finnzymes (Espoo, Finland)) according to themanufacturer’s
protocol.All establishedconstructswereconfirmedbysequencing
as above.
Expression and Co-expression of ASL Constructs in Human
Embryonic Kidney 293T Cells
Three different mammalian cell lines (COS-1, HeLa, and
293T) were tested for their background ASL activity before
establishing the eukaryotic ASL expression system. ASL
expression levels after transfection with P-WT were deter-
mined by Western blot. Cells were grown in Dulbecco’s
modified Eagle’s medium  GlutaMAX (DMEM, Invitrogen)
supplemented with 10% fetal bovine serum (FBS) and 1% anti-
biotic/antimycotic solution (both from PAA (Pasching, Aus-
tria)) and maintained in an incubator containing 5% CO2 at
37 °C in a humidified atmosphere.
Based on the lowest ASL background activity, 293T cells
were considered as ideal for the ASL expression system in this
study. The cells were transiently (48 h) transfected with a total
of 7g of the construct P-WT, P-ex2del, or P-ex7del in 60-mm
dishes using LipofectamineTM LTX and PLUSTM reagents
according to the manufacturer’s instructions (Invitrogen). A
total of 7 or 10.5 g of plasmids was used for co-transfection
with two or three plasmids; if not indicated otherwise, we used
the same amount of the respective constructs (3.5 g each) in
co-transfectants. For the co-transfection of P-WTandP-ex2del
at different ratios, 1.75g of P-WT and 1.75g of P-ex2del was
used for the ratio 1:1; 1.75 g of P-WT and 3.5 of g P-ex2del
for 1:2; 1.75 g of P-WT and 8.75 g of P-ex2del for 1:5; 3.5 g
of P-WT and 1.75 g of P-ex2del for 2:1; and 8.75 g of P-WT
and 1.75g of P-ex2del for 5:1. The empty vector (EV) pcDNA3
was used either as negative control or to set up the same
amounts of total plasmids for co-transfection.
RNA was isolated from the cells transiently transfected with
P-WT, P-ex2del, or P-ex7del, respectively, using the QIAamp
RNA bloodminikit according to themanufacturer’s protocol
(Qiagen GmbH, Hilden, Germany). The concentration of
nucleic acids was determined by a NanoDrop spectrophotom-
eter. RT-PCR was performed as a standard protocol using
primers ASL-SF-F3 (5-atccacacagccaatgagcgc-3) (forward,
derived from ASL exon 3 sequence) and ASL-SF-R for amplifi-
cation of a short fragment containing exons 4–9 with a frag-
ment size of 535 bp.
Protein Extraction,Western Blot Analysis, and
Immunoprecipitation
Cells were harvested and lysed in Lubrol WX lysis buffer
containing 0.15% (w/v) of LubrolWX (Sigma) and 10 mM Tris-
HCl (pH 8.6). Human liver tissue (n  3, shock-frozen needle
biopsy samples for diagnostic purposes in non-ASLD patients
after informed consent for scientific use was obtained) was
homogenized in complete Nonidet P-40 (Roche Applied Sci-
ence) lysis buffer containing 1%Nonidet P-40, 50 mMTris-HCl
(pH 8), 125mMNaCl, 1mM EDTA, and protease inhibitors (1
Complete EDTA-free  1 mM of PMSF) (Roche Applied Sci-
ence) in a prechilled glass grinder by quickly grinding on ice.
Cell lysates and liver homogenates were then centrifuged at
maximum speed at 4 °C for 15 min. Protein concentrations in
the supernatants (equivalent to cell extracts) were determined
by themethod of Lowry (40) using bovine serumalbumin (BSA)
as a standard.
Western blotting was performed as described previously
(41). 30g of total protein of cell extracts was separated by 10%
denaturing SDS-PAGE or native PAGE (without SDS in the
Laemmli loading buffer and electrophoresis buffer), and subse-
quently transferred to nitrocellulose transfer membranes
(Whatman GmbH, Dassel, Germany). The primary polyclonal
antibody anti-ASL (GeneTex, Irvine, CA), recognizingASL res-
idues 13–261 according to the manufacturer, was used at a
dilution of 1:1000, and the horseradish peroxidase (HRP)-con-
jugated secondary antibody anti-rabbit (Santa Cruz Biotechnol-
ogy, Inc.)was used at a dilutionof 1:5000.Antibodies against-ac-
tin or glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(both from Santa Cruz Biotechnology) served as loading controls.
Protein detection was done using ECL reagents (GE Healthcare)
for chemiluminescent labeling.
Fibroblasts derived from three ASA patients as well as one
control were cultured under the same conditions as for 293T
cells. Immunoprecipitation analysis was done as a standard
protocol using 5 mg of total protein of fibroblasts, followed by
Western blot analysis as described above. HRP-conjugated
mouse anti-rabbit IgG (L27A9, Cell Signaling Technology, Inc.
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(Danvers, MA)), which does not recognize the denatured and
reduced rabbit IgG heavy or light chains on Western blot, was
used as secondary antibody at a working dilution of 1:2000.
Measurement of ASL Enzymatic Activity
The ASL enzyme activity was determined spectrophoto-
metrically in cell extracts after transient transfection or co-
transfection of P-WT, P-ex2del, and/or P-ex7del, using a cou-
pled assay with arginase and measuring urea production as
described before (33). Briefly, 100 l of 34 mM argininosucci-
nate (argininosuccinic acid disodium salt hydrate) in water and
100 l of arginase (50 units) (both from Sigma-Aldrich) in 66.7
mM phosphate buffer (11.1 mM potassium dihydrogenphos-
phate and 55.6mM disodiumhydrogenphosphate, pH 7.5) were
incubated at 37 °C for 5min. Then 40l of cell extract (3–14g
of total protein) and 10 l of phosphate buffer were incubated
with the above reagents at 37 °C for 30 min. The reaction was
stopped by adding perchloric acid at a final concentration of
2%. The ASL enzyme activities are given as mIU/mg total pro-
tein. The residual ASL activities of splicing variants were deter-
mined as a percentage of ASL-WTorASL-WTwith EV activity
(percentage) in each (co-)transfection under the same condi-
tions, respectively. All assays were carried out in triplicate for at
least three independent co-transfection experiments.
StructureModeling
Three-dimensional Protein Model and in Silico Mutagenesis
of ASL—The tetrameric three-dimensional structural model of
ASL (NCBI NP_000039.2, Uniprot P04424) sequence (amino
acids 1–464) was built using the ASL structure (PDB entry
1K62) as template.Model buildingwas performedwith the pro-
grams YASARA (42) and WHATIF (43). Side chains in newly
built parts were optimized by MD simulations. The geometry
information for the tetramer was extracted from the original
crystallographic data. The final model was refined by a 1000-ps
(MD) simulation using anAMBER2003 force field and checked
with the programs WHAT_CHECK (44), WHATIF (43), and
Verify3D (45, 46) and Ramachandran plot analysis (47, 48). To
create the exon 2 and exon 7 deletions, we first made the
FASTA sequence files of modified proteins and performed
model building using both the monomer and tetramer struc-
tures and performed refinements as described for WT protein.
Structureswere depictedwith PyMOL (Schro¨dinger, LLC,New
York). Structural properties of the proteins were calculated by
YASARA and WHATIF, and general protein parameters were
calculated with ExPASy protein tools (available from the
ExPASy Web site).
Molecular Dynamics Simulation forModel Refinement—The
MDsimulationswere performed using anAMBER03 force field
(42). The simulation cell was filled with water, pH was fixed to
7.4, and the AMBER03 (49) electrostatic potentials were evalu-
ated for water molecules in the simulation cell and adjusted by
the addition of sodium and chloride ions. The final MD simu-
lations were then run with the AMBER03 force field at 298 K,
0.9%NaCl, and pH7.4 for 1000 ps to refine themodels. The best
models were selected for analysis and evaluation of the effect of
exon deletions on monomer and tetramer structures.
Statistics
Statistical analyses were done using percentages of ASL-WT
activities by one-way analysis of variance with the program
GraphPad Prism 4 (GraphPad Software, San Diego, CA) to
describe the differences of ASL activities between cells co-ex-
pressing ASL-WT with EV and cells co-expressing ASL-WT
with the transcript variants. Differences were considered as sig-
nificant if the p value was0.05.
RESULTS
Expression of Wild Type ASL and of Transcript Variants in
Different Tissues—To investigate whether the expression of
ASL transcript variants is tissue-dependent and to confirm the
reported occurrence of transcripts with deletions of exon 2 or 7
(5, 36, 37), we amplified ASL cDNA either in full-length cDNA
(data not shown) or in short cDNA fragments comprising exons
1–9 from 17 different human tissues (only 16 tissues shown in
Fig. 2A) and a series of 24 skin fibroblast cell lines from ASA
patients representing 10 different genotypes (Fig. 2B). In all
tissues, WT ASL cDNA (short fragment with 864 bp) could be
detected, and in addition, in most tissues shorter transcript
variants (786 and 669 bp) could be detected (Fig. 2, A and B).
ASL-WT cDNAwas predominantly found in liver (Fig. 2A, lane
5) and kidney (Fig. 2A, lane 7), but expression was detected in
all tissues. Furthermore, a similar expression pattern of ASL
transcript variants was detected at a low level in all cDNAs
investigated for short fragments (Fig. 2, A and B). Sequencing
analysis of the shorter fragments identified them as exon 2-de-
leted (669 bp) or exon 7-deleted (786 bp) transcripts.
RNA Studies Reveal Predominant Expression of Exon 7-de-
leted ASL Transcript Variant in ASA Patients—In RNA from
both patients, ASL-ex7del variant (786 bp) was predominantly
expressed (Fig. 2,C (lanes 2 and 3) andD (lane 16)). Estimation
of expression levels by densitometry yielded similar levels of the
mutant variant (114% for Fig. 2C (lane 2) and 83% for Fig. 2C
(lane 3)) when compared withWTASL (864 bp) in lymphocyte
control (Fig. 2C (lane 4), set to 100%) but much higher levels
(330% for Fig. 2C (lane 2) and 182% for Fig. 2C (lane 3)) if
compared with the full-length band in the same patients (Fig.
2C (lanes 2 and 3), set to 100%). Notably, the full-length band
was expressed much less (34% for Fig. 2C (lane 2) and 46% for
Fig. 2C (lane 3)) comparedwithWT in lymphocyte control (Fig.
2C (lane 4), set to 100%). Expression levels of transcript variants
in controls (Fig. 2,C (lane 4) andD (lanes 1–15)) and also in the
patient’s mother (Fig. 2, C (lane 1) and D (lane 17)) were much
lower in all tissues compared with WT (lymphocytes 9%, liver
6%, and fibroblasts 10%, as shown in Fig. 2D, lanes 1–5, 6–10,
and 11–15, respectively). Sequencing confirmed that the vari-
ants represented ex2del or ex7del transcripts. To facilitate fur-
ther sequencing, only a small fragment comprising exons 1–7
was amplified using a reverse primer derived from exon 7.
Hereby, the mutation c.566A3G was confirmed in a hemizy-
gous state in one patient (Fig. 2, C (lane 2) and E) and in a
heterozygous state in the other patient (Fig. 2,C (lane 3) and F).
Endogenous ASL Expression inMammalian Cell Lines and in
Human Liver—To establish anASL expression system inmam-
malian cells lacking endogenous but allowing for high ectopic
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ASL expression, we transiently transfected P-WT as well as EV
pcDNA3 into COS-1, 293T, andHeLa cells, respectively.West-
ern blot analysis indicated that 293T cells fulfilled the above
criteria in an optimal way, whereas COS-1 cells showed endog-
enousASL expression andHeLa cells failed to expressASL after
transfection (Fig. 3A). These results were further confirmed by
analysis of ASL activity (ASL endogenous activity in 293T cells
shown in Table 1).
Although ASL splice variants (ASL-ex7del and ASL-ex2del)
were present in all cDNAs from various tissues (Fig. 2, A–D),
there was no corresponding signal detected when human liver
homogenates from controls were investigated by Western blot
analysis (Fig. 3B). Likewise, immunoprecipitation did not yield
a detectable WT signal when patient and control fibroblasts
were used (data not shown). This points toward and is probably
explained by the low level of ASL expression in this cell type,
which is obviously not suited for further investigation of ASL
wild type and mutants on the protein level.
Expression andCo-expression of ASLWildType,Mutant, and
Transcript Variants in 293T Cells—To study the role of natu-
rally occurring ASL splice variants in wild type as well as in
mutant p.E189G, we first introduced diverse ASL recombinant
constructs P-WT, P-E189G, P-ex2del, and P-ex7del into 293T
cells to (co-)express ASL WT or mutant p.E189G, ex2del, or
ex7del ASL, respectively. At the protein level, expression of
ASL-WT or ASL-ex2del was detected either as monomers (Fig.
3, C (top, lanes 3 and 4) andD (top, lanes 1 and 5), respectively)
or as homotetramer (Fig. 3,C (middle, lanes 3 and 4) and E (top,
lanes 1 and 5), respectively). Moreover, ASL-ex2del could also
be co-expressed with ASL-WT as well as with mutant p.E189G
(Fig. 3,D–G). Densitometry analysis of the detectable bands by
Western blotting showed that ASL-WT was less expressed in
cells co-expressed with transcript variants (71.7% in co-trans-
fectant with ASL-ex2del (Fig. 3D, lane 2), 88.7% in co-transfec-
tant with ASL-ex7del (Fig. 3D, lane 3), and 71.2% in co-trans-
fectant with ASL-ex2del and ASL-ex7del in Fig. 3D (lane 4); all
done after normalization according to expressed loading con-
trol GAPDH, respectively) compared with co-expression with
EV (Fig. 3D (lane 1), set to 100%). Additionally, ASL-ex2del was
expressed at higher levels (55.4, 53.6, 60, or 61%) than ASL-WT
(44.6, 46.4, or 40%) or mutant p.E189G (39%) (cells co-trans-
fected with ASL-ex2del and ASL-WT (Fig. 3, A (lanes 2 and 4)
and G (lane 4)) and cells co-transfected with ASL-ex2del and
p.E189G in Fig. 3G (lane 6)). However, ASL-ex7del was not
found (Fig. 3, C (lane 5), D, E (top, lane 6), and G (lane 9),
respectively), although ASL-ex7del-RNA derived from cells
transfected with P-ex7del could be detected by RT-PCR (data
not shown). These results suggest that deletion of ASL exon 2
results in a truncated but stable ASL protein, whereas deletion
of ASL exon 7 probably leads to an unstable protein.
Structure of ASL Monomers and Homotetramer—To study
the structural implications of exon 2 and 7 deletions, we made
computational structural models of exon-deleted ASL variants
based on known structures of ASL available from the RCSB
database.We first performed a PhiBlast search of the PDBdata-
basewith themodified amino acid sequences to create a custom
position-specific scoring matrix that was then used in further
runs of PhiBlast searches to identify structurally similar
FIGURE 2.Occurrence of transcript variants of theASLgene in different tissues. PCR products representing short fragments of ASL cDNA from16 different
tissues (A), from cultured skin fibroblasts derived from12ASA patients (B), from lymphocytes derived from twoASA patients and one patient’smother (C), and
from controls’ lymphocytes, livers, and fibroblasts as well as lymphocytes derived from one ASA patient and his mother (D). A, lane 1, skin fibroblast; lane 2,
brain; lane 3, placenta; lane 4, lung; lane 5, liver; lane 6, skeletalmuscle; lane 7, kidney; lane 8, pancreas; lane 9, spleen; lane 10, thymus; lane 11, prostate; lane 12,
testis; lane 13, ovary; lane 14, small intestine; lane 15, colon; lane 16, peripheral leukocytes. B, lanes 1–12 (obtained from three different investigations), skin
fibroblasts from12ASApatientswith 10 different genotypes.C, lane 1, mother of patient in lane 2; lanes 2 and 3, twoASApatients; lane 4, control.D, lanes 1–15,
five controls’ lymphocytes (lanes 1–5), livers (lane 6–10), and fibroblasts (lanes 11–15); lane 16, lymphocytes from one patient (same patient as in Fig. 2C, lane
2); lane 17, lymphocytes from mother of patient in lane 16 (same as in Fig. 2C, lane 1). E, sequencing chromatogram of PCR product from lane 2 in Fig. 2C. F,
sequencing chromatogram of PCR product from lane 3 in C.M, peqGOLD 100-bp DNA ladder plus (Peqlab, Erlangen, Germany);M, 100-bp DNA ladder (Solis
BioDyne, Tartu, Estonia). Gel electrophoresis was done in 1% agarose.
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sequences. Then a secondary structure prediction of the origi-
nal WT sequence was used to perform the structure-based
alignment of the sequences (Fig. 4). Aligned sequences were
loaded in the programs YASARA andWHATIF for generating
structuralmodels. Some of the loops in exon-deleted sequences
were modeled separately by scanning a library of loop data-
bases. For our model building, we used the information avail-
able in the PDB_REDOdatabase,which re-refines the old struc-
tures in the PDB database using the latest methods based on
original structural data deposited in the PDB and corrects the
errors in structures found in the PDB database. This is achieved
by employing current state of the art refinement methods and
software to the older crystallographic data. For the ASL struc-
ture (PDB code 1K62), the overall Ramachandran plot appear-
ance improved from2.514 to0.803 for the optimized entry,
and the total number of bumps/structural clashes was reduced
from 150 in the original entry to 54 in the optimized structure,
-1/-2 rotamer normality improved from 2.186 to 0.576,
first generation packing quality improved from 0.148 to 0.466,
backbone conformation improved from0.369 to0.168, and
the R-free value changed from 0.2290 to 0.1909 in the fully
optimized version used by us.
TheASL structure is composed of residues 5–464 of theASL
protein. The enzymatically active ASL tetramer is formed by
four identical subunits of ASL, comprising mainly  helices,
and contains three structurally distinct domains. Domains 1
and 3 have similar topology and contain two helix-turn-helix
motifs, whereas domain 2 has nine helices, of which five helices
form the core monomer structure in an up-down-up-down-up
sequence (Fig. 5A). Two sets of dimers come together in an
antiparallelmanner to form the tetramer (Figs. 5A and 6A). The
core of the homotetramer is composed of a four-helix bundle,
with each monomeric subunit contributing one helix to the
central core, and the tetramer is held together by hydrophobic
FIGURE 3. Expression or co-expression of ASL wild type and transcript variants in different mammalian cell lines and human livers. Western blot
analysis of ASL expression in cell extracts of COS-1, 293T, and HeLa cells (A); in human livers (B); or in transfected 293T cells (C–G). 30 g of total protein was
separated by 10% SDS-PAGE (A, B, D, F, G, and top panel in C) or by native PAGE (E andmiddle panel in C) for analyzing ASL expression. A, NT, non-transfected;
wt, pcDNA3-ASL-WT (P-WT). B, lanes 1–3, human liver samples from three controls. C, ASL expression in 293T cells non-transfected (NT) or transfected with EV,
P-WT, pcDNA3-ASL-ex2del (P-ex2del), or pcDNA3-ASL-ex7del (P-ex7del), respectively.D, (co-)expression of ASLmonomers in 10%SDS-PAGE (ASL-WT, 52 kDa;
ASL-ex2del, 45 kDa). Lane 1, P-WTwith EV; lane 2, P-WTwith P-ex2del and EV; lane 3, P-WTwith P-ex7del and EV; lane 4, P-WTwith P-ex2del and P-ex7del; lane
5, P-ex2del; lane 6, P-ex7del; lane 7, EV. E, (co-)expression of ASL homotetramers in 10% native PAGE (ASL-WT,200 kDa; ASL-ex2del,180 kDa). Lanes 1–7,
same as inD. Asterisks, nonspecific bands. F, ASL expression in 293T cells co-transfectedwith P-WT and P-ex2del at different ratios. Lane 1, P-WT (1.75g); lane
2, 1:1; lane 3, 1:2; lane 4, 1:5; lane 5, P-WT (3.5 g); lane 6, 2:1; lane 7, P-WT (8.75 g); lane 8, 5:1; lane 9, ASl-ex2del (3.5 g). G, (co-)expression of ASL mutant
p.E189G (P-E189G) with transcript variants. Lane 1, P-WT with EV; lane 2, P-E189G with EV; lane 3, P-WT with P-E189G; lane 4, P-WT with P-ex2del; lane 5, P-WT
with P-ex7del; lane 6, P-E189Gwith P-ex2del; lane 7, P-E189Gwith P-ex7del; lane 8, P-ex2del; lane 9, P-ex7del.Asterisks, nonspecific bands.-Actin (42 kDa) and
GAPDH (37 kDa) served as loading control.
TABLE 1
Residual ASL activities in 293T cells (co-)transfected with recombinant ASL-WT and transcript variants
Data were obtained under standard conditions (13.6 mM argininosuccinate) after at least three independent experiments. ASL activity in cells (co-)expressing ASL-WT or
ASL-WTwith EV is set to 100% in each transfection (7g of plasmid) or co-transfection (total 10.5g of plasmids, each 3.5g) under the same condition, respectively. NT,
non-transfected cells; EV: empty vector.
293T whole cell
extracts NT EV ex2del ex7del WT WT EV
WT EV
ex2del
WT EV
ex7del
WT ex2del
ex7del
ex2del
ex7del EV
ASL activity in mIU/mg
total proteina
1.2 1.9 1.6 2.2 3.2 3.0 1.9 1.4 830.2 78.8 520.1 297.5 307.5 151.4 466.1 232.7 305.3 201.7 3.2 1.5
ASL activity in % of
ASL-WTa
0.4 0.4 0.3 0.2 0.5 0.4 0.4 0.2 100.0 7.8 100.0 2.6 62.5b 7.2 94.2 9.4 55.5b 7.2 0.7 0.3
aMean S.D. (in triplicate).
b Significant difference compared with ASL-WT activity (p 0.05).
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interactions between the four central helices as well as ionic
interactions between arginines and glutamic acid residues on
two distinct dimeric structures.
Role of Exon 2 Residues—The amino acid residues contrib-
uted by exon 2 (residues 5–69) form the N terminus of the ASL
protein (Figs. 4 and 5A) and are needed for the enzymatic activ-
ity because the previously described R12Q mutation in exon 2
has been shown to result in loss of activity. Two of the helices in
domain 2 of ASL monomeric structure are formed by residues
from exon 2 and are missing in the ex2del variant of ASL (Fig.
5B). Most of the N-terminal chain in the ASLmonomer is flex-
ible, and duringmolecular dynamic simulations, it was found to
fluctuate during the whole run, indicating a dynamic arrange-
ment in both the monomeric and tetrameric form. There were
FIGURE 4. Positions of exons 2 and 7 in secondary structure of the ASL protein. The helices are in yellow, sheets in green, and turns in cyan; exons 2 and 7
are depicted inmagenta. Amino acids are colored based on their chemical properties with aspartic and glutamic acid in red, arginines and lysines in blue, and
aromatic amino acids in green.
FIGURE 5.Monomeric structure of wild type and models of ASL exon 2- or exon 7-deleted transcript variant. A, monomeric structure of WT ASL. ASL
monomer has three distinct subdomains, domains 1 and 3 have similar structure and topology with two helix-turn-helix motifs in a perpendicular arrange-
ment. Domain 2 has nine helices, and five of them form the central five-helix bundle with up-down-up-down-up topology. B, monomeric structural model of
ex2del ASL. Two critical helices that are part of domain 1 (indicated by a black arrow) and contribute to the active site are missing in the ex2del variant of ASL.
C, monomeric structural model of ex7del ASL. Exon 7 residues are part of domain 2 in the ASL monomer comprising the central five-helix bundle. Deletion of
exon 7 results in a disordered central core with one of the five central helices partially replaced by an unstructured loop (indicated by a black arrow). N, N
terminus; C, C terminus.
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few contacts between the N-terminal loops of any individual
subunit and other subunits in the tetrameric structure, indicat-
ing that it probably does not influence tetramer formation. The
role of N terminus residues on the catalytic activity is not clear,
but one side of the active site is covered by these residues (Fig. 6,
B and C). The flexible nature of amino acids 5–18 suggests that
although exact conformation of the N terminus does not influ-
ence the overall tetrameric structure or active site of the
enzyme (Fig. 6, B and C), the structural requirements for sub-
strate binding and retention in the active sitemay depend on an
intact N terminus. Residues 23–32 of the ASL have been pro-
posed to be important for substrate binding (50, 51).
From our computational analysis, we found that exon 2-de-
leted protein can form a stable monomer (Fig. 5B) and homo-
tetramer (Fig. 6D), which was confirmed by Western blots
showing a smaller sized complex from the cell-based assays
(Fig. 3, C–G). However, such a homotetramer will be devoid of
activity due to loss of N-terminal residues needed for substrate
binding. Therefore, although an exon 2-deleted transcript of
ASL is still capable of expressing a stable monomer that can
form a tetrameric complex, the loss of residues involved in
catalysis means that such a complex cannot be enzymatically
active. It is possible that ASL-WT and ex2del monomers can
form heterotetramers with different combinations of the two
FIGURE 6. Tetrameric structure of wild type andmodels of ASL exon 2- or exon 7-deleted transcript variant. A, tetrameric structure of WT ASL showing
the positions of active site histidine 160 and exons 2 and 7. The structure is shown as a ribbonmodel in light blue; amino acids contributed by exon 2 are colored
in red, whereas aminoacids contributedbyexon7are colored inmagenta. Theactive site residues are colored ingreenwithHis-160at the catalytic center shown
a spheremodel. B, location of exon 2 in relation to the active site. In the ASL homotetramer, active site residues are contributed by three different subunits. The
ASL structure is shownas a ribbonmodelwith different subunits colored in green, cyan,magenta, and yellow. The green and cyan subunits formadimer and join
with another dimer formedbymagenta and yellow subunits to form the tetramer. Active site residues fromoneof the sites are shown as solid surfaces, whereas
the catalytic center (His-160) is shown as spheres. Residues contributed by exon 2 are shown in red.C, role of theN terminus tail in stabilizing the active site. The
ASL homotetramer is shown as a solid surface model with different subunits colored in green, cyan,magenta, and yellow. Residues contributed by exon 2 are
shown in red. The N terminus tail surrounds the active site and provides the stability required for binding of substrate. D, conjectural prediction of exon
2-deletedASLbasedonhomologymodeling. The core structureof theASLhomotetramer can still be formed in theabsenceofN terminus residues contributed
by exon 2. The model of the ex2del tetrameric complex is similar to the WT ASL, and the central four-helix bundle comprising the tetramer remains intact,
resulting in a stable structure. However, the loss of the N terminus required for substrate binding will result in an enzymatically inactive protein. E, theWT ASL
tetramer structure showing the locations of residues contributed by exon 7. The homotetramer structure is shown as a ribbon model with different subunits
colored in green, cyan,magenta, and yellow. The amino acids contributed by exon 7 are shown as surface models in two of the adjacent dimeric structures that
form the tetramer. Chains shown in green and yellow are from two different dimers that join together to form the tetramer. The His-160 residue at the catalytic
center is shown as spheres. F, a space-filled surface model of homotetrameric ASL structure showing the role of exon 7 in tetramer formation. Interactions
between charged residues on adjacent dimeric ASL subunits stabilize the tetrameric structure.G, a structuralmodel of exon 7 deleted variant of ASL transcript.
One subunit of the exon 7-deleted variant is superimposed on theWT ASL homotetramer to show the structural differences. The protein is shown as a ribbon
model with the exon 7-deleted variant colored in gray, whereas WT subunits in the tetramer are colored in green, cyan, magenta, and yellow. The residues
involved in charge-based interaction located on two adjacent subunits in the WT protein are shown as sticks in the larger oval red dotted box. The secondary
structure elements altered in the exon 7-deleted variant are marked in a smaller oval box. H, a close-up of the structural changes resulting from the exon 7
deletion. The exon 7-deleted variant (gray) and WT (green) are superimposed, and residues contributed by exon 7 in the WT protein are shown in red. Two of
the central helices in theWT protein are altered to flexible loops in the exon 7-deleted variants, resulting in an unstable protein due to the requirement of core
helices in domain 2 of the ASL monomers for overall stability. The resultant protein was found to be highly unstable and unlikely to participate in tetramer
formation.
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transcript variants. Because the active site of the ASL protein is
formed by contributions from three different monomeric sub-
units, each unit of exon 2-deleted transcript variants in the het-
erotetramer will result in loss of one active site, without com-
promising the overall structure. Because the N-terminal
residues affected by deletion of exon 2 do not participate in the
formation of ASL dimers, we propose that a combination of
WT, ex2del, and WT-ex2del versions of the dimers is gener-
ated, which will then further oligomerize to form the tetra-
meric structures. WT and ex2del variants of the monomers
may have a preference for similar sized proteins and only
form homodimers, which will result in at least two functional
active sites in a 2:2 heterotetramer. Functional data from cell-
based assays that show that even a 1:5 combination of
WT-ex2del ASL retained about 30% activity (Fig. 7C) seem to
support this model. A combination of WT-ex2del dimers may
also give similar activities.
Role of Exon 7 Residues—Residues 175–200 are contributed
by exon 7 in theWTASL transcript. Exon 7-deleted variant was
found to be capable of forming a monomeric structure still
composed of three distinct domains, similar to that ofWTASL
(Fig. 5C). Although the core of the homotetramer of ASL is
formed by  helices of monomers formed by residues 291–314,
we found ionic interactions between adjacent dimeric subunits
in the tetramer to stabilize the structure (Fig. 6, E and F). From
the molecular dynamic simulations and structural analysis, we
found that charge pair interactions between Arg-193 on one
subunit and Glu-189 and Glu-185 of another adjacent subunit
in the tetramer stabilize the structure (Fig. 6G). The loss of ionic
interactions contributed by exon 7 residues will result in an
unstable tetramer. Computational potential energy of WT and
ex7del tetramers supported this theory with an increase in
potential energy for the ex7del tetramer (76,378 kJ/mol for
ex7del compared with 95,229 kJ/mol for WT) (Table 2).
Moreover, a change in core structure of the monomers was also
observed with the loss of two central helices and formation of a
structurallyunstable loop in themiddleof thehelical core (Figs. 5C
and6,GandH). Suchachange is likely to impact the stabilityof the
monomersandmayresult inanunstableprotein thatwill probably
be degraded, especially in the absence of a stable tetrameric com-
plex. Significantly, due to this unstructured loop formation, the
accessible surface area of the ex7del variant increased significantly
(65,259 Å2 compared with 53,534 Å2 for the WT), whereas the
solvent-accessible surface remainedsimilar (326,476Å3compared
with 322,934 Å3 for theWT), which further points toward struc-
tural instability of ex7del variant (Table 2). This was also further
supported by Western blots showing no detectable ASL-ex7del
expression (Fig. 3,C–E andG).
FIGURE 7. Analysis of recombinant ASL activities. Shown is ASL enzymatic activity analysis in non-transfected or (co-)transfected 293T cell extracts. Each
4.8–14 g of total protein of cell extracts was used for the enzyme assay. The residual ASL activities are represented as a percentage of ASL-WT activity
(percentage of ASL-WT or of ASL-WT with EV). A, 293T cells were transiently transfected with 7 g of P-WT (wt), P-ex2del (ex2del), or P-ex7del (ex7del),
respectively.NT, non-transfected. Non-transfected cells and those transfectedwith EV served as negative control. B, 293T cells were transiently co-transfected
with 10.5g of total plasmids at a ratio of 1:1 (each 3.5g) of P-WT to P-ex2del or P-ex7del plasmid, respectively. C, 293T cells were transiently co-transfected
with 7 g of total plasmids at a ratio of 1:1 (each 3.5 g) of P-WT to P-ex2del or P-ex7del and of P-E189G to P-ex2del or P-ex7del plasmid, respectively. D, ASL
enzymatic activity in 293T cell extracts co-transfected with P-WT and P-ex2del at different ratios. 3–12 g of cell extracts was used for ASL enzyme analysis
depending on the amount of P-WTused for the co-transfections. For co-transfections, different ratios of ASL-WT to ex2del splice variant (1:1, 1:2, 1:5, 2:1, or 5:1)
were used, respectively. The residual activity of each co-transfectant comparedwith ASL-WT under the same condition is indicated as a percentage of ASL-WT
activity (percentage of ASL-WT co-transfected with EV to use identical amounts of total plasmids and of P-WT for all experiments). EV was used to set up the
same amount of total plasmids for the co-transfections. Levels of significance are given as p values obtained by one-way analysis of variance using GraphPad
software from triplicate measurements of at least three independent experiments, respectively. Differences were considered as significant if the p value was
0.05. Error bars, S.D.
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Residual ASL Enzymatic Activities in (Co-)transfected 293T
Cell Extracts—To determine whether the expressed ASL splice
variants have any residual enzyme activity, we performed ASL
enzyme activity assays with the cell extracts used for Western
blot analysis (summary of data in Table 1, Table 3, and Fig. 7).
There was no relevant background activity in cells transfected
with the empty vector or non-transfected cells (Fig. 7A, col-
umns 1 and 2, respectively). No significant residual activity was
detected in exon 2- and exon 7-deleted ASL splice variants (Fig.
7A, columns 3 and 4, respectively), whereas ASL-WT transfec-
tion yielded high enzymatic activity (Fig. 7A, column 5).
To study the effect of ASL splice variants on the function of
the ASL homotetramer and the possibility of a heterotetramer
formation with reducedASL activity thatmay contribute to the
biochemical and clinical variability in ASA patients, we mea-
sured the ASL activity after co-transfections. The residual ASL
activities in cells co-expressing P-WT and P-ex2del (Fig. 7, B
and C, column 2) or co-expressing P-WT, P-ex2del, and
P-ex7del (Fig. 7B, column 4) showed a significant decrease to
62.5  7.2 or 55.5  7.2% (mean  S.D.), respectively, of cells
co-transfected with P-WT and EV (Fig. 7, B and C (column 1),
and Table 1). Cells co-transfected with P-WT and P-ex7del
(Fig. 7,B andC, column 3) displayed no decrease of ASL activity
(94.2  9.4% of ASL WT). Cells co-transfected with P-ex2del
and P-ex7del (Fig. 7B, column 5) showed no relevant residual
ASL activity. Furthermore, the reduced level of residual ASL
activities exhibited no significant difference between cells co-
expressing P-WT and P-ex2del and cells co-expressing P-WT,
P-ex2del, and P-ex7del (Fig. 7B, column 4). Interestingly, cells
expressing only the ASL mutant P-E189G had a similar level of
ASL-WT activity (Fig. 7C, column 4), but cells co-expressing
P-WT and P-E189G showed 2-fold levels of WT activity (Fig.
7C, column 7). However, the residual activity in cells co-trans-
fected with P-E189G and P-ex2del or co-transfected with
P-E189G and P-ex7del (Fig. 7D, column 5 or 6) exhibited a
significant decrease to 16.6 5.3 or 57.5 3.2% (mean S.D.),
respectively, of cells co-transfected with P-WT and EV (Table
3). These findings indicate that the truncated protein caused by
deletion of ASL exon 2, although showing no relevant residual
activity, has a dominant negative effect on theASL activity after
co-expression with P-WT or P-E189G. In contrast, deletion of
exon 7 seems to have no significant effect on ASL-WT activity
after co-expression with P-WT, because it probably forms an
unstable protein according toWestern blot analysis (Fig. 3,C–E
and G) and computational predictions (Figs. 5C and 6 (G and
H)), but it nevertheless has a potential dominant negative effect
on ASL mutant activity after co-expression with P-E189G (Fig.
7C, column 6).
In order to further assess whether the negative effect of the
simultaneous expression of ex2delmutant onASL-WT is dose-
dependent in vitro, we performed transient co-transfections
with P-WT and P-ex2del at different ratios (1:1, 1:2, 1:5, 2:1, or
5:1). The co-expression of ASL-WT and ASL-ex2del at the dif-
ferent ratios above could be detected by Western blot analysis
(Fig. 3F). In cells co-expressing ASL-WT and ASL-ex2del with
a higher proportion of mutant DNA, we observed a significant
gradual decrease of ASL activity when compared with cells co-
expressingWT and EV (Fig. 7D).Moreover, cells co-expressing
ASL-WT and ASL-ex2del with a higher proportion of WT
DNA showed a significant gradual increase of ASL activity (Fig.
7D). These findings indicate that the negative effect of ASL-
ex2del on the WT activity is dose-dependent.
DISCUSSION
To date, the mechanism of the broad biochemical and clini-
cal heterogeneity in ASA patients still remains to be fully
explained because it is not just the result of different genotypes.
Possible hypotheses include ASL tissue-specific expression (27,
28), genetic variability (29), intragenic complementation (7,
30–32), the DNA methylation status (35), and the frequent
occurrence of alternative splicing variants at the ASL locus (5,
36, 37). In addition, several hormones, such as glucocorticoste-
roids and insulin, influence the regulation of ASL mRNA (52).
Recently, a complex formation with the enzymes argininosuc-
cinate synthetase and nitric-oxide synthase required for nitric
oxide synthesis was described (2), adding further to the com-
plexity of this, obviously not only, urea cycle enzyme. In the
present study, we were interested in the tissue dependence of
ASL transcript variants and their role for the clinical and bio-
chemical phenotype in ASA.
RT-PCR yielded comparable expression levels for the
detected transcript variants in 17 different human tissues (Fig.
2), suggesting that the expression of transcript variants is not
tissue-dependent. These findings are consistent with earlier
reports, in which full-length ASL expression was studied in 11
different human tissues (53) and with previous reports on the
frequent skipping of exons 2 or 7 (5, 36).
However, it remains pivotal to understand whether the fre-
quent transcript variants in this gene indeed play a role in ASA
patients at physiological levels or if they are present at higher
concentrations. To do so, we further investigated the expres-
sion levels of transcript variants as well as their enzymatic char-
acteristics in vitro. Establishment of an ASL expression system
in 293T cells (Fig. 3A) allowed us to investigate the ASL activi-
ties after ectopically expressing or co-expressing ASL-WT and
one ASL mutant (p.E189G) and/or splicing variants. Immuno-
blotting showed non-detectable ASL expression in cells trans-
fected with the ex7del construct (Fig. 3, C–E and G), yielding
unchanged ASL activity levels after co-expression of ASL-WT
and ASL-ex7del (Fig. 7, B and C, and Table 1) but having a
potential dominant negative effect on the ASL mutant activity
after co-expression of ASL mutant p.E189G and ASL-ex7del
(Fig. 7C and Table 3). Moreover, the observation of a 2-fold
increase in the ASL activity after co-expressing P-WT and
TABLE 2
Computational determination of structural properties of ASL-WT,
ASL-ex2del, and ASL-ex7del proteins
Computational parameters were determined with WHATIF and YASARA.
ASL-WT ASL-ex2del ASL-ex7del
Molecular mass 51,658 Da 44,471 Da 48,733 Da
Theoretical pI 6.04 5.90 5.76
Solvent-accessible surface 322,934 Å3 296,898 Å3 326,476 Å3
Accessible surface area 53,534 Å2 55,904 Å2 65,259 Å2
Potential energy 95,229 kJ/mol 77,219 kJ/mol 76,378 kJ/mol
Radius of gyration 36.3 Å 36.1 Å 36.9 Å
Electrostatic solvation
energy
29,769 kJ/mol 24,454 kJ/mol 27,781 kJ/mol
Electrostatic potential 14.89 kJ/mol 20.4 kJ/mol 43.07 kJ/mol
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P-E189G (Fig. 7C, column 7) further supports the view that the
negative effect on ASL mutant activity in cells co-transfected
with P-E189G and P-ex7del is not caused by the mutant itself.
Computational structure modeling revealed that the ex7del
variant was capable of forming a monomeric structure with
three distinct domains, similar to that of ASL-WT (Fig. 5C). As
predicted by structural analysis, ex7del may interfere with
tetramer formation and seriously impact the stability of the
core monomeric structure (Fig. 5), leading to premature degra-
dation of the monomers. This may explain the undetectable
ASL-exdel7 monomers after co-expression with ASL-WT or
with p.E189G (Fig. 3, D and G). Nevertheless, the ex7del ASL
monomer may still form a heterotetramer with other mono-
mers before degradation occurs, especially with easily accessi-
ble mutants, such as p.E189G, which then would result in
reducedASL activity. It should be noted that exon 7 contains 78
bases, allowing formation of an in-frame mutant ASL protein
(5). This finding is somewhat different from that of an earlier
study (54), inwhich a small amount of a 49 kDa band in addition
to the expected ASL-WT band on Western blots was specu-
lated to be an exon 7 skipping product that may be due to
proteolysis (5). However, the details of the possible degradation
of ex7del ASL were not investigated in this study.
Although exon 2 skipping was observed in previous studies
(29, 36), these authors did not determine the molecular basis
and impact of this deletion. As one of the main findings of our
investigations, we could show that exon 2-splicedASL can form
a stable truncated protein (Fig. 3,C–G), but it lacks any relevant
activity (Fig. 7A andTable 1). This finding is consistentwith our
prediction explored by computational structure modeling that
exon 2 is in close vicinity to the active site (Fig. 6, B and C), and
its deletion is probably deleterious. Surprisingly, this stable
truncatedmutant protein has a dominant negative effect on the
ASL activity after co-expressing ASL-WT as well as ASL-
p.E189G with ASL-ex2del (Fig. 7, B and C); in the latter case,
this was evenmore relevant. Furthermore, this negative effect is
ASL-ex2del DNA dose-dependent (Fig. 7D). The reduced ASL
activity may result from the formation of a heterotetramic
structure between ASL-WT and ASL-ex2del mutant protein as
well as homotetrameric ex2del variants that are enzymatically
inactive, competing for the substrate, depending on their pro-
portions. Because three different subunits of ASL contribute to
the active site in the tetrameric structures, different combina-
tions of WT and ex2del variant subunits may combine to form
tetramers with three, two, one, or zero active sites. It is possible
that proteins of different size resulting fromWT or exon 2-de-
leted transcripts may have a preference for each other when
forming the dimeric units before joining to form tetramers. In
such a scenario, only 2:2 versions of the heterotetramersmay be
the preferred assembly in addition to the fully functional and
non-functional molecules with four or zero active sites. Due to
a lack of liver samples derived fromASA patients, we could not
show whether a different amount of ASL-ex2del mutant pro-
tein is expressed in the ASA patients, which may interact with
ASL-WT to form a heterotetramer, leading to a different level
of residual ASL activity.
Although this study clearly shows that transcript variants
under physiological conditions are only present at low concen-
trations (Fig. 2, A–D), the situation was found to be different in
two patients affected by late onset ASA (Figs. 1D (lane 16) and
2C (lanes 2 and 3)). Both patients were shown to carry the same
known ASL missense mutation (p.E189G) with low residual
ASL activity in red blood cells found in one of the patients (25)
and absent activity after bacterial overexpression (33) but sig-
nificant residual activity in yeast experiments (55). Although
the mutation was found in a heterozygous state by genomic
DNA sequencing, the level of the ASL-ex7del transcript variant
observed by RNA studies was much higher (Fig. 2, C (lanes 2
and 3) and D (lane 16)). Under standard PCR conditions (38
cycles), no full-length ASL transcript was amplified, but a faint
full-length band was detected after 42 PCR cycles, indicating
the low expression of this transcript. Sequencing confirmed the
mutation c.566A3G in a hemizygous state in one patient (Fig.
2E), suggesting that the ASLWT allele in this particular patient
is completely subject to alternative splicing, and hence, noWT
transcript is expressed, whereas in the other patient heterozy-
gosity was found (Fig. 2F). We suggest here that the high
expression level of the ASL-ex7del variant contributed to the
ASA phenotype in the patients in addition to the missense
mutation. From the finding in these patients, we deduce that
the same phenomenon may also play a role in other patients
possibly affected by any of the transcript variants (such as
patient 16 in Ref. 25 with no mutation found but skipping of
exon 5).
In conclusion, this study suggests that transcript variants of
ASL exist at high frequency in different tissues and play a role in
the clinical and biochemical variability in ASA patients in
whom they are expressed at high levels. If this occurs with an
increased expression level of a stable expressed truncated vari-
ant, such as the ASL-ex2del variant, the effect may be even
more prominent because the likelihood of stablemutant homo-
or heterotetramer formation increases, impairing overall ASL
activity. Although the unstable splice variant ASL-ex7del has
no effect on ASL-WT activity, it probably shows a dominant
negative effect on ASL mutant activity. The findings from this
study expand our knowledge of the molecular background in
TABLE 3
Residual ASL activities in 293T cells co-transfected with recombinant ASL-WT, mutant p.E189G, and transcript variants
Data were obtained under standard conditions (13.6 mM argininosuccinate) after three independent experiments. ASL activity in cells co-expressing ASL-WT with EV is
set to 100% in each co-transfection (total 7 g of plasmids, each 3.5 g) under the same conditions. All measurements were in triplicate.
293T whole cell extracts WT EV
WT
ex2del
WT
ex7del
E189G
EV
E189G
ex2del
E189G
ex7del
WT
E189G
Mean ASL activity in mIU/mg total protein
(mean S.D.)
450.2 38.3 286.1 5.5 363.5 15.0 389.1 30.8 78.4 26.4 257.2 10.5 883.8 80.0
Mean ASL activity in % of ASL-WT EV
(mean S.D.)
100.0 7.1 61.9a 5.8 88.5 11.5 88.4 11.9 16.6a 5.3 57.5a 3.2 197.6 8.9
a Significant differences compared with ASL-WT activity (p 0.05).
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ASA patients, rendering further studies into transcript variants
necessary, especially in patients with no or only single
mutations.
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3.2 Chapter 2  
Variant Forms of the Urea Cycle Disorder Argininosuccinic Aciduria 
are Caused by Folding Defects of Argininosuccinate Lyase 
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Abstract 
Loss of function of the urea cycle enzyme argininosuccinate lyase (ASL) is caused by 
mutations in the ASL gene leading to ASL deficiency (ASLD) with a broad clinical 
spectrum ranging from life-threatening severe neonatal to asymptomatic forms. 
Different levels of residual ASL activity probably contribute to the phenotypic 
variability but reliable expression systems allowing clinically useful conclusions are 
not yet available. In order to define the molecular characteristics underlying the 
phenotypic variability, we investigated all ASL mutants that were hitherto identified in 
patients with late onset or mild clinical and biochemical courses by ASL expression in 
human embryonic kidney 293T cells. We found residual activities >3% of ASL wild 
type (WT) in nine of eleven ASL mutants. Six ASL mutants (p.Arg95Cys, p.Ile100Thr, 
p.Val178Met, p.Glu189Gly, p.Val335Leu, and p.Arg379Cys) with residual activities 
≥18% of ASL WT showed no significant or less than 2-fold reduced Km values, but 
displayed thermal instability. Computational structural analysis revealed a multitude 
of effects ranging from protein instability, disruption of ionic interactions and hydrogen 
bonds between residues in monomeric form of protein, to disruption of contacts 
between adjacent monomeric units in the ASL tetramer complex. These findings 
suggest that variations in residual levels of ASL activity as well as folding defects of 
mutant ASL proteins contribute to the clinical and biochemical variability of ASLD. 
Since at least 25% of known ASLD genotypes are affected by folding mutations, 
ASLD should be considered as a candidate for chaperone treatment to improve 
mutant protein stability. 
 
Introduction 
Argininosuccinate lyase deficiency (ASLD, MIM #207900) is a rare autosomal-
recessive urea cycle defect caused by mutations in the ASL gene encoding 
argininosuccinate lyase (ASL, EC 4.3.2.1, MIM *608310). ASL catalyzes the 
hydrolytic cleavage of argininosuccinate into arginine and fumarate and is, as part of 
the urea cycle, essential for ammonia detoxification and L-arginine synthesis (1). 
ASLD is considered the second most common urea cycle disorder (UCD) with an 
estimated incidence of 1:70’000 live births (1-3).  
Biochemically, ASLD is characterised by hyperammonemia, an unspecific 
finding, and accumulation of argininosuccinic acid in tissues and body fluids (hence 
the synonymous term argininosuccinic aciduria, ASA), the latter being a specific and 
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thus diagnostic biochemical marker (4-6). Levels of argininosuccinic acid in blood or 
urine vary between patients but there is no useful correlation between this marker 
and the severity of disease.  
Clinically, patients with ASLD show a continuum from asymptomatic 
individuals over mild late onset forms to severe neonatal onset presentations with 
fatal hyperammonemic encephalopathy within the first few days of life (3). In contrast 
to most other UCDs, patients with ASLD seem to be affected by mental retardation 
independent from the occurrence of hyperammonemic decompensations. Other, for 
UCDs unusual and not fully understood complications of ASLD are the frequent 
findings of hepatic disease (7, 8) and of arterial hypertension (9) indicating to 
additional and possibly tissue-specific biological functions of ASL (10). The ASL gene 
is located on chromosome 7cen-q11.2 and comprises 16 coding exons (NM_000048) 
(11-13). The coding region of 1392 base pairs encodes a polypeptide of 464 amino 
acids (NP_000039), which forms as active enzyme a cytosolic homotetramer 
consisting of four subunits of identical molecular weight (~ 52kDa) (14, 15). ASL is 
ubiquitously expressed in the human body with highest levels in the liver. A sequence 
on chromosome 22 was previously considered as a pseudogene (11, 12) but later 
found to encode Ig-λ like mRNA (11). Recently, an ASL pseudogene, which includes 
sequences from intron two to in-tron three, was identified upstream of the human 
ASL gene on chromosome 7 (16). Mutations are spread almost all over the ASL gene 
and have recently been reviewed (17). 
Several attempts have been made to accomplish a prognostic marker and 
improve our understanding of the biochemical and clinical variability of ASLD. 
Enzymatic assays in erythrocytes (18, 19) or in cultured skin fibroblasts by direct (5) 
or indirect ASL measurement (20, 21) have proven to be of some prognostic value for 
selected patients but lacked predictive reliability. Nevertheless, the indirect ASL 
assay by analysis of 14C-citrulline incorporation in intact fibroblasts yielded sufficient 
sensitivity for detection of residual activities in variant forms of ASLD (11, 21, 22) 
comprising patients with non-classical ASLD affected by only mild clinical symptoms, 
slight biochemical abnormalities, but no, or only mild, hyperammonemia.  
In addition to measurements in patients’ samples, there are some in vitro 
assays investigating naturally occurring ASL mutants in bacterial (E. coli) (23-25), 
yeast (26, 27) and eukaryotic (COS1-cells) (28, 29) expression systems. While 
identification of severely affected ASL proteins was feasible in all of these, there was 
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overall no satisfying sensitivity for residual ASL activities and hence the predictive 
value was limited. In order to achieve an improved eukaryotic expression system 
allowing more sensitive analysis of residual ASL activities, we recently established 
the measurement of ASL activity in human embryonic kidney 293T cell lysates after 
transient transfection of ASL wild type (WT) and mutants (30).  
In the present study, we investigated all naturally occurring ASL mutants up till 
now identified in patients with a variant biochemical or clinical phenotype (17) and 
aimed to better understand the cause of the broad variation in ASLD phenotypes. We 
found evidence for thermal instability as well as low expression levels pointing 
towards a hampered stability due to a folding defect in these mutant ASL proteins. 
Besides contributing to our understanding of the underlying pathology in ASLD, this 
finding suggests that novel therapeutic approaches such as chaperone treatment 
aiming at stabilization of mutant ASL should be pursued with high priority in ASLD.  
 
Material and methods 
Patients and choice of ASL mutations 
In this study, 13 known ASL sequence changes, including the severe mutants 
p.Gln286Arg (c.857A>G) and p.Arg385Leu (c.1154G>T) as negative controls, were 
investigated together with WT ASL (Figure 1). Of the total 13 mutations, eleven 
(p.Arg12Gln (c.35G>A), p.Asp31Asn (c.91G>A), p.Arg95Cys (c.283C>T), p.Ile100Thr 
(c.299T>C), p.Val178Met (c.532G>A), p.Glu189Gly (c.566A>G), p.Arg193Trp 
(c.577C>T), p.Val335Leu (c.1003G>T), p.Arg379Cys (c.1135C>T), p.Arg385Cys 
(c.1153C>T), and p.Arg445Pro (c.1334G>C)) are, according to literature (17), always 
associated with a variant clinical course, defined as late onset and/or mild clinical and 
biochemical phenotype. This list of eleven mutations comprises all known base pair 
substitutions meeting the criteria of a variant change (Table 1). The amino acid 
substitutions p.Ile100Thr and p.Arg379Cys belong to the two most frequent changes 
in ASLD that were initially described in Finish patients (11). Notably, the mutations 
c.1153C>T (p.Arg385Cys) and c.1154G>T (p.Arg385Leu) affect the same amino acid 
but are reported to result in variant and severe clinical courses, respectively (17).  
 
Construction of recombinant ASL mutantsFull-length ASL cDNA (1395 bp, 
RefSeq NM_000048.3) was cloned into the expression vector pcDNA3 (Invitrogen, 
Carlsbad, CA, USA) at BamHI and NotI restriction sites yielding pcDNA3-ASL-WT (P-
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WT) as described previously (30). The mutant plasmids were constructed based on 
P-WT by site-directed mutagenesis (Phusion Site-directed mutagenesis Kit, 
Finnzymes, Espoo, Finland) according to manufacturer’s protocol. Oligonucleotide 
primers designed to achieve the respective point mutations are listed in 
Supplemental Table 1. PCR products obtained after mutagenesis were subjected to 
BamHI (New England Biolabs, Beverly, MA, USA) digestion and their size compared 
to P-WT by gel electrophoresis. The PCR products with correct size were then 
transformed into chemically competent DH5αTM-T1R E.coli cells (Invitrogen, 
Carlsbad, CA, USA) by using the heat shock method and selected by growth on 
ampicillin-containing (100μg/ml) LB-agar. Screening-PCR with primers T7 forward 
[5’TAATACGACTCACTATAGGG3’] and Sp6 reverse [5’ATTTAGGTGACACTATAG3’] 
was used to identify positive clones. Then, mutant plasmids were isolated from E. coli 
and purified by using standard procedures (QIAprep spin column Miniprep Kit, 
Qiagen, Hombrechtikon, Switzerland). The yielded mutant plasmids (P-mutant) were 
named as P-R12Q, P-D31N, P-R95C, P-I100T, P-V178M, P-E189G, P-R193W, P-
Q286R, P-V335L, P-R379C, P-R385C, P-R385L, and P-R445P. All established 
constructs were confirmed by sequencing using the BigDye Terminator cycle 
sequencing kit V.1.1 (Applied Biosystems, ABI sequence). 
 
Expression of ASL constructs in human embryonic kidney 293T cells 
We have previously shown that 293T cells were an ideal ASL expression system 
lacking endogenous ASL but allowing for high ectopic ASL expression (30). Cells 
were grown, maintained and transiently transfected as described before (30). In brief, 
293T cells were grown in Dulbecco’s modified Eagle’s medium + GlutaMAX (DMEM, 
Gibco, Paisley, UK) supplemented with 10% fetal bovine serum (FBS) and 1% 
antibiotic/antimycotic solution (both PAA, Pasching, Austria) and maintained in an 
incubator containing 5% CO2 at 37oC in a humidified atmosphere. Total 7 μg of 
plasmid carrying ASL WT or the intended mutations was introduced into the cells in a 
60 mm-dish format, using Lipofectamine™ LTX and PLUS™ Reagents (Invitrogen, 
Basel, Switzerland) according to manufacturer’s instructions. The empty vector (EV) 
pcDNA3 was used as negative control. 
 
Protein extraction and Western blot analysis 
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Cells were harvested 48 hours post-transfection and lysed in Lubrol WX lysis buffer 
containing 0.15% (w/v) of Lubrol WX (Sigma Chemical Co., Poole, Dorset, UK) and 
10 mM of Tris-HCl (pH 8.6) for 1 hour on ice. Cell lysates were then centrifuged at 
maximum speed at 4oC for 15 min. Protein concentrations in the supernatants (cell 
extracts) were determined by Bradford assay (31) using bovine serum albumin as 
standard. Western blotting was performed as previously described (32). Cell extracts 
(30 μg total protein) were separated by 10% denaturing sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and subsequently transferred to 
nitrocellulose transfer membranes (Whatman GmbH, Dassel, Germany). The primary 
polyclonal antibody anti-ASL (GeneTex, Irvine CA, USA), recognizing ASL residues 
13 to 261 according to the manufacturer, was used at a dilution of 1:1000 and the 
horseradish peroxidase (HRP)-conjugated secondary antibody anti-rabbit (Santa 
Cruz Biotechnology, Santa Cruz CA, USA) was used at a dilution of 1:5000. 
Antibodies against glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Santa 
Cruz Biotechnology) served as loading control. ECL reagents (GE Healthcare, 
Glattbrugg, Switzerland) were used for chemiluminescent labelling to detect protein. 
To estimate expression levels of recombinant ASL mutants, densitometry analysis of 
bands detected by Western blotting was performed by using Carestream Molecular 
Imaging software (Carestream Health, Germany). 
 
ASL enzymatic activity assay, kinetic study and thermal stability assay 
The ASL enzymatic activity was determined spectrophotometrically in cell extracts 
after three independent transient transfections of P-WT or P-mutants, using a 
coupled assay with arginase and measuring urea production as described before 
(23). In short, 100 μl of 34 mM argininosuccinate (argininosuccinic acid disodium salt 
hydrate) in water and 100 μl arginase (50 units) (both Sigma-Aldrich, Buchs, 
Switzerland) in 66.7 mM phosphate buffer (11.1 mM potassium dihydrogenphosphate 
and 55.6 mM disodium hydrogenphosphate, pH 7.5) were incubated at 37oC for 5 
min. Then 40 μl of cell extract (6 μg of total protein diluted in albumin buffer yielding 
0.15 mg/ml of concentration for WT and all mutants except for p.Arg95Cys, in which 
we adapted protein quantity to 0.65 mg/ml according to low expression levels) and 10 
μl phosphate buffer were incubated with the above reagents at 37oC for 30 min. The 
reaction was stopped by adding perchloric acid at a final concentration of 2%. In this 
assay, the measured extinctions are corrected with the extinctions of a blank 
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containing all the reagents and cells as well as perchloric acid before the reaction 
started. The ASL enzyme activities are given as mIU/mg total protein indicating nmol 
of urea production/min/mg total protein and normalized according to the expressed 
ASL protein levels by densitometry analysis using GAPDH as control. The residual 
activities of ASL mutants are determined as percentage of ASL WT under same 
conditions in triple measurements, respectively. 
Kinetic studies and thermal stability assays were performed for ASL WT and 
mutants (p.Arg95Cys, p.Ile100Thr, p.Val178Met, p.Glu189Gly, p.Val335Leu and 
p.Arg379Cys) with residual ASL activities ≥18% of ASL WT. The measured 
enzymatic activities were normalized according to the expressed ASL protein levels 
by densitometry using GAPDH as control. The kinetic parameters were determined 
by Michaelis-Menten analysis at 10 different argininosuccinate concentrations (0.045, 
0.068, 0.136, 0.272, 0.544, 0.907, 1.813, 3.4, 6.8 and 13.6 mM) after curve fitting 
using GraphPad Prism 4 (GraphPad Software, San Diego, CA, USA). For ASL 
thermal stability assay all ASL proteins were diluted at 0.15 mg/ml in albumin buffer 
(pH 7.4) and heated at different temperatures for 30 min in a PCR machine, and then 
immediately cooled down to 0oC on ice followed by measuring ASL enzymatic 
activity as above (incubation temperatures in °C for WT: 37, 42, 47, 52, 54, 56, 57; 
mutant p.Arg95Cys: 37, 40, 43, 45, 47, 49, 51; mutants p.Ile100Thr, p.Glu189Gly and 
p.Val178Met: 37, 42, 47, 48.5, 50, 51.5, 53; mutant p.Val335Leu: 37, 40, 42, 44, 46, 
47, 48, 50; mutant p.Arg379Cys: 37, 42, 47, 48, 48.5, 50, 51, 51.5, 53). The mutant 
protein p.Arg95Cys, which is expressed less efficient and exhibited only low enzyme 
activity, was diluted at 0.65 mg/ml. The value V50 (oC) indicating the temperature at 
which 50% of protein is inactivated, was determined by Boltzmann sigmoidal curve 
fitting of the data using GraphPad Prism 4 (GraphPad Software). All assays were 
carried out in triplicate using cell lysates from the same transfection experiment. 
 
Structure Models of ASL mutants 
3D protein model and in-silico mutagenesis of ASL 
The tetrameric 3D structural model of ASL (NCBI NP_000039.2, Uniprot P04424) 
sequence (AA 1-464) was built using the ASL structure (PDB 1K62) as described 
previously (30). Model building was performed with programs YASARA (33) and 
WHATIF (34). Side chains were optimized by molecular dynamic (MD) simulations. 
The geometry information for the tetramer assembly was extracted from the original 
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crystallographic data. The final model was refined by a 1000 ps (MD) simulation 
using AMBER 2003 force field and checked with the programs WHAT_CHECK (35), 
WHATIF (34), Verify3D (36, 37), and Ramachandran plot analysis (38, 39). 
Information about the residues located at the argininosuccinic acid binding pocket 
was extracted from the duck crystallin structure (PDB 1DCN) (40) using the program 
SiteEngines (41, 42). Structures were depicted with Pymol (www.pymol.org) and 
rendered as ray-traced images using the program POV-RAY (www.povray.org). 
Structural properties of the proteins were calculated by YASARA and WHATIF and 
general protein parameters were calculated with Expasy protein tools 
(www.expasy.ch). 
 
Molecular Dynamics simulation for model refinement 
The MD simulations were performed using AMBER03 force field as described 
previously (33, 43). The simulation cell was filled with water, pH was fixed to 7.4 and 
the electrostatic potentials were evaluated for water molecules in the simulation cell 
and adjusted by addition of sodium and chloride ions. The final MD simulations were 
then run with AMBER03 force field at 298K, 0.9% NaCl and pH 7.4 for 1000 ps to 
refine the models. Best models were selected for analysis and evaluation of the effect 
of mutations on monomer and tetramer structures.  
 
Predicting the effect of mutants on protein stability using site directed mutator 
(SDM) 
The SDM tool (44) (45) was used for predicting the effect of mutants on ASL protein 
stability. SDM software uses environment-specific substitution frequencies within 
homologous protein families to calculate a stability score. The mutant structures used 
for analysis were generated using the program ANDANTE (46). SDM provides a 
pseudo delta G score for prediction of protein stability. 
 
RNA structure and stability prediction 
RNA structure and stability prediction was performed using the program RNAsnp (47). 
A cutoff p value of 0.2 was used for predicting the effect on RNA stability. Both the 
global as well as local effects were evaluated for predicting the changes in the RNA 
structure upon mutations. The minimum free energy structures of the WT and mutant 
RNA were used to display the secondary structures in the graphic format. 
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Statistics 
Statistical analyses were done using student one-tailed T-test using the program 
GraphPad Prism 4 (GraphPad Software) to describe the differences of Km and V50 
values in kinetic and thermal stability assays, respectively, between ASL WT and 
mutants with significant residual activities. Differences were considered as significant 
if the p value was <0.05. 
 
Results 
Expression of recombinant ASL WT and mutants in 293T cells 
In order to investigate the molecular characteristics of all known naturally occurring 
ASL missense mutations associated with a variant clinical course in ASA patients 
(17), we first constructed the recombinant ASL WT and mutant plasmids followed by 
introducing them into 293T cells, respectively. To check whether the recombinant 
diverse ASL mutants can be expressed at the protein level, Western blot analysis 
was performed. ASL expression could be detected as monomer in cells expressing 
all recombinant ASL mutant proteins (Figure 2A). Moreover, a similar level of ASL 
expression as in WT was observed in all ASL mutants except for p.Arg95Cys, 
p.Arg193Trp and p.Arg445Pro with lower protein yields (37%, 37% and 40% of WT 
after normalisation with loading control GAPDH by densitometry) indicating that these 
mutants are less stable at either protein or RNA level. We performed RNA secondary 
structure prediction to check whether substantial variations from the WT RNA were 
the cause of lower expression levels. Our analysis showed significant differences for 
the p.Arg193Trp (p-0.157) and p.Arg445Pro (p-0.118) variants (Figure 3). Thus, 
combination of RNA and protein stability effects may be responsible for lower 
expression of some mutant proteins. 
 
Residual ASL enzymatic activities in transfected 293T cell extracts 
To determine whether the expressed ASL mutants have any residual enzyme activity, 
we performed ASL enzyme activity assays with the cell extracts used for Western 
blot analysis (summary of data in Table 1 and Figure 2B). The residual enzymatic 
activities were normalized according to the expressed ASL protein levels by 
densitometry using GAPDH as control. There was no relevant endogenous ASL 
activity in cells transfected with EV. No significant residual activity (≤ 2% of ASL WT) 
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was observed in cells respectively transfected with two severe mutants p.Gln286Arg 
and p.Arg385Leu as well as with two variant mutants p.Asp31Asn and p.Arg385Cys, 
whereas cells expressing ASL WT yielded high enzymatic activity (Figure 2B). Cells 
expressing other nine variant mutants (p.Arg12Gln, p.Arg95Cys, p.Ile100Thr, 
p.Val178Met, p.Glu189Gly, p.Arg193Trp, p.Val335Leu, p.Arg379Cys and 
p.Arg445Pro) showed a residual activity >3% of ASL WT. Surprisingly, six of them 
(p.Arg95Cys, p.Ile100Thr, p.Val178Met, p.Glu189Gly, p.Val335Leu, and 
p.Arg379Cys) displayed a high level of ASL residual activity ≥18% of ASL WT (Table 
1 and Figure 2B). 
 
Kinetic study of variant mutants with high residual ASL activities 
Next, we wanted to study the molecular pathology in ASA patients identified with 
variant mutants (p.Arg95Cys, p.Ile100Thr, p.Val178Met, p.Glu189Gly, p.Val335Leu, 
and p.Arg379Cys) harbouring residual activities ≥18% of ASL WT. Therefore, we 
analyzed whether the kinetic parameters were impaired in these mutants using 
different concentrations of the substrate argininosuccinate (summary of data in Table 
1 and Figure 2C). The normalized maximal reaction velocity (Vmax) value in cells 
expressing recombinant mutant protein p.Arg95Cys showed about 13% of that in 
cells expressing ASL WT, whereas other five mutants (p.Ile100Thr, p.Val178Met, 
p.Glu189Glp, Val335Leu, and p.Arg379Cys) exhibited ≥58% of Vmax of ASL WT. 
Moreover if compared with WT, the Vmax values of mutants were consistent with 
their residual activities and were all significantly lower (p<0.05). Interestingly, Km 
values were not significantly changed in mutants p.Ile100Thr (0.46 mM), p.Val178Met 
(0.44 mM), p.Glu189Gly (0.49 mM), and p.Val335Leu (0.53 mM). In contrast, Km 
values were even slightly decreased in mutants p.Arg95Cys (0.18 mM) and 
p.Arg379Cys (0.25 mM) compared with that of ASL WT (0.44 mM) indicating an 
increased substrate affinity in these two mutants. Furthermore, the ratios of Vmax/Km 
in four mutants (p.Arg95Cys, p.Ile100Thr, p.Glu189Gly and p.Val335Leu) were 
decreased (32%, 61%, 78%, and 48% of ASL WT, respectively), while two mutants 
p.Val178Met and p.Arg379Cys showed similar Vmax/Km ratios (93% and 112%, 
respectively) compared to that of WT indicating an unchanged catalytic efficiency in 
these mutants. 
 
Thermal stability analysis of variant mutants with high residual ASL activities 
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In order to further investigate the molecular basis in variant ASL mutants with 
significant residual activity, we measured the thermal stability of mutant proteins by 
incubating the protein at different temperatures prior to activity determination 
(summary of data in Table 1 and Figure 2D). The V50 values, indicating the 
temperatures at which 50% of ASL activity is lost, were dropped to 46.5, 48.4, 49.9, 
48.2, 42.4, and 48.0oC for mutants p.Arg95Cys, p.Ile100Thr, p.Val178Met, 
p.Glu189Gly, p.Val335Leu and p.Arg379Cys, respectively, compared with ASL WT 
(52.7oC). All V50 values of mutants were significantly decreased (p<0.05) suggesting 
thermal instability of these ASL variants. 
 
Structural model of ASL tetramer 
We analyzed the mutated residues in human ASL by making a structural model using 
known x-ray crystal structures of ASL protein as template. The structural model of 
ASL tetramer was generated using the known x-ray crystal structures of ASL 
available in the PDB database (PDB # 1K62, 1AOS) (25, 48) as templates with 
YASARA (33) and WHATIF (34). We used in-silico mutagenesis to replace amino 
acids as utilized previously for other proteins to preserve the core-structure (49). The 
amino acids identified from structural studies were checked by comparing the 
positions of these amino acids in different ASL sequences available in the NCBI 
protein database. We compared human, horse, cow, cat, pig, chimpanzee, dog and 
rat ASL protein sequences, and amino acids near the substrate binding site and 
interaction points of the tetrameric protein complex were checked for conservation 
(Figure 4). Amino acids involved in substrate access and catalysis were conserved 
across species and no structurally significant substitutions were observed in any of 
the sequences analyzed (Figure 4). A high resolution x-ray crystal structure of ASL 
that describes the conformations and topologies of ASL monomers has been 
described by Sampaleanu et al (25) which formed the basis of our structural analysis. 
The enzymatically active form of ASL is a homotetramer which is formed by four 
identical 100A monomer units which have three distinct helix rich subdomains (Figure 
5) (25). Domains 1 and 3 of ASL monomeric structure have similar structure and 
topology with two helix-turn-helix motifs in perpendicular arrangement, while domain 
2 has nine helices and five of them form the central five helix bundles with up-down-
up-down-up topology (Figure 5) (25).  
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Three of these five central helices interact with another subunit of ASL to form 
the dimeric structures. In the catalytically active complex each monomeric chain 
contributes one central helix that becomes part of the four helix central cores. Three 
distinct and highly conserved regions (C1, C2 and C3, shown in grey in Supplemental 
Figure 1) on the ASL monomers contribute towards the formation of active sites in 
the functional tetramer. In the monomeric structure these conserved regions are 
located on different domains of the protein but in the tetramer these regions connect 
together and form an active site of multiple subunits where each region (C1, C2 or 
C3) is contributed by a different monomeric subunit. The histidine 160 residue 
located in the conserved region C2 is proposed as the catalytic centre. A comparison 
with similar structures suggests that histidine 160 in ASL may be involved in binding 
and neutralizing the carboxylate group of ASA (40). The glutamine 286 residue is 
located on the highly conserved and flexible loop C3 comprising of residues 270-290 
(called 280`s loop) that has been proposed to be involved in entry of the substrate 
and exit of the product at the catalytic centre (25). The lysine 287 and 288 located on 
280`s loop are highly conserved and may be involved in neutralizing negative 
charges of the reaction intermediate carbanion dicarboxylate or fumarate which is the 
final product of the reaction. 
 
Structural properties of the ASL mutants 
The location of ASL mutants studied in this report on one subunit was depicted in 
Figure 5. We investigated the structural properties of these mutants to better 
understand their diseasecausing nature. We created structural models of 13 ASL 
mutants (Figures 6-8). Amino acids were mutated in-silico and side-chains of mutated 
residues were optimized by MD simulations. The MD simulations were performed 
with YASARA using the AMBER03 (43) force field as described previously (33). 
Refined structures were evaluated with WHAT_CHECK (35), Verify3D (36, 37) and 
analyzed by programs YASARA (33) and WHATIF (34) for a variety of structural 
parameters like breaking of salt-bridges and hydrogen bonds, changes in charge, 
size and volume of the altered amino acid and interaction with neighbouring residues, 
to evaluate the impact of mutations as described previously for several other proteins 
and structures (49-51).  
Prediction of disorder due to structural changes was done with the site-
directed mutator tool based on statistical potential energy calculations (44). In the 
                                                                                                 Manuscripts—Chapter 2 
 73 
 
SDM analysis a negative score is indicative of a destabilizing effect and a positive 
score suggests a stabilizing effect. A cut-off of 2 kcal.mol-1 was used for predicting a 
disease causing effect. The p.Ile100Thr, p.Glu189Gly and p.Arg445Pro mutants in 
ASL were predicted to decrease the structural stability and cause disease (Table 2). 
Structural stability of the tetramer interface is also crucial for the complex formation 
which was analyzed in detail by looking at ionic interactions and hydrogen bond 
network of residues at the interface of central helices in tetrameric structure (Table 
3). 
 
Role of arginine 12: The arginine 12 residue is located on the flexible N-terminus 
loop of the protein (Figure 6A), which does not seem to influence the overall tetramer 
structure or active site of the enzyme but this loop is very close to the active site and 
therefore may influence binding/exit of substrate. During MD simulations we found 
arginine 12 to be located near glutamate 138 and aspartate 145 of another ASL unit 
and to form ionic contacts. In addition the arginine 12 formed hydrogen bonds with 
threonine 142, threonine 347 and glycine 348 which were broken in the arg12gln 
mutant (Table 3). Sampaleanu et al have proposed that due to mutation of arg12 the 
arg12-asp18 salt bridge is disrupted, allowing alternate confor-mations of the N-
terminal loop which come in contact with 280`s loop domain and disturb the 
conformation of substrate binding site (25). The p.Arg12Gln mutation had been 
reported to cause a milder form of disease (25). 
 
Role of aspartate 31: The aspartate 31 residue is situated close to the catalytic 
centre and is part of the substrate access channel formed by three different units of 
ASL monomers (Figure 6B). A change from aspartate to aspargine seems to result in 
additional hydrogen bonding with aspartate 87 of the same monomeric unit of ASL. 
This might cause restrictions in binding of the substrate or exit of the catalytic 
product. 
 
Role of arginine 95: Arginine 95 forms 4 hydrogen bonds with the glutamate 73 
located on a parallel helix within the same monomeric subunit (Figure 6C) which is 
important for protein stability. The mutation of arginine 95 to cysteine abolished the 
hydrogen bonds with the glutamate 73, which would impact protein stability. 
Confirming this hypothesis the p.Arg95Cys variant of ASL showed lower expression 
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levels and was adversely affected by temperature increases in the protein stability 
assays. The mutation of arginine 95 to cysteine may have increased the flexibility of 
the substrate access to the active site and an increase in binding affinity, as 
implicated from a reduced Km value, was observed. 
 
Role of isoleucine 100: The isoleucine 100 residue is located in the highly 
conserved C1 region of the protein and is located near the active site but does not 
have any direct role in substrate binding or catalysis (Figure 6D). The isoleucine 100 
residue is participating in multiple interactions with the isoleucine 63, aspargine 62 
and 99 leucine. The mutation of isoleucine 100 to threonine did not affect the 
interactions with neighbouring residues to any significant extent and is predicted not 
to have any drastic effects on catalytic activity (Figures 2B,C and 6D). The 
p.Ile100Thr mutation has been reported to cause a mild effect (11) and enzyme 
kinetic analysis revealed a slight reduction in activity. 
 
Role of valine 178: The valine 178 residue is located in the central core helix bundle 
that forms the tetramer structure of ASL (Figure 7A) but is not directly involved in 
stabilizing the central core of the structure. The substitution of valine by methionine 
group is predicted to have only minor effects on tetramer stability. Moreover, several 
strong ionic interactions, especially between Arg186, Arg193 and Glu185 and Glu189 
on different subunits were not impacted by mutation of valine 178 and the tetrameric 
structure was not affected. The p.Val178Met mutation had close to WT activity in 
enzymatic analysis and was comparatively stable in thermal instability assay and has 
been reported to allow a milder ASLD phenotype in patients carrying this mutant (11, 
19, 21). 
 
Roles of glutamate 189 and arginine 193: The ASL tetramer is held together by 
hydrophobic interactions between the four central helices as well as ionic interactions 
between arginine and glutamic acid residues on two adjacent dimeric ASL units 
(Figure 7B). Our structural analysis using in-silico mutagenesis and MD simulations 
revealed a central role for arginine 193 in the tetramer formation and any changes to 
arginine 193 residue was predicted to adversely affect the protein stability. We found 
that charge pair interactions between Arg193 on one subunit with Glu189 and Glu185 
of another adjacent subunit are important for the core structure (Figure 7C). The 
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p.Glu189Gly mutant has been reported to be milder (19) and enzyme assays also 
showed only a mild effect on activity (23). Analysis of dynamic hydrogen binding 
patterns and salt bridges in the mutant structure suggested that in addition to 
glutamate 189, the glutamate 185 also participates in interactions with arginine 193 
of the adjacent ASL subunit to stabilize the tetramer. In the p.Glu189Gly variant of 
ASL tetramer, the arginine 193 of the adjacent ASL monomer formed hydrogen 
bonds with glutamate 185. This would suggest that the effect of Glu189 mutation is 
not severe due to compensatory mechanism of alternate interactions in the mutated 
protein. The partial disruption of salt bridges is reflected in lower thermal stability of 
the p.Glu189Gly variant. 
 
Role of glutamate 286: The glutamine 286 residue located on the conserved C3 
region of the ASL is part of the flexible 280’s loop and although it does not seem to 
participate directly in substrate binding, its mutation affects catalysis and results in 
severe form of disease (25, 27). It has been suggested that 280`s loop is important 
for substrate entry and exit (25) and mutation of Gln286 to arginine changes the 
interactions of this loop by formation of two hydrogen bonds with the glutamine 399, 
which is part of the active site. This would stabilize the flexible 280’s loop and 
adversely affect substrate binding and exit from the active site (Figure 7D). This is 
reflected by almost complete loss of activity in the p.Gln286Arg mutant. 
 
Role of valine 335: The valine 335 group is involved in multiple hydrophobic 
interactions with residues on the same alpha helix as well as another adjacent 
parallel alpha helix of the same ASL unit (Figure 8A). The mutation of valine 335 to 
leucine does not seem to impact the structure adversely. An additional hydrophobic 
interaction with arginine 302 of the same ASL unit was observed upon mutation of 
valine 335 to leucine. The mutation did not have severe impact on ASL activity but its 
thermal stability was remarkably lower than the WT protein. 
 
Roles of arginines 379 and 385: The arginine 379 residue has only a minor role in 
protein stability of the ASL monomer (Figure 8B), mainly through hydrogen bonding 
with histidine 432 on the same ASL unit and through hydrophobic interactions to 
leucine 209 of adjacent ASL unit. The mutation of arginine to cysteine abolished both 
of the contacts but several other interactions are probably able to compensate and 
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any major impact on protein stability was not predicted. The p.Arg379Cys variant has 
similar to WT catalytic efficiency (Vmax/Km) but there was a significant impact on 
thermal stability (Table 1 and Figure 2D). The arginine 385 residue is located near 
the active site and interacts with Glu389 by formation of two hydrogen bonds for 
stabilization of the carboxy terminus helix bundle (Figure 8C). The mutation of 
Arg385 has given mixed phenotypes with p.Arg385Cys reported as mild (11, 21, 23) 
while p.Arg385Leu causes severe form of disease and clinical details of p.Arg385His 
mutation are unknown (17). It is likely that its impact is determined by side chains of 
the mutated residue that may interfere with residues near the active site. In our 
analysis the interactions with Glu389 and of the same ASL unit and Gly105 of the 
adjacent unit were affected by mutation to cysteine or leucine. In the enzymatic 
analysis both the p.Arg385Cys and p.Arg385Leu resulted in loss of activity and could 
not explain the differences in disease phenotype. 
 
Role of arginine 445: The arginine 445 residue is involved in stabilizing the carboxy 
terminus helix of the ASL monomeric structure (Figure 8D) and its mutation to proline 
was predicted to have drastic consequences. The hydrogen bonds formed between 
arginine 455 and aspartate 152 and glutamate 435 were disrupted upon mutation to 
proline (Table 3). The SDM prediction gave a disordered structure upon mutation of 
arginine 445 to proline. The loss of enzymatic activity seems to support this 
prediction. 
 
Discussion 
The broad clinical and biochemical variability of ASLD has been subject of various 
investigations over recent years. More specific, the presence of residual enzyme 
activities was confirmed in different expression systems, both prokaryotic (23-25) and 
eukaryotic (26-30), and this was considered as a factor contributing to the spectrum 
of disease. On the other hand, the finding of cognitive impairment despite higher ASL 
activity (22) and, in other patients, of normal outcome despite undetectable ASL 
activities (19) led to the assumption of “no correlation between enzyme activity and 
neuro-clinical outcome” (3). This overall inconsistent situation may in part be 
explained by the variety of methods employed including different enzymatic 
measurements, direct (5, 22) as well as indirect (20, 21) assays, and likewise 
different ways of expression, yielding recombinant purified ASL protein from 
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prokaryotic overexpression (23) as well as eukaryotic systems using yeast (26) or 
human embryonic kidney 293T cell lysates (30).  
Here, we exploited our recently established eukaryotic expression system that 
is based on crude cell extracts of transfected 293T cells (30) to study in detail all 
known variant ASL mutants (17). The term variant ASL mutant refers to non-classical 
presentations either as late onset or as mild clinical and biochemical phenotypes. We 
studied in total eleven variant and two severe missense mutations. The eleven 
variant mutations represent a substantial proportion of the total 92 known ASL 
missense mutations of which 25 are known to be associated with a severe phenotype 
(17).  
We confirmed high levels of ASL enzyme activity in the recombinant WT, 
further validating our expression system. In contrast, severe mutants p.Gln286Arg 
and p.Arg385Leu yielded levels of residual ASL activity < 1.5% if compared with the 
WT level. Western blotting confirmed sufficient expression of recombinant protein for 
all transfected constructs (Figure 2A). Interestingly, while most mutants, including the 
severe changes p.Gln286Arg and p.Arg385Leu, expressed at levels comparable to 
ASL WT, we found three variant mutants that yielded clearly lower protein expression 
(p.Arg95Cys, p.Arg193Trp, p.Arg445Pro) indicating their disease causing role and 
already pointing towards instability of the mutant proteins. The RNA secondary 
structure may also play a role in lower levels of expression. Therefore, a combination 
of lower translation as well as protein instability may affect the overall outcome of 
some ASL variants.  
In the eleven variant ASL constructs, we found levels of residual activity ≥18% 
of WT in p.Arg95Cys, p.Ile100Thr, p.Val178Met, p.Glu189Gly, p.Val335Leu, and 
p.Arg379Cys while residual activities were much lower in the remaining mutants 
(Table 1 and Figure 2B). Based on this, we decided to add kinetic as well as thermal 
stability studies for the above six mutants. Four of the mutant ASL proteins 
(p.Ile100Thr, p.Val178Met, p.Glu189Gly, and p.Val335Leu) showed no significant 
changed Km values and two mutants (p.Arg95Cys and p.Arg379Cys) even displayed 
slightly decreased Km values (Table 1), which would explain their milder phenotype. 
The findings of a decreased thermal stability for mutants p.Arg95Cys, 
p.Ile100Thr, p.Val178Met, p.Glu189Gly, p.Val335Leu, and p.Arg379Cys as well as 
the low expression level for mutants p.Arg95Cys, p.Arg193Trp, and p.Arg445Pro 
point towards an instable and/or lower expressed ASL protein in the aforementioned 
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mutants. This opens the possibility of stabilising these mutants by pharmacological 
chaperons as a new therapeutic approach in ASLD. Such small molecule treatment 
has been well established in experimental settings in other diseases (52, 53) but has 
not been tested yet for ASLD. Since all of the mutants that possibly qualify for 
chaperone treatment are recurrent and some even belong to the most frequently 
found mutants in ASLD patients (17), identification of compounds that can be used 
for this purpose should become a research priority. This is underlined by the fact that 
about 25% (n=43) of the 160 known different genotypes (17) are affected at least on 
one allele by any of the mutations described here as possible targets of chaperone 
treatment.  
Our findings are further substantiated by predictions from structure modelling. 
The variants studied in this report can be divided in two different groups based on 
their impact on the structure of the ASL protein. Most of the variants affect the atomic 
interactions within a monomeric ASL unit while variants p.Glu189Gly and 
p.Arg193Trp were found to impact the tetramer formation. The enzyme kinetic data 
and thermal stability analysis were in general agreement with the structural analysis. 
Mutants with complete or near-complete effects on activity were either near the active 
site (p.Arg12Gln, p.Asp31Asn, p.Gln286Arg, p.Arg385Cys, and p.Arg385Leu) or 
hampered the structural stability of monomer (p.Arg445Pro) or tetramer 
(p.Arg193Trp). Two variants near the tetrameric interface, p.Val178Met and 
p.Glu189Gly did not have severe effects on enzymatic activity. Further computational 
analysis showed that multiple strong ionic interactions between arginine 193, lysine 
192 of one subunit with the glutamate 185 and glutamate 189 of another interacting 
ASL monomeric unit could compensate for loss of some interactions. The major 
result of this analysis is the role of arginine 193 in the structural stability of the ASL 
complex. Involvement of arginine 193 with several adjacent acidic residues meant 
that any mutation of arginine 193 residue would have a strong negative impact on 
protein stability and catalytic activity.  
In conclusion, we have found significant residual levels of ASL activity in some 
of the mutants that are associated with a variant clinical and biochemical phenotype 
of ASLD. Likewise, this study provides evidence for instability of the mutant proteins 
and adds ASLD to the list of target diseases for novel therapeutic approaches with 
small molecules allowing scaffolding to improve folding and stability. Based on recent 
data on the genotypes found in ASLD it is obvious that the search for compounds 
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that stabilize the ASL protein should be pursued with highest priority to eventually 
gain benefit for a substantial proportion (~25%) of ASLD patients. 
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Table 1: Details of naturally occurring ASL missense mutations, clinical course 
and enzymatic characteristics of recombinant mutant proteins 
ASL activity (± S.D.)a Vmax (± S.D.)b
Km  
(± S.D.)b 
Vmax/Km   
ratiob V50 (± S.D.)
b
Nucleotide 
level 
Protein 
level 
Clinical 
course 
(mIU/mg) (% of WT) (mIU/mg) (mM) (% of WT) (
oC) 
WT WT  - 1077.2 ± 506.1 100 ± 5.4 769.0 ± 14.2 0.44 ± 0.03 100 52.7 ± 0.2 
c.35G>A p.R12Q variant 33.4 ± 3.9 4.3 ± 0.5 n.d. n.d. n.d. n.d. 
c.91G>A p.D31N variant 22.8 ± 2.5 2.0 ± 0.7 n.d. n.d. n.d. n.d. 
c.283C>T p.R95C variant 192.5 ± 86.5 18.0 ± 5.7 99.2c ± 2.7 0.18c ± 0.02 32 46.5c ± 0.1 
c.299T>C p.I100T variant 969.0 ± 397.2 98.0 ± 18.3 488.0c ±15.1 0.46 ± 0.06 61 48.5c ± 0.1 
c.532G>A p.V178M variant 877.1 ± 335.3 92.1 ± 21.8 714.0c ± 14.1 0.44 ± 0.04 93 49.9c ± 0.2 
c.566A>G p.E189G variant 1048.8 ± 426.3 90.3 ± 13.7 669.3c ± 16.1 0.49 ± 0.05 78 48.1c ± 0.1 
c.577C>T p.R193W variant 51.3 ± 26.9 4.1 ± 1.3 n.d. n.d. n.d. n.d. 
c.857A>G p.Q286R severe 9.0 ± 5.9 1.2 ± 0.8 n.d. n.d. n.d. n.d. 
c.1003G>T p.V335L variant 535.1 ± 130.8 45.2 ± 21.5 443.6c ± 10.8 0.53 ± 0.05 48 42.39c ± 0.5
c.1135C>T p.R379C variant 649.6 ± 244.7 68.0 ± 16.9 487.3c ± 9.0 0.25c ± 0.02 112 47.95c ± 0.1
c.1153C>T p.R385C variant 11.6 ± 1.8 1.5 ± 0.2 n.d. n.d. n.d. n.d. 
c.1154G>T p.R385L severe 10.4 ± 3.3 1.3 ± 0.4 n.d. n.d. n.d. n.d. 
c.1334G>C p.R445P variant 28.8 ± 2.1  3.2 ± 0.2 n.d. n.d. n.d. n.d. 
aASL activities were measured under standard conditions using 13.6 mM 
argininosuccinate and normalized with GAPDH according to the expressed ASL 
protein levels by densitometry indicating in mIU/mg protein. The residual activities of 
ASL mutants were determined as percentage of ASL WT in each transfection under 
same conditions in triple measurements from at least three independent transfection 
experiments, respectively. 
bVmax and Km values were determined by Michaelis-Menten analysis and V50 values 
by Boltzmann sigmoidal analysis using GraphPad Prism 4 for curve fitting in triple 
measurements from the same experiment. Vmax values were normalized according to 
the expressed ASL protein levels using the same samples for kinetics assay by 
densitometry. 
cSignificant difference compared with ASL WT (p<0.05) 
± S.D.: standard deviation; n.d.: not determined 
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Table 2: Prediction of protein stability using SDM 
ASL Mutants Sec Str WT Sec Str mut Pseudo ΔΔ G 
(kcal.mol-1) 
R12Q L L -0.38 
D31N H H -0.17 
R95C H H 1.84 
I100T T T -2.02 
V178M H H 0.98 
E189G H H -3.18 
R193W H H 1.29 
Q286R T T -0.29 
V335L H H 0.20 
R379C L L -1.88 
R385C H H -0.21 
R385L H H -0.08 
R445P H H -2.28 
Prediction of structural changes were done based on statistical potential energy 
calculation [300]. In the SDM analysis a negative score is indicative of a destabilizing 
effect and positive score suggests a stabilizing effect. A cut-off of 2 kcal.mol-1 was 
used for predicting a destabilizing effect (in bold). L: loop; H: helix; T: turn. 
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Table 3: List of important atomic contacts in WT and mutant ASL tetrameric 
structures 
Mutation Amino 
Acid 
Residue Dist Surf HB Phob 
R12Q Arg 142C Thr 5.5 4.4 + - 
 Arg 347C Thr 4.7 5.7 + - 
 Arg 348C Gly 5.8 1.2 - - 
 Arg 351C Ser 3.5 39.9 + - 
R12Q Gln 351C Ser 3.7 29.4 + - 
R95C Arg 73A Glu 2.8 37.9 + - 
 Arg 80A Lys 6.1 1.6 - - 
R95C Cys 73A Glu 3.8 15.9 - - 
V178M Val 451A Gln 5.2 1.8 - - 
E189G Glu 193D Arg 3.0 43.7 + - 
R193W Arg 185D Glu 3.8 19.0 + - 
R193W Trp 185D Glu 2.8 43.3 - + 
Q286R Gln 399B Glu 4.6 22.0 + - 
R379C Arg 432A His 5.5 8.9 + - 
 Arg 209D Leu 5.5 2.0 - + 
R379C Cys 209D Leu 4.9 10.8 - - 
R385C Arg 105D Gly 4.8 10.6 + - 
R445P Arg 152A Asp 3.3 31.7 + - 
 Arg 435A Glu 5.6 3.6 + + 
R445P Pro 152A Asp 5.0 3.4 - - 
 Pro 435A Glu 4.2 17.5 - + 
Dist: distance (A) between the atoms; Surf: contact surface area (A2) between the 
atoms; HB: hydrogen bond; Phob: hydrophobic-hydrophobic contact. +/- indicates 
presence/absence of a specific contact. Important interactions are shown in bold. For 
the hydrogen bond formation contact analysis is based upon the approach developed 
in (54).  
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Figure 1: Mutations in the ASL protein mapped onto the secondary structure of 
the human ASL protein sequence.  
Mutations are indicated with red triangles. Helices are shown in light blue and beta 
strands are shown as cyan arrows. Amino acids are coloured according to chemical 
properties, with aspartic and glutamic acids are in red, arginines and lysines in blue 
and aromatic amino acids are shown in green. Secondary structure information was 
extracted from the known crystal structures of ASL (PDB 1K62) and figure was 
created with the program CLC Workbench. 
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Figure 2: Expression and enzymatic properties of the ASL WT and mutants.  
A: Expression of recombinant ASL WT and mutants in 293T cells. 293T cells 
were transiently transfected with empty vector pcDNA3 (EV), recombinant ASL WT 
and mutant plasmids, respectively. ASL expression was detected by Western blot 
analysis using 30 μg of total protein separated by 10% SDS-PAGE. GAPDH (37 kDa) 
served as loading control. B: Residual ASL activities of recombinant ASL 
proteins in 293T cells. ASL enzymatic activity was measured under standard 
conditions using 13.6 mM argininosuccinate in cells transiently transfected EV or 
diverse ASL constructs (6 μg of whole cell extracts), respectively. The residual ASL 
activities are represented as a percentage of ASL WT activity yielded under same 
conditions and normalized with GAPDH according to the expressed ASL protein 
levels by densitometry. ASL severe mutants (Q286R and R385L) and EV served as 
negative control and were marked in black. Nine variant mutants yielded residual 
activities >3% of ASL WT (in red) were marked in different colours: R95C in salmon, 
I100T in purple, V178M in green, E189G in blue, V335L in cyan, R379C in orange, 
and R12Q, R193W and R445P in grey. Two variant mutants (D31N and R385C) 
yielded no significant residual activities (≤2% of WT) and were marked also in black. 
All assays were carried out in triplicate measurements of at least three independent 
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experiments, respectively. C: Kinetic study of recombinant ASL proteins showing 
significant residual activities. Kinetic study was performed for ASL WT and six 
variant mutants (R95C, I100T, V178M, E189G, V335L, and R379C) (6 μg of whole 
cell extracts) with ≥18% of WT activity using 10 indicated different argininosuccinate 
concentrations (ranging from 0.045 to 13.6 mM), respectively. The measured 
enzymatic activities were normalized according to the expressed ASL protein levels 
by densitometry using GAPDH as control and represented as mIU/mg of whole cell 
extract. The kinetic parameters Vmax in mIU/mg and Km in mM of argininosuccinate 
were determined by Michaelis-Menten analysis after curve fitting using GraphPad 
Prism 4. D: Thermal stability of recombinant ASL proteins with high residual 
activities. A total of 6 μg of protein diluted at 0.15 mg/ml (except for 26 μg of mutant 
R95C protein, which is expressed less efficient and exhibited only low enzyme 
activity and was therefore diluted at 0.65 mg/ml) in albumin buffer was heated at the 
indicated temperatures for 30 min and immediately cooled down on ice prior to ASL 
activity measurement. ASL activity indicates in percentage of activity of respective 
protein heated at 37oC. The horizontal dashed line marks 50% of ASL activity, 
whereas the vertical dashed lines crossing the X-axis indicate the temperatures (V50) 
at which 50% of each protein is inactivated. The value V50 (oC) was determined by 
Boltzmann sigmoidal analysis after curve fitting using GraphPad Prism 4. All assays 
were carried out in triplicate. Error bars indicate the standard deviation. 
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Figure 3: A comparison of the WT and mutant RNA secondary structures of the 
R193W and R445P variants. The minimum free energy structure of the WT and 
mutant RNA were used to provide graphical representation of the secondary 
structures.  
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Figure 4: A multiple sequence alignment of ASL protein sequences from 
human, cow, horse, cat, chimpanzee, pig, dog and rat.  
Structurally and catalytically important residues including all residues studied here 
are conserved across species. As the only exception, in case of rat ASL the arginine 
445 residue is replaced by glutamine which may impact the core structure and 
complex formation of activity. Asterisk indicates mutated residues studied here. 
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Figure 5: Three dimensional structure of ASL tetramer showing overall 
structure of ASL tetramer and the location of mutants on one subunit. 
Monomeric structure of WT ASL has three distinct subdomains. Domains 1 and 3 
have similar structure and topology with two helix-turn-helix motifs in perpendicular 
arrangement. Domain 2 has nine helices and five of them form the central five helix 
bundle with up-down-up-down-up topology. In the ASL homotetramer, active site 
residues are contributed by three different subunits. ASL structure is shown as a 
ribbons model with different subunits coloured in rainbow, cyan, magenta and yellow. 
The green and cyan subunits form a dimer and join with another dimer formed by 
magenta and yellow subunits to form the tetramer. Active site residues from one of 
the sites are shown as solid surfaces while catalytic centre (H160) is shown as 
spheres. For clarity, helices and sheets are only shown for one subunit shown in 
rainbow colours violet at N-terminus and red at C-terminus. The mutations studied in 
this report are shown as ball and stick models. Each active site is formed by residues 
from three different monomeric subunits, with contributions from three conserved 
sequences coming from a different subunit. The histidine 160 residues at the catalytic 
centres are shown for each subunit. 
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Figure 6: Structural analysis of the ASL mutants R12Q, D31N, R95C and I100T. 
ASL structure is shown as a ribbons model with different subunits coloured in green, 
cyan, magenta and yellow. Interacting residues are shown as ball and stick models. 
Mutated residue is shown in red. WT and mutant structures were aligned and 
superimposed to depict the differences between WT and mutated residue. A: 
Molecular contacts of arginine 12 and mutagenesis to glutamine. The arginine 12 
residue forms ionic contacts with glutamate 138 and  aspartate 145 of the adjacent 
ASL unit (shown in magenta) forms hydrogen bonds with threonine 142, threonine 347 
and glycine 348 which were found to be broken in the arg12gln mutant shown in red. 
B: Molecular contacts of asparate 31 and mutagenesis to asparagine. The 
aspartate 31 residue is located close to histidine 160 at catalytic centre and is part of 
the substrate access channel formed by three different units of ASL monomers, shown 
in green, magenta and yellow. A change from aspartic acid to aspargine seems to 
result in hydrogen bond formation with aspartate 87 of the same ASL monomer. This 
will introduce structural rigidity and may affect the substrate binding and catalysis. C: 
Interactions of arginine 95. The arginine 95 residue is also located near the active 
site and forms hydrogen bonds with the glutamate 73 on the same ASL monomeric 
unit (shown in green). The arginine 95-glutamate 73 interaction is stabilizing the ASL 
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monomeric structure and the mutation of arginine 95 to cysteine disrupts the hydrogen 
bonds with the glutamate 73 which would impact protein stability. D: Interactions of 
isoleucine 100. The isoleucine 100 residue is located near the active site but does 
not have any direct role in substrate binding or catalysis. The isoleucine 100 residue 
is participating in multiple interactions with the isoleucine 63, aspargine 62 and 99 
leucine but mutation to threonine 100 does not seem to affect the interactions with 
neighbouring residues. 
 
 
 
Figure 7: Structural analysis of the ASL mutants V178M, E189G, R193W and 
Q286R. 
ASL structure is shown as a ribbons model with different subunits coloured in green, 
cyan, magenta and yellow. Interacting residues are shown as ball and stick models. 
Mutated residue is shown in red. A: Interactions of valine 178. The valine 178 
residue is located at the end of the central core helix bundle that forms the ASL 
tetramer but does not have a major role in formation of the central core of the 
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structure. The minor effects caused by mutation of valine 178 to methionine are 
predicted to be stabilized by ionic interactions between arginine 193 and glutamate 
185 and glutamate 189 on different subunits (shown in green and yellow). B: 
Interactions of glutamate 189. The ASL tetramer is formed by ionic interactions 
between arginine and glutamic acid residues on two adjacent dimeric ASL units 
(green-cyan, magentayellow). Ionic interactions between arginine 193 on one subunit 
with glutamate 189 and glutamate 185 of the adjacent subunit are crucial for the 
central core helix structure. Upon Glu189Gly mutation, the arginine 193 of the 
adjacent ASL monomer still forms hydrogen bonds with the glutamate 185 so the 
structure will still be stable but the overall stability is predicted to be lower than in the 
WT enzyme. C: Interactions of arginine 193. The arginine 193 residue is crucial for 
complex formation and its mutation to tryptophan destroys ionic interactions with the 
glutamate 185 and glutamate 189 residues on the opposite subunit (shown in yellow) 
and results in an unstable structure. D: Interactions of glutamate 286. The 
glutamine 286 residue is part of the flexible 280`s loop which is important for 
substrate entry and exit and mutation of gln286 to arginine results in hydrogen bond 
formations with the glutamine 399 from another ASL unit (shown in cyan). The 
structural rigidity imposed on the flexible 280’s loop would impact substrate binding 
and catalysis. 
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Figure 8: Structural analysis of the ASL mutants V335L, R379C, R385C and 
R445P. 
ASL structure is shown as a ribbons model with different subunits coloured in green, 
cyan, magenta and yellow. Interacting residues are shown as ball and stick models. 
Mutated residue is shown in red. A: Interactions of valine 335. The valine 335 
group interacts with residues on same alpha helix as well as another adjacent parallel 
alpha helix of the same ASL unit (shown in green). The valine 335 to leucine 
mutation does not have major impact on the structure. An extra hydrophobic 
interaction with arginine 302 of the same ASL unit occurs after the mutation of valine 
335 to leucine. B: Interactions of arginine 379. The arginine 379 forms hydrogen 
bonds with histidine 432 located on same ASL unit and has hydrophobic interactions 
with leucine 209 of the adjacent ASL unit. Any major impact on protein structure and 
function was not predicted. C: Interactions of arginine 385. The arginine 385 
residue is located near the active site histidine 160 and forms hydrogen bonds with 
glutamic acid 389 to stabilize the C-terminus helix bundle of ASL monomer. 
Interactions with glutamic acid 389 of the same ASL unit (green) and glycine 105 of 
the adjacent unit (yellow) were affected by mutation to cysteine. D: Interactions of 
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arginine 445. The arginine 445 residue is involved in stabilizing the C-terminus helix 
of the ASL monomeric structure (green) by formation of hydrogen bonds with 
aspartate 152 and glutamate 435 which are disrupted after mutation to proline 
(shown in red). 
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Supplemental Table 1: Oligonucleotide primers used for mutagenesis reactions 
Mutation Primer sequence (5’-3’)* Annealing T (°C) 
c.35G>A p.Arg12Gln 
forward: TGGGGTGGCCAGTTTGTGGGTGCA 
reverse: AAGCTTCCCACTCTCCGAGGCCAT 
81.2 
74.4 
c.91G>A p.Asp31Asn 
forward: TCCATTGCCTACAACCGGCACCTT 
reverse: CGCGTTGAACTTCTCCATGATGGG 
74.6 
74.2 
c.283C>T p.Arg95Cys  forward: CAATGAGCGCTGCCTGAAGGAGCT 
reverse: GCTGTGTGGATGTCCTCATCATTG 
75.2 
70 
c.299T>C p.Ile100Thr  forward: AGGGAAGCTGCACACGGGACGGAG reverse: GCCGTTGCACCAGTGAGCTCCTTC 
78.5 
75.7 
c.532G>A p.Val178Met 
forward: TGAGCCACGCCATGGCACTGACCC 
reverse: GAATCCAGTGGCTCCAGCGGATGG 
77 
81.3 
c.566A>G p.Glu189Gly 
forward: CGGATCAATGTCCTGCCCCTGGGG 
reverse:  CTTCCGCACCCCCAGCAGCCGCTC 
79.8 
83.2 
c.577 C>T p.Arg193Trp  
forward: GAGGTGCGGAAGTGGATCAATGTC 
reverse: CAGCAGCCGCTCAGAGTCTCGGGT 
71.5 
77.4 
c.857A>G p.Gln286Arg 
forward: CCTGATGCCCCGGAAGAAAAACCC 
reverse: CTGCTTCCCGTGCTGTAGGCATCT 
73.2 
75.9 
c.1003 
G>T p.Val335Leu  
forward: GCTGTGTTTGAATTGTCAGACACT 
reverse: TTCCTTGTCCTCCTGTAAGTCTTTG 
64.6 
65.7 
c.1135C>T p.Arg379Cys 
forward: ATTACCTGGTCTGCAAAGGGATGC 
reverse: AGGCAAGGTCAGTGGCCAGCATGT 
70 
75.6 
c.1153C>T p.Arg385Cys 
forward: GATGCCATTCTGCCAGGCCCACGA 
reverse: CCTTTGCGGACCAGGTAATAGGCA 
79.9 
72.3 
c.1154G>T p.Arg385Leu 
forward: GATGCCATTCCTCCAGGCCCACGA 
reverse: CCTTTGCGGACCAGGTAATAGGCA  
79 
72.3 
c.1334 
G>C p.Arg445Pro 
forward: GGCACTGCGCCCTCCAGCGTCGAC 
reverse: GCCCAGGGCACCATACTGCTCCAC 
83.2 
76.9 
* Primers were purified with high performance liquid chromatography (HPLC) and 
phosphorylated at the 5’-end. Bold and underlined letters indicate the position of the 
point mutation. 
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Supplemental Figure 1: Structure of human ASL monomer shown as a ribbon 
model.  
The protein is shown in rainbow colours with violet at N-terminus and red at C-
terminus. The three distinct helix bundles forming distinct domains of the ASL 
monomer are visible. The highly conserved residues are shown as ball and stick 
models in grey. The three conserved regions are labelled as C1, C2 (contains active 
site His160) and C3 (contains 280’s loop with Gln286).  
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Abstract  
Carbamoyl phosphate synthetase 1 deficiency (CPS1D), due to CPS1 mutations, is a 
rare autosomal-recessive urea cycle disorder causing hyperammonemia that can 
lead to death or severe neurological impairment. CPS1 catalyzes carbamoyl 
phosphate formation from ammonia, bicarbonate and two ATPs, and requires the 
essential allosteric activator N-acetyl-L-glutamate. Clinical mutations were found 
spreading over the entire CPS1 coding region, occurring mainly in single families, 
with little recurrence. We characterize here the only known frequently recurrent CPS1 
mutation, p.Val1013del, found in nine unrelated patients of Turkish descent using 
recombinant His-tagged wild type (WT) or mutant CPS1 expressed in 
baculovirus/insect cells. The global CPS1 reaction and the ATPase and ATP 
synthesis partial reactions that reflect, respectively, the bicarbonate and the 
carbamate phosphorylation steps, were assayed. Structural modelling was performed 
to rationalize the p.Val1013del effects. We found that CPS1 WT and V1013del 
mutant were expressed at comparable level and were purified to homogeneity but the 
mutant CPS1 exhibited no significant residual activities in the assays for the global or 
partial reactions. In the CPS1 structural model, V1013 belongs to a highly 
hydrophobic β-strand at the middle of the central β-sheet of the A subdomain of the 
carbamate phosphorylation domain (an ATP-grasp domain). It is close to the 
predicted carbamate tunnel that links both phosphorylation sites, being just five 
residues away from E1018, which is predicted to belong to the tunnel wall. The 
mutation p.V1013del inactivates the enzyme but does not render the enzyme grossly 
unstable or insoluble. The deletion, by shortening the β-strand, could pull E1018 
away from the carbamate tunnel, distorting this tunnel and possibly hampering the 
connection between both phosphorylation steps. 
 
Introduction  
Carbamoyl phosphate synthetase 1 deficiency (CPS1D; OMIM #237300) caused by 
mutations in the human Carbamoyl phosphate synthetase 1 (CPS1, MIM #608307) 
gene is a rare autosomal-recessive urea cycle disorder (UCD) with an estimated 
incidence of 1:50,000-1:100,000 based on the reports of the Japanese and American 
cohorts [1]. Like in other urea cycle disorders, CPS1D patients present 
hyperammonemia leading to death or to severe neurological impairments. CPS1D is 
biochemically in plasma characterized by high ammonia and glutamine and low 
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citrulline levels with no increase in urine orotic acid (which is the marker for another 
mitochondrial UCD, ornithine transcarbamylase (OTC) deficiency). CPS1D can be 
identified as lethal neonatal onset within the first days of life but also less severe late 
onset is described in children or adults [2-3]. The severity of the clinical presentation 
varies depending on the time of onset and the level of residual enzyme activity.  
Human CPS1 is located on chromosome 2q34-35 [4] and is comprised of 38 
exons with 4500 nucleotides coding sequence [5-7]. To date, more than 220 
mutations have been detected over the entire hCPS1 coding region [1-3, 8-13]. 
Different types of mutations were described, including single-nucleotide substitutions 
(~77%) with preference of missense changes (~61%), deletions (~14%), small 
insertions or duplications (~7%), indels (~2%), and nonsense mutations (~7%) [1]. A 
certain number of missense mutations are non-recurrent [1, 5-6, 8, 10, 12-14]. Only 
very few of the missense mutations (<10%) recur in different families [1].  
CPS1 (EC 6.3.4.16) is the first rate-limiting urea cycle enzyme which catalyzes 
the synthesis of carbamoyl phosphate (CP) from ammonia, bicarbonate and two 
molecules of ATP [1, 7, 15-22]. The complex reaction requires the cofactor N-acetyl-
L-glutamate [23] and takes place in three sequential steps, namely, bicarbonate 
phosphorylation, carbamate formation from carboxyphosphate and ammonia, and 
carbamate phosphorylation [24-25]. The bicarbonate-dependent ATPase partial 
reaction and the partial reaction of ATP synthesis from ADP and carbamoyl 
phosphate reflects the steps of bicarbonate phosphorylation, respectively [18, 24-26]. 
CPS1 is highly expressed in liver [27] and can also be detected in small intestine [28] 
as well as in pancreas [27].  
Expression systems for investigations of the functional relevance of missense 
mutations associated with CPS1D were developed using bacteria [26] or insect cells 
[29-30], or, in the case of a common single nucleotide polymorphism (p.Thr1406Asn), 
yeast (Schizosaccharomyces pombe) [31]. Hereby, the role of specific residues and 
amino acid changes and their functional consequences for CPS1 function were 
defined. Importantly, at least the recombinant human CPS1 expressed in the 
baculovirus/insect system showed essentially the same kinetic and molecular 
properties as the natural human enzyme allowing reliable characterization of disease-
causing mutations [30].  
In this study, we expressed the recombinant human CPS1 in insect Sf9 cells 
to characterize the molecular basis of the only recurrent mutation, the deletion of a 
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valine 1013 residue (p.Val1013del) in the carbamate phosphorylation domain of the 
CPS1 gene, which was found in nine Turkish CPS1D patients from apparently 
unrelated families. We found that CPS1 WT and p.Val1013 deleted mutant (CPS1-
V1013del) were expressed at comparable level and both purified to >97% purity as 
judged by SDS-PAGE. However, the CPS1-V1013del mutant yielded no significant 
residual activity in the global as well as the partial reactions and exhibited thermal 
instability.  
 
Materials and Methods  
Patients’ information 
The mutation p.Val1013del was found in a homozygous state in nine CPS1D patients 
of Turkish origin with neonatal onset of disease when mutation analysis using cDNA 
derived from cultured fibroblasts or stimulated lymphocytes were used as described 
[8, 32]. Although some of the families originated from Eastern regions in Turkey, 
there was no apparent relationship between the families. All parents of whom DNA 
was available (which was the case in five of the nine families) were carriers of the 
respective mutation confirming segregation on each one parental allele. Clinical 
information was available for 5/9 patients confirming the severity of CPS1D in all 
cases. Detailed are listed in Table 1.  
 
Table 1: Details to patients and their families described in this study 
Patient Consanguinity 
(of parents) 
Onset Max. 
ammonia 
(μmol/L) 
Extracorporeal 
detoxification 
outcome 
1 n.a. n.a. n.a. n.a. n.a. 
2 2nd degree 
cousins 
day 3 2400 PD died month 4 
3 n.a. n.a. n.a. n.a. n.a. 
4 “related” day 2 1700 CAVHDF died day 6 
5 n.a. n.a. n.a. n.a. n.a. 
6 “related” day 3 2400 HDF died week 3 
7 “related” day 3 2500 n.a. died week 1 
8 1st degree 
cousins 
day 1 1980 PD died day 5 
9 n.a. n.a. n.a. n.a. n.a. 
CAVHDF: continuous arterio-venous hemodiafiltration; HDF: hemodiafiltration; n.a.: 
no information available; PD: peritoneal dialysis 
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Generation of wild type and mutant CPS1 constructs  
The recombinant mature human CPS1 WT construct carrying a His6-tag at the N-
terminal position hereby replacing the mitochondrial targeting sequence (pFastBac-
CPS1-WT) was generated as described previously [30]. Based on the pFastBac-
CPS1-WT, site-directed mutagenesis was performed by the overlapping extension 
method (Quickchange kit from Stratagene) using the forward V1013delF’ 
(5’GACGGTGGTGAATTGCAATCCTGAGAC3’) and reverse V1013delR’ 
(5’GTCTCAGGATTGCAATTCACCACCGTC3’) primers yielding the mutant 
pFastBac-CPS1-V1013del. The established CPS1 constructs were verified by 
sequencing using the BigDye Terminator cycle sequencing kit version 1.1 (ABI 
sequence, Applied Biosystems).  
 
Recombinant human CPS1 protein expression, purification and Western blot 
analysis  
The CPS1 constructs were expressed by using the Bac-to-Bac® Baculovirus 
Expression System (Invitrogen) as described before [30]. In brief, the plasmids 
pFastBac-CPS1-WT and pFastBac-CPS1-V1013del were transformed into E. coli 
DH10Bac competent cells by heat shock. The individual bacmids containing the 
recombinant CPS1 constructs were extracted using the blue white screen and further 
verified by PCR screening. The Sf9 insect cells were grown in a shaker flask with 
serum-free SF 900 II SFM cell culture medium (Invitrogen) containing 0.1% Pluronic 
F-68 (Invitrogen) and 0.5% penicillin/streptomycin solution (Sigma) and incubated at 
27oC with orbital shaking at 125 rpm in a humidified atmosphere. Cells were 
transfected with bacmids carrying CPS1 WT or mutant (CPS1 c.3037-3039del) cDNA 
using Cellfectin II Reagent/Grace medium in a 6-well plate for 5 hours according to 
the manufacturer’s instructions (Invitrogen) followed by 3-day culture in growth 
medium without shaking. The produced baculovirus was enriched for 2 days prior to 
infecting the Sf9 cells for CPS1 expression. The infected cells were harvested after 3 
days by centrifugation at 300g for 10 min.  
The cell pellets containing recombinant His-tagged human CPS1 WT or 
mutant proteins were lysed followed by purification using a HisTrap HP 1-ml column 
fitted in an AKTA FPLC system (GE Healthcare). The CPS1-containing fractions 
monitored by SDS-PAGE (8% polyacrylamide gel) with Coomassie staining were 
pooled, concentrated to >1 mg protein/ml using centrifugal ultrafiltration (100-kDa 
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cutoff membrane, Amicon Ultra, Millipore), enriched with extra 10% glycerol and 1mM 
dithiothreitol (DTT), and snap frozen at –80°C. The concentrations of purified CPS1 
proteins were determined by the method of Bradford [33] using bovine serum albumin 
as a standard.  
Western blotting was performed as described by Laemmli [34]. Cell extracts (~ 
20 μg of with baculovirus infected CPS1 protein) were separated by 8% denaturing 
SDS-PAGE, and subsequently transferred to nitrocellulose transfer membranes 
(Whatman GmbH, Dassel, Germany). The primary monoclonal antibody anti-6xHis 
(Clontech, CA) was used at a dilution of 1:7500, and the horseradish peroxidase-
conjugated secondary antibody anti-mouse (Santa Cruz Biotechnology) was used at 
a dilution of 1:5000. Antibody against β-actin (Santa Cruz Biotechnology) served as 
loading controls. Protein detection was done using ECL reagents (GE Healthcare) for 
chemiluminescent labelling and the densitometry of detected bands was analysed by 
Carestream Molecular Imaging software (Carestream Health) to judge the purity of 
produced proteins.  
 
Enzyme activity assays  
The CPS1 enzyme overall and partial activities were determined colorimetrically as 
described before [26, 30, 35-36]. The overall CPS1 activity was measured as the 
citrulline production converted from CP by coupling with ornithine and ornithine 
transcarbamylase (OTC) [37-38]. Briefly, the purified CPS1 proteins were diluted at 1 
mg/ml in a solution (50mM glycyl-glycine pH 7.4, 0.5 M NaCl, 10% Glycerol and 2 
mM DTT) and incubated at 37oC for 10 min following another incubation for 10 min in 
a standard assay mixture (50mM glycyl-glycine pH 7.4, 70 mM KCl, 1 mM DTT, 20 
mM MgSO4, 5 mM ATP, 35 mM NH4Cl, 50 mM KHCO3, 10 mM NAG, 5 mM L-
ornithine, and 4 U/ml OTC (Sigma)). The reaction was stopped by adding 800 μl of a 
stop solution containing 0.04 M antipyrine, 0.01 M ammonium iron (III) sulphate, 50% 
sulfuric acid, 50% orto-phosphoric acid, 7.5% NaCl and 0.4% 2,3-butanedione and 
followed by incubation in a boiling water bath for 16 min prior to photometrically 
measurement at 464 nm. The partial ATPase reaction was measured in pyruvate 
kinase/lactate dehydrogenase coupled assay by monitoring continuously ADP 
production as NADH oxidation at 340 nm [30, 39] with the following modifications: 50 
mM KHCO3 and 10 mM NAG were sequentially added to the assay mixture after 
respective measurement for 10 min at 37oC. The partial reaction of ATP synthesis 
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was measured by monitoring continuously ATP production with the increase in the 
absorbance at 340 nm [26, 30] with the following modifications: 50 mM, 6 μg/ml and 
20 μg/ml replaced 15 mM MgSO4, 0.1 mg/ml hexokinase and 25 μg/ml glucose-6-
phosphate dehydrogenase, respectively; 5 mM CP and 10 mM NAG were 
sequentially added to the assay mixture after respective measurement for 10 min at 
37oC. The measured extinctions were corrected with the extinctions of a blank 
containing protein and all reagents except for NAG. One CPS1 unit produces per 
minute 1 μmol citrulline or 2 μmol ADP. All assays were carried out in duplicate for at 
least three independent measurements. 
 
Differential scanning fluorimetry  
To monitor thermal unfolding of proteins in the presence of a fluorescent dye, 
differential scanning fluorimetry (DSF) was performed and analyzed as described 
previously [40-41] with following modifications: purified CPS1 proteins were diluted to 
0.1 mg/ml in buffer (50mM glycyl-glycine pH 7.4) with Sypro Orange (Roche) at final 
concentration of 2-folds and run in duplicate. Briefly, the proteins were heated from 
20 to 95oC with a ramp rate of 0.57oC/sec in a LightCycler 480 (Roche, Switzerland). 
The obtained fluorescence was normalized as relative fluorescence so that minimum 
fluorescence was set to 0 and maximum fluorescence set to 1. The value V50 (
oC) 
indicating the temperature at which 50% of protein is melted (Tm), was determined by 
Boltzmann sigmoidal analysis after curve fitting using GraphPad Prism 4 (GraphPad 
Software, San Diego, CA, USA).  
 
Structural modelling  
The computational structural modelling was performed using previously reported 
atomic structure model of CPS1 based on the experimental crystal structure of E. coli 
CPS [42] to rationalize the mutation effect. Pymol (DeLano Scientific; 
http://www.pymol.org) was used for visual analysis, for structural superimposition and 
for depicting protein structures.  
 
Statistics  
All statistics were analysed by one-tailed and two-tailed Student’s T-tests using the 
program GraphPad Prism 4 (GraphPad Software). Differences were considered as 
significant if the p value was <0.05.  
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Results  
Recombinant CPS1-V1013del mutant yields highly purified protein production  
In order to characterize the molecular basis of the only known frequently recurrent 
CPS1 mutation p.Val1013del, we first introduced recombinant His-tagged CPS1 
constructs carrying WT or mutant V1013del cDNA into insect Sf9 cells to express 
CPS1 proteins using the previously reported baculovirus/insect cell system. At the 
protein level, expression of mature CPS1 WT or V1013del was detected in the 
infected Sf9 cells at comparable level by Western blot analysis (Fig. 1A) indicating 
the recombinant mutant V1013del was as stable expressed as WT. A multiplicity of 
bands of lower molecular weight could be observed in both CPS1 forms indicating 
the occurrence of CPS1 degradation. Next, we purified the two CPS1 proteins using 
Ni-affinity chromatography and yielded >97% purity for both as judged by 
Coomassie-stained SDS-PAGE (Fig. 1B). Taken together, these findings suggest 
that the deletion of valine 1013 in the CPS1 protein does not lead to misfolding or 
lower expression levels of mutated CPS1.  
 
Figure 1: Expression and purification of CPS1 WT and V1013del  
 
Fig. 1: A: Western blot analysis of CPS1 expression (~163 kDa) of WT and 
V1013del in baculovirus-infected Sf9 cell extracts (~20 μg of total protein) by 8% 
SDS-PAGE. NT: non-transfected Sf9 cells. β-actin (~ 43 kDa) served as loading 
control. B: Coomassie-stained SDS-PAGE (8%) analysis showing the purity of 
purified CPS1 WT and V1013del proteins. M: protein ladder.  
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CPS1-V1013del yields no significant CPS1 activity  
To determine whether the stably expressed CPS1-V1013del mutant harbours 
residual CPS1 activity compared to WT, we measured the CPS1 global activity as 
well as the partial reactions of ATPase and ATP synthesis by monitoring continuously 
ADP or ATP production, respectively (Table 2, Fig. 2). The mutant V1013del yielded 
no significant residual activities in the enzyme activity assays for the CP synthesis 
reaction or for the ATPase and ATP synthesis (Fig. 2) partial reactions compared to 
those of WT, suggesting that the deletion strongly impaired global CPS1 activity as 
well as both ATPase and ATP synthesis partial CPS1 activities reflecting the 
bicarbonate and the carbamate phosphorylation reactions, respectively. Our findings 
indicate that the deletion of V1013 residue hampers both bicarbonate and carbamate 
phosphorylation steps.  
 
Table 2: Enzymatic properties of CPS1 WT and mutant V1013del 
Enyzme 
Global reaction     
(µmol CP/min*mg) 
Partial reactions                 
(µmol ADP/min*mg) Thermostability 
 CP synthesis ATPase ATP synthesis Tm=V50 (oC) 
WT 
(± S.D) 0.8184 ± 0.1441 0.0561 ± 0.0046 0.0233 ± 0.0136 58.99 ± 0.49 
V1013del 
(± S.D) 0.0056 ± 0.0023 0.0010 ± 0.0017 0.0004 ± 0.0002 57.51 ± 0.66# 
Assays were carried out at 37oC. S.D.: standard deviation.  
# indicates a V50 value significantly lower than WT (p<0.0001). 
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Figure 2: Relative CPS1 enzyme global activity and partial activities  
 
Fig. 2: Relative CPS1 enzyme global activity and partial activities of ATPase and 
ATP synthesis (standard assay conditions) of the purified V1013del to WT CPS1 
protein. CPS1 global activity in μmol CP/min*mg protein, partial ATPase and ATP 
synthesis activity in μmol ADP/min*mg protein. Error bars indicate standard 
deviations.  
 
CPS1-V1013del is less stable than wild type  
In order to further investigate whether the mutation p.Val1013del causes protein 
instability, we performed the thermostability assay by DSF. The melting point of the 
protein (Tm) is determined by using heat-caused denaturated protein which is bound 
to a sensitive dye (such as Sypro orange) with high fluorescence [43-44]. We found 
that the mutant V1013del showed a lower melting temperature (57.51 ± 0.66oC) than 
that of WT (58.99 ± 0.49oC) (Table 2 and Fig. 3), and this difference was significant 
(p<0.0001) indicating that the mutant V1013del is less stable than WT CPS1.  
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Figure 3: Thermostability assay of CPS1 WT and V1013del 
 
Fig. 3: Protein stability was determined by DSF. The horizontal dashed line marks 
50% of fluorescence, whereas the vertical dashed lines crossing the X-axis indicate 
the melting temperatures (Tm) at which 50% of each protein is melted. The value V50 
(oC) was determined as Tm by Boltzmann sigmoidal analysis after curve fitting using 
GraphPad Prism 4. All assays were carried out in duplicate at least from three 
experiments. Error bars indicate the standard deviation.  
 
Role of V1013 residue in the CPS1 protein structure  
To rationalize the mutation effect, the computational structural modelling was 
performed based on the experimental crystal structure of E. coli CPS [42]. In the 
CPS1 structural model, valine 1013 belongs to a highly hydrophobic β-strand at the 
middle of the central β-sheet of the A subdomain of the carbamate phosphorylation 
domain (the second ATP-grasp domain) (Fig. 4). It is close to the predicted 
carbamate tunnel that links both phosphorylation sites, being just 5 residues away 
from E1018, which is predicted to belong to the tunnel wall and located near the 
carboxy phosphate binding site [26, 45-46]. Additionally, V1013 residue also belongs 
to a hydrophobic core consisting of 3 consecutive valines, which is conserved in all 
CPS1 and CPSIII. Moreover, V1013 residue is in the vicinity of a D1025-K450 
interaction. The residue K450, located at bicarbonate phosphorylation domain, was 
shown to be important since there exists a mutation affecting this residue, 
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p.Lys450Glu [1]. Taken together, the deletion of V1013, by shortening the β-strand, 
could pull E1018 away from the carbamate tunnel, distorting this tunnel and possibly 
hampering the connection between both phosphorylation steps abolishing CP 
production. Moreover, the deletion could abolish the D1025-K450 interaction by 
shifting the peptides in the vicinity of V1013del, leading to interference of the 
allosteric signal transmitted between ATP-grasps. Although the mutation inactivates 
the CPS1 enzyme activity (Table 2, Fig. 2), it does not render the enzyme grossly 
unstable or insoluble (Fig. 1). 
 
Figure 4: CPS1 computational structural modelling based on the crystal 
structure of E. coli CPS 
 
Fig. 4: A: Location of V1013 residual (big atomic structure in pink) in structural model 
of CPS1 consisting of small subunit of N-terminal domain (intersubunit interaction 
domain (ISD, in light blue) and glutaminase domain (GSD, in blue)), bicarbonate 
phosphorylation domain (BPSD, in light green), integrating domain (ID, in yellow), 
carbamate phosphorylation domain (CPSB, in ligh pink) and allosteric NAG binding 
domain (in black). Other atomic structures indicate the locations of ligands. B: Close-
up of V1013 residue and its relevant surrounding residues E1018 (in orange), D1025 
and K450 (both in blue).  
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Discussion  
Most mutations known so far in the CPS1 gene are “private” to the individual families 
[1]. In this study, we characterized the only frequently recurrent CPS1 mutation 
p.V1013del using the recombinant hCPS1 protein expressed in baculovirus/insect 
cells which allowed production of sufficient amounts of pure CPS1. Importantly, this 
expression system was shown to reliably predict the disease-causing nature of CPS1 
mutations as demonstrated in 35 mutations studied so far [29-30, 47]  
The naturally occurring recurrent deletion located at the carbamate 
phosphorylation domain was found in CPS1D patients with neonatal onset of 
disease. Since all patients, of whom data were available (5/9), presented shortly after 
birth on day 1 to 3 and furthermore all died during the neonatal period or in early 
infancy, a severe impact of p.Val1013del on CPS1 function could be expected. In 
fact, we show here that the mutant p.V1013del, despite high protein expression 
levels and purity (>97%) (Fig. 1) did not exhibit any significant residual activities in 
the global reaction of CP production or in both ATPase and ATP synthesis partial 
reactions (Fig. 2). The low yields of most mutants studied so far were considered to 
be due to poor CPS1 polypeptide production and to gross misfolding resulting in less 
solubility of pure CPS1 protein and this was identified as a key element in 
determining the disease-causing role in missense mutations [47]. Our results indicate 
that the deletion of valine1013 residue does not hamper global CPS1 folding and 
architecture, as suggested by the unaffected production of soluble CPS1 protein.  
The CPS1 activity assays for the overall and partial reactions allow a detailed 
investigation of the single CPS1 reactions and, in addition, to reveal the specific role 
of individual residues [26]. In general, the CPS1 mutations located within the 
bicarbonate domain interfere with the enzyme’s ability to phosphorylate bicarbonate, 
whereas mutations in the carbamate domain specifically perturbe carbamate 
phosphorylation, which is reflected in the ATPase and ATP synthesis partial 
reactions, respectively [26, 46, 48]. As expected, the mutant p.V1013del yielded no 
significant residual activity in the overall rate of CP synthesis nor in ATP synthesis 
partial reaction compared with CPS1 WT protein (Fig. 2A,C). The perturbation of the 
rate of the partial ATP synthesis reaction indicates that the catalytic machinery at the 
carbamate phosphorylation domain is seriously affected. Furthermore, the mutant 
also completely impaired the ATPase partial reaction, even though the site of 
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mutation is distant from the catalytic site of bicarbonate phosphorylation domain (Fig. 
2B).  
Since the human CPS1 crystal structure is not yet elucidated, structural 
predictions rely on the E. coli CPS structural modelling. According to this, the deletion 
of V1013 residue is expected to deform the carbamate tunnel, since it is located 
close to Glu1018, which is part of the carbamate tunnel, and corresponds to Glu604 
in E. coli CPS [42, 46, 49]. Additionally, deletion of V1013 residue probably causes 
the abolishment of an interaction K450-D1025, which bridges the two ATP grasps, 
leading to the blockage of allosteric signal transmission between ATP-grasps. 
Moreover, deletion of V1013 residue perturbs the conserved hydrophobic core which 
might result in instability in the enzyme. Indeed, the thermostability analysis using 
DSF showed that the mutant is less stable (Fig. 3). Thus, the diminished rate of CP 
production can be rationalized by a deformed carbamate tunnel resulting in 
disconnection between both phosphorylation sites and by the perturbation of an 
interaction between both ATP-grasps. Taken together, these findings suggest the 
pathogenic role of this recurrent deletion found in CPS1D patients.  
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4 Concluding remarks and future prospects 
In the present work, the established eukaryotic expression systems in mammalian 
HEK 293T cells and in insect Sf9 cells allow us to study the molecular basis of 
phenotypic variability and pathology in UCDs referring to ASA and CPS1D, 
respectively. For instance, we were able to reveal the role of the naturally occurring 
ASL transcript variants in the phenotypic variability in ASA by co-expression with ASL 
WT or mutants in 293T cells [159]. This provides a new explanation for the molecular 
basis in an inherited disease and adds to our understanding of the clinical variability 
in ASA patients. Further, the established expression system was validated as a 
reliable system to confirm that relevant residual enzyme activities contribute to the 
clinical and biochemical variability of ASA.   
In addition, we were able to characterize the molecular basis of the only 
known frequently recurrent CPS1 mutation (p.Val1013del) using human recombinant 
CPS1 in a baculovirus/insect cell expression system. This mutation, affecting 
Val1013 residue, is predicted to be involved in the structural elements of the 
carbamate tunnel and hereby explains the pathological effect of the mutation. This 
underlines the value of this model by elucidating the effect of a mutation based on 
structural and biochemical properties.  
With the development of the technology in next generation sequencing and 
NBS, an increasing number of disease-causing genetic alterations will be identified. 
However, it remains challenging to determine the relevance of clinical mutations. 
Generally, genotype-phenotype correlations are still poor in all UCDs. The expression 
systems we have established can serve as a tool with the intention to facilitate 
genotype-phenotype studies, in particularly those involving late-onset missense 
mutations with partial residual enzyme activities. By expression of all known variant 
ASL mutants associated with late-onset and/or mild clinical and biochemical courses 
of ASA in 293T cells, this expression system provides higher sensitivity for enzymatic 
activities and better correlations between the enzyme activity and phenotype 
compared to those in other reported systems so far [141, 279].   
While establishment of in vitro-in vivo correlation is feasibly in severe neonatal 
mutations which cause complete absence of enzyme activity, it is rather difficult in 
variant mutants with partial residual catalytic activity. In addition, environmental, 
genetic and biochemical factors need to be considered. First, the in vivo enzyme 
                                                                      Concluding remarks and future prospects 
 120 
 
activity might be sufficient or insufficient to detoxify the nitrogen load depending on 
the external conditions (e.g. increased protein intake, stress, and medication), 
intrinsic factors (e.g. age, pregnancy, and health state) or other regulatory factors 
(e.g. hormones such as glucocorticosteroids and insulin). Second, mechanisms of 
intragenic complementation within the ASL gene [182-185] and of allelic imbalance 
affecting the CPS1 gene [261] may also contribute to the difficulty in predicting 
outcome in these UCDs. Additionally, the co-occurrence of a missense mutation and 
a splicing variant can contribute to the clinical and biochemical variability [159]. 
Moreover, the urea cycle enzymes such as ASS and ASL, and intermediate 
metabolites such as citrulline and arginine are involved in further pathways such as 
the citrulline-NO cycle. Besides for ureagenesis, arginine is substrate for synthesis of 
NO, creatine, and polyamines. The involvement of urea cycle metabolites in other 
pathways adds further to the complexity of disease(s). Ultimately, the different 
sensitivity of in-vitro enzymatic measurements can also be a factor. Thus, additional 
research is required to further establish more reliable genotype-phenotype 
correlations.     
Better understanding of the disease-causing mechanisms of clinical mutations 
in UCDs can provide more clues for development of novel therapeutic strategies. 
Interestingly, in addition to generating a tool for the study of genotype-phenotype 
correlations, our results also elucidated that some ASL mutants, despite displaying 
high residual activity, probably affect protein folding caused by thermal instability. 
This indicates potential novel therapeutic approaches with small molecules as 
pharmachaperone treatment in order to stabilize those mutants in ASLD, as well as in 
other UCDs.  
Recently, structurally intact ASL was described as a requirement for NO 
production [124]. Frequent occurrence of alternative splicing is a common 
phenomenon in ASL gene. We identified a predominant presence of one of the most 
common transcript variants, ex7del ASL, in two ASA patients [159]. In view of these 
findings, it will be interesting to investigate whether the ASL transcript variants as well 
as those instable mutants will affect the formation of the NOS complex ultimately 
leading to NO deficiency. Additionally, it was suggested that NO supplementation 
should be considered to treat or prevent long-term complications in ASA [237]. 
However, more clinical trials are necessary to evaluate the effect of NO donor 
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therapy. Further, a better understanding of the genotype-phenotype correlations will 
be useful to select certain ASA patients who will benefit from NO therapy.  
Currently, the mortality of UCDs is still high and the outcome of severely 
affected patients is generally poor. Novel therapeutic strategies are required. An 
optimized reliable animal model for individual UCDs will be helpful to explore 
potential novel treatment modalities including liver and hepatic cells transplantation, 
pharmachaperons as well as gene therapy.     
In the past few years, there has been a dramatic increase in studying UCDs. 
Since UCDs are rare inherited disease, a large network including UCD patients and 
families, clinicians, researchers, and pharmaceutical companies around the world will 
facilitate joint projects, as already shown by recently established “The Urea Cycle 
Disorders Consortium (UCDC)” in the USA and “European Initiative for Intoxication 
Type Metabolic Disorders (E-IMD)” in Europe. This will contribute to create a global 
knowledge about the prevalence of individual UCDs, clinical and biochemical 
phenotypes, diagnosis, prognosis, care and treatment, from which the prevention of 
the disease and the development of novel therapeutic strategies will eventually 
result.   
In summary, the studies on ASLD and CPS1D can serve as examples for 
understanding the molecular basis and pathology of phenotypic variability in UCDs. 
Accordingly, the strategies and models used in this work provide a general 
applicability which can be further adapted to study other UCDs or to be extended to 
other IEMs. 
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